Refine
Has Fulltext
- yes (403)
Is part of the Bibliography
- yes (403)
Year of publication
Document Type
- Doctoral Thesis (291)
- Journal article (110)
- Conference Proceeding (1)
- Review (1)
Keywords
- HPLC (15)
- Pharmakokinetik (14)
- Aminosäuren (11)
- Arzneimitteldesign (11)
- Fließverhalten (11)
- Arzneimittel (10)
- Inhibitor (10)
- Muscarinrezeptor (10)
- Bioverfügbarkeit (9)
- Instrumentelle Analytik (9)
- NMR-Spektroskopie (9)
- Schüttgut (9)
- Flavonoide (8)
- Kapillarelektrophorese (8)
- Löslichkeit (8)
- Nanostrukturiertes Material (8)
- Biomarker (7)
- Chemische Synthese (7)
- Ligand <Biochemie> (7)
- Molekulardynamik (7)
- Organische Synthese (7)
- Pharmakodynamik (7)
- Proteaseinhibitor (7)
- Qualitätskontrolle (7)
- Synthese (7)
- Tuberkelbakterium (7)
- Verunreinigung (7)
- metabolism (7)
- Arzneimittelforschung (6)
- Computational chemistry (6)
- Cytotoxizität (6)
- LC-MS (6)
- Legionella pneumophila (6)
- Massenspektrometrie (6)
- Metabolismus (6)
- Proteinbindung (6)
- capillary electrophoresis (6)
- flavonoids (6)
- pharmacokinetics (6)
- polyphenols (6)
- synthesis (6)
- Analoga (5)
- Anthocyane (5)
- Candida albicans (5)
- Chromatographie (5)
- Cyclodextrine (5)
- Cysteinproteasen (5)
- Fließregulierung (5)
- Impurity Profiling (5)
- LC-MS/MS (5)
- Malaria (5)
- Permeabilität (5)
- Piperidinderivate (5)
- Polymere (5)
- Polyphenole (5)
- Pulver (5)
- Reinheitsanalytik (5)
- SARS (5)
- Stereoselektive Synthese (5)
- Stoffwechsel (5)
- Struktur-Aktivitäts-Beziehung (5)
- Synthesis (5)
- Targeted drug delivery (5)
- Trypanosomiase (5)
- Validierung (5)
- Wirkstoff (5)
- population pharmacokinetics (5)
- Antibiotikum (4)
- Aroma (4)
- Aziridine (4)
- Biotransformation (4)
- Charged Aerosol Detection (4)
- Chemische Reinheit (4)
- Chemometrie (4)
- Cyclodextrin (4)
- Enzyminhibitor (4)
- Extrakt (4)
- Extrazelluläre Matrix (4)
- Fließregulierungsmittel (4)
- GC-MS (4)
- GPCR (4)
- Hitzeschock-Proteine (4)
- Ionic Liquids (4)
- Kontrollierte Wirkstofffreisetzung (4)
- Lunge (4)
- Maisstärke (4)
- Molekulardesign (4)
- Pharmakotherapie (4)
- Protonen-NMR-Spektroskopie (4)
- Stabilität (4)
- Tandem-Reaktion (4)
- Trypanosomen (4)
- Wittig-Reaktion (4)
- allosteric modulation (4)
- antibiotics (4)
- chiral separation (4)
- cyclodextrin (4)
- drug design (4)
- molecular dynamics (4)
- muscarinic receptors (4)
- protein binding (4)
- therapeutic drug monitoring (4)
- validation (4)
- virtual screening (4)
- Acetylcholinesterase (3)
- Agonist (3)
- Amino acids (3)
- Aromastoff (3)
- Arzneimittelüberwachung (3)
- Auslauftrichter (3)
- Biosynthese (3)
- Burkholderia pseudomallei (3)
- Cholinesteraseinhibitor (3)
- Coronaviren (3)
- Diabetes mellitus (3)
- Docking (3)
- Elektronensprayionisations-Massenspektrometrie (3)
- Enantioselektivität (3)
- Ephedrin (3)
- Estradiol (3)
- Fließfähigkeit (3)
- Formulierungsentwicklung (3)
- Genexpression (3)
- Glucocorticoide (3)
- Glucocorticosteroide (3)
- HIV (3)
- HPLC-MS (3)
- Heilpflanzen (3)
- Inhibition (3)
- Insulin-like Growth Factor I (3)
- Interleukin 4 (3)
- KasA (3)
- Kiefernrindenextrakt (3)
- Knockout <Molekulargenetik> (3)
- Lungenperfusionsmodell (3)
- Maus (3)
- Multiples Myelom (3)
- Naturstoff (3)
- Pharmaceutical Analysis (3)
- Pharmazeutischer Hilfsstoff (3)
- Piperidinalkaloide (3)
- Plasmozytom (3)
- Procyanidine (3)
- Pycnogenol (3)
- Quantitative Analyse (3)
- Screening (3)
- Siliciumdioxid (3)
- Solubilisation (3)
- Strandkiefer (3)
- Strukturbasiertes Wirkstoffdesign (3)
- Ultrafiltration (3)
- Wasserlöslichkeit (3)
- Wirkstofffreisetzung (3)
- Zugspannung (3)
- amino acids (3)
- biomarker (3)
- charged aerosol detector (3)
- chemistry (3)
- click chemistry (3)
- drug delivery (3)
- flow regulation (3)
- flow regulator (3)
- flowability (3)
- human (3)
- mass spectrometry (3)
- medicine (3)
- natural products (3)
- neuroprotection (3)
- nutrition (3)
- oral bioavailability (3)
- pharmacodynamics (3)
- pharmacokinetic (3)
- plant extract (3)
- positron emission tomography (3)
- protease inhibitors (3)
- solubility (3)
- stereoselective synthesis (3)
- ultrafiltration (3)
- virtuelles Screening (3)
- AMSOL (2)
- ARONJ (2)
- Allosterischer Effektor (2)
- Alzheimer-Krankheit (2)
- Alzheimerkrankheit (2)
- Alzheimer’s disease (2)
- Aminosäure (2)
- Antibiotika (2)
- Antimikrobieller Wirkstoff (2)
- Aspartatproteasen (2)
- Asthma (2)
- Authentizität (2)
- Bioassay (2)
- Biologische Aktivität (2)
- Bitopische Liganden (2)
- Blutspiegel (2)
- Burkholderia (2)
- Butyrylcholinesterase (2)
- Capillary Electrophoresis (2)
- Carbamate (2)
- Cathepsin (2)
- Chemie (2)
- Cholinesterase (2)
- Cyclo-GMP (2)
- Cytochrom P-450 (2)
- Cytokine (2)
- Derivatisierung (2)
- Diagnostik (2)
- Diffusion (2)
- Dimere (2)
- Dipolare Cycloaddition (2)
- Docking <Chemie> (2)
- Drug design (2)
- Enantiomere (2)
- Enantiomerentrennung (2)
- Enoyl-ACP-Reduktase (2)
- Enoyl-acyl-carrier-protein-Reductase (2)
- Enoyl-acyl-carrier-protein-Reductase <Enoyl-[acyl-carrier-protein]-Reductase> (2)
- Enterobacteriaceae (2)
- Entzündung (2)
- Erdbeere (2)
- Ernährung (2)
- Etacrynsäure (2)
- Europäisches Arzneibuch (2)
- FabI (2)
- Fettsäurebiosynthese (2)
- Fettsäuren (2)
- Fibroblastenwachstumsfaktor (2)
- Flavonoids (2)
- Fließeigenschaften (2)
- Fluoreszenz (2)
- Fluoreszenz-Resonanz-Energie-Transfer (2)
- Formulation development (2)
- Formulierung (2)
- Furaneol (2)
- GTP-bindende Proteine (2)
- Gentamicin (2)
- Glutathion (2)
- Granulieren (2)
- Gyrasehemmer (2)
- Heidelbeere (2)
- Hepatotoxizität (2)
- Hispidulin (2)
- Hitzeschocktranskriptionsfaktor (2)
- Humanstoffwechsel (2)
- Imatinib (2)
- In vitro (2)
- InhA (2)
- Isotopenverhältnis-Massenspektrometrie (2)
- Kräuterbücher (2)
- Lebensmittelchemie (2)
- Lebertoxizität (2)
- Legionärskrankheit (2)
- Leishmania (2)
- Lipide (2)
- Lipoxygenase <5-> (2)
- Marcophage-infectivity-potentiator-Protein (2)
- Maschinelles Lernen (2)
- Medizin (2)
- Melatonin (2)
- Membran (2)
- Merkaptursäuren (2)
- Metabolit (2)
- Metabolom (2)
- Mikroemulsion (2)
- Mittelalter (2)
- Molekülbibliothek (2)
- Multiple Myeloma (2)
- Muskarinrezeptor (2)
- Mutagenität (2)
- NMR spectroscopy (2)
- NMR-spectroscopy (2)
- Nanopartikel (2)
- Neuroprotektion (2)
- Osteoarthritis (2)
- Paracetamol (2)
- Permeation (2)
- Pharmacokinetic (2)
- Pharmacokinetics (2)
- Pharmakologie (2)
- Pharmazeutische Technologie (2)
- Pharmazie (2)
- Plasmodium falciparum (2)
- Polydimethylsiloxane (2)
- Polyethylenglykole (2)
- Polysiloxan-Membranen (2)
- Polysiloxane-Membranes (2)
- Poorly water soluble drugs (2)
- Populationskinetik (2)
- Populationspharmakokinetik (2)
- Positronen-Emissions-Tomografie (2)
- Proliferation (2)
- Protease (2)
- Protease-sensitive release (2)
- Protein-Protein-Wechselwirkung (2)
- Proteine (2)
- Pseudodistomin E (2)
- Pseudodistomine (2)
- QSAR (2)
- Random Chemistry (2)
- Regulation (2)
- Rezeptor (2)
- Rinde (2)
- S-ADAPT (2)
- STEC (2)
- Schlafkrankheit (2)
- Schüttgüter (2)
- Selektivität (2)
- Serumalbumine (2)
- Signaltransduktion (2)
- Spiralstrahlmühle (2)
- Stability (2)
- Staphylococcus aureus (2)
- Statistische Thermodynamik (2)
- Stickstoffmonoxid (2)
- Structure-based drug design (2)
- Supersaturation (2)
- T cells (2)
- T-Zellen (2)
- Tandem Wittig-[3+2]-Cycloaddition (2)
- Tandem-Massenspektrometrie (2)
- Therapeutic Systems (2)
- Therapeutische Systeme (2)
- Therapeutisches Drug Monitoring (2)
- Thermodynamik (2)
- Tissue Engineering (2)
- Totalsynthese (2)
- Tryptophan (2)
- Tuberkulose (2)
- Valeriana wallichii (2)
- Verkapselung (2)
- Verunreinigungsprofil (2)
- Virtuelles Screening (2)
- Wirbelschichtgranulation (2)
- Wirbelschichtverfahren (2)
- Wirkstoffdesign (2)
- Würzburg / Institut für Geschichte der Medizin / Forschungsgruppe Klostermedizin (2)
- Zellkultur (2)
- albumin (2)
- allometric scaling (2)
- amino acid (2)
- anthocyanins (2)
- antibiotic (2)
- antileishmanial (2)
- apple juice (2)
- authenticity (2)
- aziridines (2)
- azobenzenes (2)
- baclofen (2)
- body composition (2)
- body size (2)
- bulk powders (2)
- butyrylcholinesterase (2)
- chirale Trennung (2)
- clinical study (2)
- corn starch (2)
- coronavirus (2)
- crystal structure (2)
- cyclodextrins (2)
- cysteine protease (2)
- cystic fibrosis patients (2)
- cytochrome P450 3A4 (CYP3A4) (2)
- cytotoxicity (2)
- dendritic cells (2)
- docking (2)
- drugs (2)
- drug–drug interactions (DDIs) (2)
- dualsteric ligands (2)
- endothelium (2)
- estrogens (2)
- etacrynic acid (2)
- extracellular matrix (2)
- fatty acid biosynthesis (2)
- fatty acids (2)
- flavor (2)
- flavour (2)
- gene expression (2)
- glidants (2)
- glutathione (2)
- graft versus host disease (2)
- healthy volunteers (2)
- herbal medicines (2)
- hispidulin (2)
- human breast (2)
- impurities (2)
- impurity profiling (2)
- in vitro (2)
- inflammation (2)
- inhibitors (2)
- ion-pair chromatography (2)
- isotope ratio mass spectrometry (2)
- kinetics (2)
- leishmaniasis (2)
- liquid chromatography (2)
- malaria (2)
- marine sponge (2)
- matrix metalloproteinase (2)
- mercapturic acids (2)
- metabolomics (2)
- molecular modeling (2)
- molekulardynamische Simulationen (2)
- multiple linear regression (2)
- muscarinic receptor (2)
- nitric oxide (2)
- norepinephrine transporter (2)
- octopamine (2)
- organic synthesis (2)
- osteoarthritis (2)
- osteonecrosis of the jaw (2)
- osteoradionecrosis (2)
- outflow funnel (2)
- permeability (2)
- pharmaceutical analysis (2)
- physiologically based pharmacokinetic (PBPK) modeling (2)
- pine bark extract (2)
- piperidine derivatives (2)
- precipitated silica (2)
- protease (2)
- protease inhibitor (2)
- pseudodistomine E (2)
- qNMR (2)
- random chemistry (2)
- regulation (2)
- screening (2)
- spiral jet mill (2)
- staphylococcus aureus (2)
- stereoselektive Synthese (2)
- strategy (2)
- structure-activity relationship (2)
- structure-activity relationships (2)
- sympathetic nervous system (2)
- tandem Wittig-[3+2]-cycloaddition reaction (2)
- therapy (2)
- thermogenesis (2)
- trypanosomiasis (2)
- Öl (2)
- "Random Chemistry" (1)
- (+)-Catechin (1)
- - (1)
- 1 (1)
- 17beta-Estradiol (1)
- 17beta-estradiol (1)
- 2 (1)
- 2,5-diketopiperazines (1)
- 2-(Phenylsulfonylmethyl)-piperidin (1)
- 2-(Phenylsulfonylmethyl)-piperidine (1)
- 2-Thiazaphospholidines (1)
- 2-a:6 (1)
- 2-chloro (1)
- 2-halo (1)
- 2-imino- (1)
- 3 (1)
- 3 D bioprinting (1)
- 3-(R)-Hydroxysäuren (1)
- 3-(R)-hydroxy acids (1)
- 3-dipolar cycloaddition (1)
- 3-dipolare Cycloaddition (1)
- 4-Chinolonamid (1)
- 4-dial (1)
- 4-quinolone (1)
- 4-quinolone-derivatives (1)
- 4D-QSAR (1)
- 5-Aminopiperidylessigsäuren (1)
- 5-Dimethyl-4-hydroxy-3(2H)-furanon (1)
- 5-Dimethyl-4-hydroxy-3(2H)-furanone (1)
- 5-Dimethyl-4-methoxy-3(2H)-furanon (1)
- 5-Dimethyl-4-methoxy-3(2H)-furanone (1)
- 5-a']diindol (1)
- 5-a']diindole (1)
- 5-aminopiperidylaceticacid (1)
- 5-b']diindol (1)
- 5-b']diindole (1)
- 5]diazocino[1 (1)
- 77-LH-28-1 (1)
- 8-Oxo-2’-desoxyguanosin (1)
- 8-oxo-2'-deoxyguanosine (1)
- AAA+ ATPase p97 (1)
- ABC-Transporter (1)
- AChE inhibitor (1)
- AD mouse modele (1)
- ADAM-10 (1)
- ADAMTS (1)
- AFM (1)
- AGP (1)
- AL amyloidosis (1)
- AL-Amyloidose (1)
- AOM/DSS (1)
- Acetaminophen (1)
- Acetylcysteinderivate (1)
- Achillea Fragrantissima (1)
- Acrylamid (1)
- Acrylamide (1)
- Actinomycetes (1)
- Active pharmaceutical ingredients (1)
- Acylierte Quercetin-Tri-Glukoside (1)
- Acyltransferasen (1)
- Addukt (1)
- Adenosin (1)
- Adhäsion (1)
- Aerosil (1)
- Aerosile (1)
- Aescin (1)
- Affinitätsindex (1)
- African Trypanosomiasis (1)
- Agomelatin (1)
- Ah Rezeptor (1)
- Ah receptor (1)
- Akt (1)
- Akt/PKB (1)
- Alanyl-Aminopeptidase (1)
- Albendazol (1)
- Albumin (1)
- Aldehyde (1)
- Aldehydreductase (1)
- Aldose Reductase (1)
- Aldose Reduktase (1)
- Aldosteron (1)
- Alkamiden (1)
- Alkamides (1)
- Alkylpyrazine (1)
- Allostere Modulation (1)
- Allosterer Modulator (1)
- Allosteric Modulator (1)
- Allosterisch Modurator (1)
- Alzheimer (1)
- Alzheimer's Disease (1)
- Alzheimer's diseas (1)
- Alzheimer's disease (1)
- Alzheimer′s disease (1)
- Ambulante Behandlung (1)
- Amino Acids (1)
- Aminoethanolderivate (1)
- Aminoglykoside (1)
- Ammoniumverbindungen (1)
- Amphetamin (1)
- Amyloid <beta-> (1)
- Amyloidose (1)
- Anacardic acid derivatives (1)
- Anacardsäurederivate (1)
- Analyse (1)
- Analytical Quality by Design (1)
- Analytik (1)
- Analytische Chemie (1)
- Anandamid (1)
- Angeborene Immunität (1)
- Angiogenese (1)
- Angiotensin II (1)
- Antagonist (1)
- Antibiotic (1)
- Antifungal (1)
- Antigen (1)
- Antigen CD163 (1)
- Antiinfektiva (1)
- Antiinflammatorisch (1)
- Antikörper (1)
- Antimykotika (1)
- Antioxidans (1)
- Antiphlogistikum (1)
- Antitrypanosomal (1)
- Antitrypanosomen (1)
- Antitumor (1)
- Antivira (1)
- Apfelsaft (1)
- Apobec (1)
- Arabischer Kaffee (1)
- Arbutin (1)
- Aromaprofil (1)
- Artemisia dracunculus (1)
- Arthrose (1)
- Arylamine (1)
- Arylgruppe (1)
- Arzneimittelfälschungen (1)
- Arzneimittelwechselwirkung (1)
- Arzneistoffanalytik (1)
- Arzneistoffe (1)
- Arzneistofftransporter (1)
- Aspartat-Proteasen (1)
- Aspergillosis (1)
- Aspergillus (1)
- Asymmetrie (1)
- Asymmetrische Synthese (1)
- Atropin (1)
- Auflösungsraten (1)
- Aufmerksamkeitsdefizit-Syndrom (1)
- Aurora-A (1)
- Aurora-A-MYCN-Komplex (1)
- Automatisierung (1)
- Autoradiographie (1)
- Außenluftfeuchte (1)
- Aza-Peptide (1)
- Aza-Peptides (1)
- Azapeptide (1)
- Aziridin (1)
- Aziridin-2-carboxylate (1)
- Aziridines (1)
- BRAF mutation (1)
- Bacillus megaterium (1)
- Baclofen (1)
- Bacteria (1)
- Bakterien (1)
- Beclomethason (1)
- Beclomethasondipropionat (1)
- Benzimidazole (1)
- Benzodiazepin-Rezeptor-Liganden (1)
- Benzodiazepine receptor ligands (1)
- Beta-2-Rezeptor (1)
- Betalaine (1)
- Betanin (1)
- Betanine (1)
- Bile (1)
- Bindemechanismus (1)
- Bindungsaffinität (1)
- Bindungskonstante (1)
- Bioaccessibility (1)
- Bioaktivität (1)
- Bioanalytik (1)
- Bioavailability (1)
- Bioconjugate (1)
- Biodistribution (1)
- Biofunctionality (1)
- Biofunktionalität (1)
- Biohydroxylierung (1)
- Bioinks (1)
- Biokatalyse (1)
- Biokonversion (1)
- Biologischer Abbau (1)
- Bioreactor System (1)
- Biosensor (1)
- Biostatistik (1)
- Biosynthesis (1)
- Bipyridinediylbisboranes / Redox systems / Cyclovoltammetry (1)
- Bis-Tacrine (1)
- Bisoprolol (1)
- Bisphosphonate (1)
- Bitopic Ligands (1)
- Bivalente Hybridverbindungen (1)
- Blaubeere (1)
- Blinddarm (1)
- Blockcopolymere (1)
- Blut (1)
- Blut-Hirn-Schranke (1)
- Bodenbakterien (1)
- Bronchialasthma (1)
- Brunschwig (1)
- Brust (1)
- Brustdrüse (1)
- Brückenbildung (1)
- Burkholderia pseudomallei Mip (1)
- C-3-substituiert (1)
- C-3-substituted (1)
- CAD detection (1)
- CAR T cells (1)
- CAR T-Zellen (1)
- CCl4-induzierte Leberfibrose (1)
- CD163 (1)
- CE (1)
- CFC replacements (1)
- CNS (1)
- COSMOtherm (1)
- CO‐releasing molecules (CORMs) (1)
- CYP2C9 (1)
- CYP3A4 (1)
- CZE (1)
- CaCo-II-Zellen (1)
- Cabozantinib (1)
- Calmodulin (1)
- Campylobacter jejuni (1)
- Candida auris (1)
- Cannabidiol (1)
- Cannabidivarin (1)
- Cannabinoid Receptor (1)
- Cannabinoide (1)
- Carbocistein (1)
- Carbolin <beta-> (1)
- Carboxylates (1)
- Cassins (1)
- Catechin C-glykoside (1)
- Catechin C-glykosides (1)
- Catechine (1)
- Catecholestrogene (1)
- Catecholmethyltransferase <Catechol-0-Methyltransferase> (1)
- Cecropia telenitida (1)
- Cerulenin (1)
- Characterization (1)
- Charged Aerosol Detektion (1)
- Charged aerosol detection (1)
- Charged aerosol detector (CAD) (1)
- Chemical stability (1)
- Chemische Analyse (1)
- Chemometric (1)
- Chemometrics (1)
- Chewing Gum (1)
- Chinazoline (1)
- Chinazoliniumverbindungen (1)
- Chinazolinone (1)
- Chinolinderivate (1)
- Chinolon <2-> (1)
- Chinolonamide (1)
- Chinolonderivate (1)
- Chinolonderivate <2-> (1)
- Chinolone (1)
- Chinon-oxidoreduktase (1)
- Chirale Trennung (1)
- Chiralität (1)
- Chlorfluorkohlenstoffe (1)
- Chondrogenesis (1)
- Chondrozyten (1)
- Chromatographischer Detektor (1)
- Chromone (1)
- Cisaprid (1)
- Cisapride (1)
- Citrus (1)
- Click-Chemie (1)
- Clotrimazol (1)
- Codon (1)
- Coffea arabica (1)
- Coffein (1)
- Colon-Targeting (1)
- Commercial preparations (1)
- Computational drug-design (1)
- Confocal Raman-Spectroscopy (1)
- Contaminants (1)
- Controlled release (1)
- Corona charged aerosol detector (1)
- Coronavirus (1)
- Counterfeit Medicines (1)
- Cutaneous leishmaniasis (1)
- Cyclo-AMP (1)
- Cycload (1)
- Cycloaddition (1)
- Cyclooxygenase (1)
- Cyperus (1)
- Cystein (1)
- Cystein-Protease (1)
- Cystein-Proteasen (1)
- Cytochrom-P450-Enzym (1)
- Cytochrom-P450-Enzyme, Carboxylesterasen, Glutathion-S-Transferasen (1)
- Cytochromperoxidase (1)
- Cytotoxicity (1)
- Cytotoxiticity-Assay (1)
- DAF-2 (1)
- DNA base excision repair (1)
- DNA-Basen (1)
- DNA-Reparatur (1)
- DNA-encoded library synthesis (1)
- DNA-tagged amines (1)
- DNS-Chip (1)
- DPP IV (1)
- Daptomycin (1)
- Datenanalyse (1)
- Datenauswertung (1)
- Deep Eutectics (1)
- Demethylierung (1)
- Deoxyhypusinhydroxylase (1)
- Derivatization (1)
- Derivsatisierung (1)
- Destillierbücher (1)
- Detektor (1)
- Determination of compound purity (1)
- Deubiquitinasen (1)
- Diazabicyclononan (1)
- Diazabicyclononane (1)
- Diazabicyclononanone (1)
- Dicarbonyl (1)
- Dickdarm (1)
- Dickdarmkrebs (1)
- Differentielle Genexpression (1)
- Differenzierung (1)
- Diffusionskonstante (1)
- Dihydroisochinolinderivate (1)
- Dihydroisochinolinonderivate (1)
- Dihydroxynaphthaline (1)
- Dimere Tacrinverbindungen (1)
- Dimerisierung (1)
- Dioxine (1)
- Dioxygenasen (1)
- Dipeptide (1)
- Diphosphonate (1)
- Direkttablettierung (1)
- Diskriminanzanalyse (1)
- Dissertation (1)
- Docking protein (1)
- Dockingstudien (1)
- Dosis (1)
- Dosislinearität (1)
- Dreistoffgemisch (1)
- Dronabinol (1)
- Druck (1)
- Drug Delivery (1)
- Drug delivery platform (1)
- Drug delivery platforms (1)
- Drug form selection (1)
- Dünnschichtchromatographie (1)
- EA.hy 926 (1)
- EDC-NHS chemistry (1)
- EDTA (1)
- ESI-MS (1)
- East Africa (1)
- Echium spp. (1)
- Effluxpumpen (1)
- Einschlusskomplex (1)
- Einschlussverbindungen (1)
- Electron Density (1)
- Electrospinning (1)
- Elektronendichte (1)
- Elongin-C Protein-Protein Interaktion (1)
- Elongin-C protein-protein interaction (1)
- Enantiodifferenzierung (1)
- Enantiomerüberschuss (1)
- Enantioselectivity (1)
- Encapsulation (1)
- Endothel (1)
- Endothelzelle (1)
- Enoyl-Reduktase (1)
- Enoyl-acyl-carrier-protein-Reductase<Enoyl-[acyl-carrier-protein]-Reductase> (1)
- Enzym (1)
- Enzym Assays (1)
- Enzymatische Aktivität (1)
- Enzymatische Oxidation (1)
- Enzyme (1)
- Enzyme Assays (1)
- Enzyme inhibitor (1)
- Enzymkinetik (1)
- Epoxide (1)
- Erbse (1)
- Erdbeeren (1)
- Erdmandel (1)
- Eriodictyon californicum (1)
- Ersatzstoff (1)
- Eruca sativa Mill. (1)
- Erythromycin (1)
- Escherichia coli (1)
- EspI (1)
- Estradiolkonjugate (1)
- Estrogens (1)
- Ethambutol (1)
- European Pharmacopoeia (1)
- Europäsches Arzneibuch (1)
- Ex vivo (1)
- Ex-Chiral-Pool Synthese (1)
- Excipient selection (1)
- Excipients (1)
- Expiry date (1)
- Expositionsmarker (1)
- Expression (1)
- Exzitotoxizität (1)
- FCKW-Ersatzstoffe (1)
- FGF (1)
- FGF-2 (1)
- FKBP (1)
- FRET (1)
- FRET-Assay (1)
- FRET-assay (1)
- FSME (1)
- FV45 (1)
- FadA5 (1)
- Fatty acids (1)
- Feigenkaktus (1)
- Fentons Reagenz (1)
- Fermentation (1)
- Fertigarzneimittel (1)
- Fest-Flüssig-Extraktion (1)
- Festkörper-NMR (1)
- Festkörper-NMR-Spektroskopie (1)
- Festkörperoberfläche (1)
- Festphasenextraktion (1)
- Fett (1)
- Fettabbau (1)
- Fettgewebe (1)
- Fettkennzahlen (1)
- Fettsäureabbau (1)
- Fettsäuremetabolismus (1)
- Fettsäurestoffwechsel (1)
- Fettsäuresynthese-II (1)
- Feuchtemessung (1)
- Feuchtigkeitsmessung (1)
- Fibrinogen (1)
- Fibroblasten-Aktivierungs-Protein Alpha (1)
- Fl (1)
- FlAsH (1)
- Flammschutzmittel (1)
- Flavonglykoside (1)
- Flavoniden (1)
- Flavonoidstoffwechsel (1)
- Flavonoinds (1)
- Flavor (1)
- Fleisch (1)
- Fleischerzeugnisse (1)
- Flexibilität (1)
- Fluidized bed granulation process (1)
- Fluor-19-NMR-Spektroskopie (1)
- Fluorchinolone (1)
- Fluoreszenz <Motiv> (1)
- Fluoreszenzassay (1)
- Fluoreszenzliganden (1)
- Fluoreszenzmikroskopie (1)
- Fluoreszenzpolarisation (1)
- Fluorine (1)
- Fluorverbindungen (1)
- Flux (1)
- Flüssigkeitschromatographie (1)
- Foldamer (1)
- Foldamere (1)
- Foldamers (1)
- Formaldehyd (1)
- Formulation (1)
- Fraktale Dimension (1)
- Freeze drying (1)
- Freie Energierechnungen (1)
- Freisetzung (1)
- Fruchtreife (1)
- Fruchtsaft (1)
- Fumonisine (1)
- Fumonisins (1)
- Functional properties (1)
- Funktionalisierung <Chemie> (1)
- Funktionalisierung von elektrogesponnenen Fasern (1)
- Furan (1)
- Furanon (1)
- Furanone (1)
- Fälschung (1)
- G-Protein gekoppelte Rezeptor (1)
- G-Protein gekoppelte Rezeptoren (1)
- G-Proteine (1)
- G-protein coupled receptor (1)
- GABA (1)
- GABA-Rezeptor-Agonist (1)
- GABAB (1)
- GABAB receptor agonists (1)
- GABA\(_{A}\) receptor (1)
- GABA\(_{B}\) (1)
- GC-MS-SCD (1)
- GRK2 (1)
- Galle (1)
- Galle <Sekret> (1)
- Gallensalze (1)
- Gallensäuren (1)
- Gartenrauke (1)
- Gas chromatography (1)
- Gaschromatographie (1)
- Gastrointestinaltrakt (1)
- Gefriertrocknung (1)
- Gehaltsbestimmung (1)
- Genanalyse (1)
- Genotoxizität (1)
- Gentoxizität (1)
- Geschichte (1)
- Geschwindigkeit (1)
- Gesundheitsberatung (1)
- Gewebe (1)
- Gewebebindung (1)
- Gewebespende (1)
- Gewebespiegel (1)
- Gewinnung und Funktionale Analyse von Wirkstoffen gegen Infektionskrankheiten (1)
- Gewürz (1)
- Gewürzextrakte (1)
- Glatte Muskulatur (1)
- Glucocorticoids (1)
- Glutamate (1)
- Glutamatrezeptoren (1)
- Glycinrezeptor (1)
- Glycoengineering (1)
- Glykane <N-> (1)
- Glykoside (1)
- Glykosylierung (1)
- Gradient boosted trees (GBT) (1)
- Grüner Kaffee (1)
- Grünnoten (1)
- Guanfacin (1)
- Guanylatcyclase (1)
- Guillain-Barr'e-Syndrom (1)
- Guillain-Barré Syndrom (1)
- Guillain-Barré syndrome (1)
- Gärungsalkohole (1)
- HDMF (1)
- HIC (1)
- HILIC (1)
- HNSCC (1)
- HPLC method development (1)
- HPLC-MS/MS (1)
- HPLC-Methodenentwicklung (1)
- HPLC/UV, HPLC/fluorescence, LC/MS/MS analysis (1)
- HPLC/UV-, HPLC/Fluoreszenz-, LC/MS/MS-Analyse (1)
- HPLC–MS (1)
- HSF-1 (1)
- HSP70 (1)
- HUVEC (1)
- Harn (1)
- Hauptkomponentenanalyse (1)
- Hausner-Faktor (1)
- Haut Baleichung (1)
- Haut Bleichung (1)
- Heatshock Proteins (1)
- Hefeartige Pilze (1)
- Heparansulfat (1)
- Heparin (1)
- Hepatitis-B-Virus (1)
- Herkunft (1)
- Herkunftsnachweis (1)
- Herzschrittmacher (1)
- Hess theorem (1)
- Hess'scher Satz (1)
- Hieronymus (1)
- Hieronymus Brunschwig (1)
- High-performance liquid chromatography (1)
- High-performance liquid chromatography (HPLC) (1)
- Hildegard <von Bingen> (1)
- Hildegard von Bingen (1)
- Hilfsstoffanalytik (1)
- Hirnzelle (1)
- Hitzeschock Proteine (1)
- Hitzeschockproteine (1)
- Honig (1)
- Hsc70 (1)
- Hsp70 (1)
- Humane Afrikanische Trypanosomiasis (1)
- Humanserum (1)
- Hyaliner Gelenkknorpel (1)
- Hybrid (1)
- Hybrid GPCR Ligands (1)
- Hybrid-Molecules (1)
- Hybridliganden (1)
- Hydrogel (1)
- Hydrogels (1)
- Hydrogen-deuterium (1)
- Hydroperoxide (1)
- Hydrophobe Wechselwirkung (1)
- Hydroxycarbonsäuren (1)
- Hydroxylradikal (1)
- Hypoxanthin-Guanin-Phosphoribosyl-Transferase (1)
- Hypoxia (1)
- Hypoxie (1)
- Hülsenfrüchte (1)
- IGF-1 (1)
- IGF-I (1)
- IR (1)
- IRMS (1)
- ISPMF (1)
- Ibuprofen (1)
- Imidates (1)
- Imidoyl halides (1)
- Immunmodulation (1)
- Immunohistologie (1)
- Immunosuppressant (1)
- Immunreaktion (1)
- Immunsuppressiva (1)
- Impact-Faktor (1)
- Impurity Profile (1)
- In vivo (1)
- In vivo studies (1)
- In-vitro-Assays (1)
- Indolderivate (1)
- Infektionskrankheit (1)
- Infusionslösungen (1)
- Inhalation (1)
- Inhalationsmittel (1)
- Inhibitoren der Acetylcholinesterase (1)
- Inhibitorpeptide (1)
- Insulin-like Growth Factor (1)
- Insulin-like growth factor-I (1)
- Integrasen (1)
- Interferon <alpha-2a-> (1)
- Interleukin (1)
- Ion Pairs (1)
- Ionenchromatographie (1)
- Ionenkanal (1)
- Ionenpaarchromatographie (1)
- Ionentauscher (1)
- Ionexchange (1)
- Ionic Liquid (1)
- Ionische Flüssigkeit (1)
- Ionische Flüssigkeiten (1)
- Ipratropiumbromid (1)
- Isochinolinalkaloide (1)
- Isochinolinderivate (1)
- Isocyanate (1)
- Isoindoline (1)
- Isolation and Characterization (1)
- Isolierung <Chemie> (1)
- Isoprostaglandin (1)
- Isotopendiskriminierung (1)
- Isotopenhäufigkeit (1)
- Isotopenmarkierung (1)
- Isotopenmassenspektroskopie (1)
- Isotpe ratio mass spectrometry (1)
- JAK inhibitor (1)
- Jugend (1)
- Jugendliche (1)
- Kaktusfeige (1)
- Kaliumkanal (1)
- Kalorimetrie (1)
- Kaltgepresstes Öl (1)
- Kappa (1)
- Karibisches Meer (1)
- Kaugummi (1)
- Keimling (1)
- Keimung (1)
- Kernrezeptor (1)
- Kernspinrelaxation (1)
- Ketamin (1)
- Ketoacyl-ACP-Synthase <beta-> (1)
- Ketoacyl-ACP-Synthase <beta> (1)
- Ketoacyl-ACP-synthase (1)
- Ketosulfon (1)
- Kinaseinhibitor (1)
- Kind (1)
- Kinder (1)
- Klebsiella pneumoniae (1)
- Klinische Studie (1)
- Kniegelenk (1)
- Knochenpenetration (1)
- Knock out (1)
- Knock-out Maus (1)
- Knorpelbildung (1)
- Kohlenhydrate (1)
- Kohlenmonoxid (1)
- Kohlenstoff-14 (1)
- Kohlenwasserstoffe (1)
- Kohäsion (1)
- Kokristallisation (1)
- Konfokale Mikroskopie (1)
- Konfokale Raman-Spektroskopie (1)
- Konformationsanalyse (1)
- Konformationsänderung (1)
- Konjugate (1)
- Konjugation (1)
- Konzentrat (1)
- Kovalente Inhibitoren (1)
- Kreatinin (1)
- Kristall (1)
- Kristallisation (1)
- Kristallstruktur (1)
- Kupffer-Sternzelle (1)
- LC-ESI/MS/MS (1)
- LMICS (1)
- LPA (1)
- Lactamantibiotikum <beta-> (1)
- Lactone (1)
- Lactose (1)
- Laserbeugungsanalyse (1)
- Lebensmittel (1)
- Lebensmittelanalyse (1)
- Lebensmittelprodukte (1)
- Leber (1)
- Leberfibrose (1)
- Legionella infection (1)
- Legionellen (1)
- Legionelleninfektion (1)
- Legionnaires' Disease (1)
- Legionnaires' disease (1)
- Leishmaniose (1)
- Leitstrukturoptimierung (1)
- Leonhart Fuchs (1)
- Levodopa (1)
- Library of Phytochemicals (1)
- Library of plant species (1)
- Ligand (1)
- Linezolid (1)
- Lipid-Peroxide (1)
- Liposomen (1)
- Lipoxygenase (1)
- Lokaltherapie (1)
- Low-income Countries (1)
- LpxC inhibitors (1)
- Luftfeuchtigkeit (1)
- Lungenentzündung (1)
- Lungengewebe (1)
- Lungenkrebs (1)
- Lungenperfusion (1)
- Lyophilisate zum Einnehmen (1)
- Löslichkeitsstudien (1)
- Löslichkeitsverbesserung (1)
- Lösungsprozess (1)
- M. tuberculosis (1)
- M1 Muscarinic Receptor (1)
- M2 (1)
- M4 (1)
- MALDI-MS (1)
- MD simulation (1)
- MD simulations (1)
- MD-Simulationen (1)
- MDR (1)
- MEEKC (1)
- MEKC (1)
- MIP protein (1)
- MIR-Spektroskopie (1)
- MRONJ (1)
- MRSA (1)
- MS (1)
- MTUS1 (1)
- MYCN (1)
- MYCNv (1)
- Macrogol (1)
- Macrogole (1)
- Macrophage Infectivity Potentiator Protein (1)
- Macrophage infectivity potentiator Protein (1)
- Magnetische Kernresonanz (1)
- Makroarray (1)
- Makrophage (1)
- Manganese Carbonyl ligands (1)
- Mannich-Reaktion (1)
- Manteltiere (1)
- Markierte Verbindungen (1)
- Masernvirus (1)
- Masernvirus Inhibitoren (1)
- Mass spectrometry (1)
- Massenbilanzierung (1)
- Masspectrometry (1)
- Matrix Effekte (1)
- Matrixmetalloproteinase (1)
- Mebendazol (1)
- Mehrkomponentengemische (1)
- Melatonin-Analoga (1)
- Melatoninrezeptorliganden (1)
- Messung (1)
- Metabolisches Syndrom (1)
- Metabolism (1)
- Metabolismusstudien (1)
- Metabolomics (1)
- Metabolomik (1)
- Metabonomics (1)
- Metalloproteinasen (1)
- Metformin (1)
- Method Validation (1)
- Methode der partiellen kleinsten Quadrate (1)
- Methodenentwicklung (1)
- Methylanthranilat (1)
- Methylation (1)
- Methylierung (1)
- Micellare elektrokinetische Kapillarchromatographie (1)
- Microarray (1)
- Microglia (1)
- Microwave Assisted Extraction (1)
- Midazolam (1)
- Mikroorganismen (1)
- Mikroorganismus (1)
- Mikroskopie (1)
- Mikrosphären (1)
- Milchdrüse (1)
- Mineralokortikoidrezeptor (1)
- Mip (1)
- Mip Inhibitoren (1)
- Mip inhibitor (1)
- Mip-Inhibitor (1)
- Mischintensität (1)
- Mitochondrium (1)
- Mitsunobu (1)
- Mizellen (1)
- Modellberechnungen (1)
- Modellbindetasche (1)
- Modellierung (1)
- Modification (1)
- Modifikation von Biokeramiken (1)
- Molecular Docking (1)
- Molecular modelling (1)
- Molekular Modeling (1)
- Molekulardynamik-Simulationen (1)
- Molekulardynamiksimulationen (1)
- Molekulargenetik (1)
- Mometasone furoate (1)
- Mometasonfuroat (1)
- Monocyten (1)
- Monodisperse PDMS (1)
- Monodisperses System (1)
- Monoklonaler Antikörper (1)
- Monomere (1)
- Monozyt (1)
- Monozyten (1)
- Monte Carlo Simulation (1)
- Monte Carlo simulation (1)
- Mucorales (1)
- Mucormycosis (1)
- Mucus (1)
- Mukovisdizose (1)
- Mukoviszidose (1)
- Multidimensionale Skalierung (1)
- Multidrugresistant (1)
- Muscarinic receptor (1)
- Muscarinischer Rezeptor (1)
- Muskelatrophie (1)
- Mutagenitätstest (1)
- Mutationsfrequenz (1)
- Mutationsrate (1)
- Mykobakterien (1)
- Mykotoxine (1)
- Myositis (1)
- N-Acyl-Ethanolaminphosphate (1)
- N-Demethylierung (1)
- N-Glykane (1)
- N-demethylation (1)
- NACE (1)
- NIR-Spektroskopie (1)
- NMR (1)
- NMR Spektroskopie (1)
- NO-sensitive Guanylyl-Cyclase (1)
- NO-sensitive guanylyl cyclase (1)
- NOX-Inhibitoren (1)
- Nahordnung (1)
- Nanaomaterialien (1)
- Nanohärte (1)
- Nanoindentation (1)
- Nanomaterialien (1)
- Nanopartikelsynthese (1)
- Naphthalimide (1)
- Naphthalinderivate (1)
- Naphthaline (1)
- Naproxen (1)
- Natural product hybrids (1)
- Nature-Insipired Synthesis (1)
- Naturidentischer Aromastoff (1)
- Nebenwirkung (1)
- Netzbogenlänge (1)
- Neuroprotection (1)
- Nichtsteroidales Antiphlogistikum (1)
- Nierenfunktion (1)
- Nipah virus (1)
- Nipha-Virus (1)
- Nuclear Receptor (1)
- Nucleinbasen (1)
- Nukleäre Rezeptoren (1)
- O157 (1)
- ONJ (1)
- ORL1 (1)
- Oberflächenbelegung (1)
- Oberflächenfunktionalisierung (1)
- Oberflächenrauhigkeit (1)
- Olivenöl (1)
- Opiatrezeptor (1)
- Opioide (1)
- Opioids (1)
- Oral Fluid (1)
- Orale Antidiabetika (1)
- Orale Applikation (1)
- Organische Sulfide (1)
- Organischer Kationentransporter (1)
- Osmunda regalis (1)
- Osteoporose (1)
- Outflow funnel (1)
- Outlier Detection (1)
- Outlier-Identifizierung (1)
- Oxidativer Stress (1)
- PDGF (1)
- PDGFR (1)
- PET (1)
- PFG-NMR-Spektroskopie (1)
- PI3K/Akt/mTor pathway (1)
- PKC (1)
- PPIase (1)
- PPIase-Aktivität (1)
- PROTAC (1)
- Pachyrhizus erosus (1)
- Paeonia (1)
- Paraffin (1)
- Parameter Quality Oil (1)
- Parenteral (1)
- Pathogenität (1)
- Patulin (1)
- Pektine (1)
- Peptidomimetikum (1)
- Peptidsynthese (1)
- Perfusion (1)
- Perizyten (1)
- Peroxidzahl (1)
- Pflanzen (1)
- Pflanzenextrakt (1)
- Pflanzenextrakte (1)
- Pflanzeninhaltsstoff (1)
- Phachyrhizus erosus (1)
- Pharmacology (1)
- Pharmacy (1)
- Pharmakometrie (1)
- Pharmazeutische Betreuung (1)
- Pharmazeutische Chemie (1)
- Phase separation (1)
- Phase solubility (1)
- Phenolcarbonsäuren (1)
- Phenolic acids (1)
- Phenylethylamine (1)
- Phosphate (1)
- Phosphoantigene (1)
- Phosphor (1)
- Phosphorylierung (1)
- Phytopathogene (1)
- Phytopathogene Pilze (1)
- Phytopharmakon (1)
- Pilocarpin (1)
- Pilokarpin (1)
- Pinus maritima (1)
- Pipecolinsäurederivate (1)
- Piperedinderivate (1)
- Piperidin (1)
- Pitot-Rohr (1)
- Plant extracts (1)
- Plants (1)
- Plasmaproteinbindung (1)
- Plasmaproteine (1)
- Plasmodien (1)
- Plasmodium (1)
- Platelet-derived Growth Factor (1)
- Point-of-Care-testing (1)
- Pollen (1)
- Poly(2-oxazolin) (1)
- Poly(ethylenglykol) (1)
- Poly(glycerol) (1)
- Polyaminstoffwechsel (1)
- Polychlorierte Biphenyle (1)
- Polydimethylsiloxan (1)
- Polygener Risikoscore (1)
- Polyglycerol (1)
- Polymer-Biokonjugate (1)
- Polymilchsäure (1)
- Polyphenol (1)
- Poorly water-soluble drug (1)
- Positronen-Emissions-Tomographie (1)
- Posttranslational modification (1)
- Posttranslationale Änderung (1)
- Potassium channel (1)
- Praziquantel (1)
- Prickly Pear (1)
- Probenaufarbeitung (1)
- Propenderivate (1)
- Prostaglandine (1)
- Prostaglandinsynthase (1)
- Protease Inhibitoren (1)
- Protease Inhibitors (1)
- Protease inhibitors (1)
- Protease-Inhibitor (1)
- Proteaseinhibitoren (1)
- Proteasen (1)
- Protein Expression (1)
- Protein crystal (1)
- Protein-Ligand Bindung (1)
- Proteinkinase C (1)
- Proteolysis-Targeting-Chimera (1)
- Proteomics (1)
- Protic Ionic Liquids (1)
- Protozoen (1)
- Präamplifizierung (1)
- Prämix (1)
- Prävention (1)
- Pseudodistomin C (1)
- Pseudomonas frederiksbergensis (1)
- Psychopharmakon (1)
- Pulmonale Applikation (1)
- Pulmonary delivery (1)
- Purity Control (1)
- Purity control (1)
- Pyridin (1)
- Pyrimidinone (1)
- Pyroglutaminsäure (1)
- Pyrrolizidinalkaloid-N-Oxid (1)
- Pyrrolizidinalkaloide (1)
- Q-T-Verlängerung (1)
- QSPR (1)
- QSPR-Modeling (1)
- QTc-Verlängerung (1)
- Quality ccontrol (1)
- Quantifizierung (1)
- Quantitative 1H NMR (1)
- Quantitative structure-property relationship modeling (QSPR) (1)
- Quercetin (1)
- Quercetinglucuronide (1)
- Quetiapin (1)
- Quinolone Amides (1)
- Quinolone amides (1)
- RESP model (1)
- RMCA (1)
- RNA degradation (1)
- Radikal (1)
- Radikalfänger (1)
- Radioindikator (1)
- Radiopharmaka (1)
- Radiosynthese (1)
- Raman-Spektroskopie (1)
- Raucher (1)
- ReAsH (1)
- Reaktive Zwischenstufe (1)
- Reaktivitätsstudien (1)
- Receptor Dynamics (1)
- Recovery-Aroma (1)
- Red Fruit Oil (1)
- Red Sea (1)
- Registrierende Härteprüfung (1)
- Reinheit <Motiv> (1)
- Reinheitsprüfung (1)
- Release system (1)
- Renin-Angiotensin-Aldosteron-System (1)
- Reproducibility challenges (1)
- Rezeptor-Kinasen (1)
- Rhizom (1)
- Rifampicin (1)
- Risikobewertung (1)
- Risk Assessment (1)
- Robuvit\(^®\) (1)
- Rohkaffee (1)
- Rucola (1)
- Ruxolitinib (1)
- Röstkaffee (1)
- SAR (1)
- SPECT (1)
- SPM (1)
- Salmeterol (1)
- Salz (1)
- Scanner (1)
- Schafgarbe <Gattung> (1)
- Schellack (1)
- Schimmelpilze (1)
- Schistosomiasis (1)
- Schleim (1)
- Schnelltest (1)
- Schrittmacher (1)
- Schwefelorganische Verbindungen (1)
- Schwein (1)
- Schweine-Caecum-Modell (1)
- Schwämme (1)
- Scoring functions (1)
- Scoring-Funktionen (1)
- Scoringfunktionen (1)
- Seide (1)
- Seiden-Fibroin (1)
- Sekundärmetabolit (1)
- Senecio spp. (1)
- Sensor (1)
- Sensoren (1)
- Sensors (1)
- Serogruppe (1)
- Sesquiterpene lactones (1)
- Sesquiterpenlactonen (1)
- Shelf-life (1)
- Silibinin (1)
- Silibinin ester (1)
- Silk Fibroin (1)
- Silk-Fibroin (1)
- Siloxane (1)
- Simulation (1)
- Sitagliptin (1)
- Site-specific protein conjugation (1)
- Solanum tuberosum (1)
- Solubility (1)
- Sorafenib (1)
- Sorbitolfermentierer (1)
- Spannungskontrollierter Ionenkanal (1)
- Species Differences (1)
- Spectrofluorimetry (1)
- Speichel (1)
- Speziesunterschiede (1)
- Sphingosin (1)
- Spiropiperidine (1)
- Spray drying (1)
- Springs and Parachutes (1)
- Sprühtrocknung (1)
- Spumaviren (1)
- Squalen (1)
- Stabilitätsstudien (1)
- Staphylococci (1)
- Staphylococcus (1)
- Statine (1)
- Stenotrophomonas maltophilia (1)
- Stereochemie (1)
- Stereoselektiv (1)
- Sternpolymere (1)
- Stickstoffmonoxid-Synthase (1)
- Stickstoffoxide (1)
- Stoffbilanz (1)
- Strawberry (1)
- Streptomyces (1)
- Streptomyces axinellae (1)
- Streptomycin (1)
- Strukturaufklärungen (1)
- Strukturoptimierung (1)
- Strychnin (1)
- Strychnosalkaloide (1)
- Strömung (1)
- Strömungsverhalten (1)
- Subtraktionsmethoden (1)
- Subtypselektivität (1)
- Sulfatkonjugate (1)
- Sulfonamide (1)
- Sulfonyldiazomethan (1)
- Sulfoxidation (1)
- Synthetische Biologie (1)
- Sythese (1)
- T cell (1)
- T lymphocytes (1)
- T-Lymphoblastomzellen (1)
- T-Lymphozyt (1)
- T-Lymphozyten (1)
- T-Zell-Leukämie (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- TCDD (1)
- TDDFT (1)
- TDM (1)
- TGF-β3 (1)
- TRESK (1)
- TRI (1)
- Tabakrauch (1)
- Tabletten (1)
- Tacrin (1)
- Tandem Mass Spectrometry (1)
- Tandem-Wittig-1 (1)
- Tanzania (1)
- Teilchen (1)
- Terpene (1)
- Terphenyl Derivate (1)
- Terphenylderivate (1)
- Tetrachlormethan (1)
- Tetracystein-Motive (1)
- Tetracystein-Motivee (1)
- Tetrahydro-15aH-azocino[1 (1)
- Tetrahydro[1 (1)
- Tetrahydrochinazoline (1)
- Thalidomid (1)
- Therapeutic Drug Monitoring (1)
- Therapeutikum (1)
- Therpeutisches Drug Monitoring (1)
- Thiazolidindione (1)
- Thin-layer chromatography (1)
- Thiolase (1)
- Tierversuche (1)
- Timolol (1)
- Toll-like-Rezeptoren (1)
- Tongue (1)
- Toxicokinetics (1)
- Toxikokinetik (1)
- Tracer (1)
- Transgene Tiere (1)
- Traubensilberkerze (1)
- Trennung (1)
- Trichter (1)
- Trimebutin (1)
- Trockenblutanalytik (1)
- Tropenkrankheit (1)
- Trypanosoma brucei brucei (1)
- Trypanosoma cruzi (1)
- Tuberculosis (1)
- Tumorsuppressor-Gen (1)
- Typanosoma (1)
- Tyrosinase (1)
- UHPLC (1)
- UHPLC-ESI-MS/MS (1)
- UV Schutzen (1)
- UV Schuzen (1)
- Ugi-Reaktion (1)
- Ugi-azide reaction (1)
- Universität Würzburg. Lehrstuhl für Pharmazeutische Technologie und Biopharmazie (1)
- Unterernährung (1)
- V. wallichii (1)
- Vaccinium myrtillus <Homöopathie> (1)
- Van-der-Waals-Kraft (1)
- Vascularisation (1)
- Verderb (1)
- Verfügbarkeit (1)
- Vernetzung <Chemie> (1)
- Verunreinigugsprofil (1)
- Verunreinigungen (1)
- Virtual Screening (1)
- Virusrezeptor (1)
- W84 (1)
- Wachstumshemmung (1)
- Wanderratte (1)
- Wassereinflüsse (1)
- Weakly chromophore impurities (1)
- West Africa (1)
- Wirkstoff-Rezeptor-Bindung (1)
- Wissenschaftliches Arbeiten (1)
- Wittig-reaction (1)
- Wurmmittel (1)
- Würzburg / Sonderforschungsbereich Erkennung (1)
- Xanomeline (1)
- Xanthinoxidase (1)
- Xenobiotikum (1)
- Zelloberfläche (1)
- Zellwand (1)
- Zellzyklus (1)
- Zentralnervensystem (1)
- Zerkleinerungsverhalten (1)
- Ziest (1)
- Zigarettenrauch (1)
- Zucker (1)
- Zuckerphosphat (1)
- Zugpannung (1)
- Zugspannungstester (1)
- Zunge (1)
- Zuordnung (1)
- Zygosaccharomyces (1)
- Zygosaccharomyces rouxii (1)
- Zytotoxizität (1)
- \(^{1}\)HNMR (1)
- abiotische (1)
- absolute bioavailability (1)
- absorption (1)
- acebutolol (1)
- acetic acid (1)
- acetones (1)
- acetonitrile (1)
- acetylcholinesterase (1)
- acetylcholinesterase inhibitors (1)
- acid value (1)
- acids (1)
- activation (1)
- active pharmaceutical ingredient (1)
- active pharmaceutical ingredients (1)
- acylated quercetin-tri-glucosides (1)
- additive manufacturing (1)
- adduct (1)
- adipose tissue (1)
- adipose tissue engineering (1)
- adolescents (1)
- advanced drug delivery system (1)
- afatinib (1)
- affinity (1)
- agar diffusion test (1)
- agomelatine (1)
- air humidity (1)
- aldehydes (1)
- alignment (1)
- alignment-free (1)
- alignment-frei (1)
- alkylpyrazines (1)
- allergic rhinitis (1)
- allostere Modulation (1)
- allosterischer Effektor (1)
- alpha Glucosidase (1)
- alpha-Dioxygenase (1)
- alpha-Oxidation (1)
- alpha-Sekretase (1)
- alpha-dioxygenase (1)
- alpha-oxidation (1)
- alzheimer's disease (1)
- amber codon suppression (1)
- amber light (1)
- aminopeptidase N (1)
- ammonium compounds (1)
- amorph (1)
- amorphous (1)
- amorphous solid dispersion (1)
- ampicillin (1)
- amyloid beta (1)
- amyloid-β (Aβ) (1)
- anandamide (1)
- angiogenesis (1)
- angiotensin II type 1 receptor (1)
- animal studies (1)
- anisotropy (1)
- anthocyanin (1)
- anthocyans (1)
- anti-infectives (1)
- anti-inflammatory activity (1)
- anti-inflammatory cytokines (1)
- anti-proliferative effects (1)
- anti-protease (1)
- anti-schistosomal activity (1)
- anti-trypanosomal (1)
- antibacterial activity (1)
- antibacterials (1)
- antibiotic bone concentration (1)
- antifungal (1)
- antifungal drug (1)
- antiinflammatory (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- antioxidant (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- antiviral agents (1)
- antiviral drugs (1)
- arbutin (1)
- arching (1)
- aroma profile (1)
- aspartic proteases (1)
- asthma (1)
- at-home sampling (1)
- atropine (1)
- autoinjector (1)
- automation (1)
- autophagy (1)
- availability (1)
- aziridin (1)
- aziridine (1)
- baclofen homologues (1)
- beclomethasone (1)
- beta-Oxidation (1)
- beta-lactam (1)
- beta-lactam antibiotics (1)
- beta-oxidation (1)
- betony (1)
- bile (1)
- bile salt (1)
- binding (1)
- binding affinity (1)
- binding analysis (1)
- binding constant (1)
- binding mechanism (1)
- bio-orthogonal chemistry (1)
- bioactivity (1)
- bioassay (1)
- bioassay-guided fractionation (1)
- bioavailability (1)
- biocatalysis (1)
- bioceramics (1)
- biochemical simulations (1)
- biocide polyhexamethylene biguanide (1)
- bioconjugation (1)
- biodegradable polymer (1)
- biodiversity (1)
- biohydroxylation (1)
- bioisosterism (1)
- biologics (1)
- biologische Körperflüssigkeiten (1)
- biomaterials (1)
- biophysics (1)
- bioresponsive (1)
- biosensor (1)
- biosynthesis (1)
- biotransformation (1)
- bisphosphonates (1)
- bitopic hybrid ligands (1)
- bitopic ligand (1)
- bitopic ligands (1)
- bivalent hybrid compounds (1)
- black cohosh (1)
- blood brain barrier (1)
- blood plasma (1)
- blueberry (1)
- boat conformation (1)
- bone marrow (1)
- bone penetration (1)
- breakage behaviour (1)
- bridge (1)
- bronchial tissue (1)
- brucei (1)
- bulk powder (1)
- bulk solid (1)
- cAMP (1)
- cDNA-Array (1)
- cDNA-array (1)
- cGMP (1)
- caffeic acid bornyl ester (1)
- calmodulin (1)
- calorimetry (1)
- carbamate (1)
- cardiac innervation imaging (1)
- cardiac neurohormonal system (1)
- cartilage (1)
- cartilage tissue engineering (1)
- catechines (1)
- cathepsin (1)
- cecropia telenitida (1)
- cefotiam (1)
- cell metabolism (1)
- cells (1)
- cerebEND cells (1)
- cerulenin (1)
- chemical crosslinking (1)
- chemically programmable (1)
- chemisch programmierbar (1)
- chemometrics (1)
- chemotherapy (1)
- chenopodium quinoa (1)
- children (1)
- chiral (1)
- chiral recognition (1)
- chiral resolution (1)
- chirale Erkennung (1)
- cholesterol and oxy-cholesterol (1)
- cholinergic system (1)
- cholinesterase (1)
- cholinesterase inhibitors (1)
- cholinesterases inhibitors (1)
- chronic IBD model (1)
- circular dichroism (1)
- cis-2-Buten-1 (1)
- citrus (1)
- clinical pharmacy (1)
- co-delivery (1)
- cocrystal (1)
- cofactors (biochemistry) (1)
- cohesion (1)
- cohesive bulk powder (1)
- cold stress (1)
- colloid (1)
- colon-targeting (1)
- commercial preparations (1)
- complementary medicine (1)
- computational chemistry (1)
- concentrate (1)
- confocal Raman-spectroscopy (1)
- conformational anylysis (1)
- contaminants (1)
- continuous ultrafiltration (1)
- counterfeit drugs (1)
- coupled (1)
- crithidia fasciulata (1)
- crystalline (1)
- crystallization (1)
- cystein (1)
- cystein protease inhibitor QSAR (1)
- cysteine proteases (1)
- cystic fibrosis (1)
- cytochrome P450 enzyme (1)
- cytochrome P450 enzymes, carboxylesterases, glutathione S-transferases (1)
- cytochrome-P-450 (1)
- cytokine modulation (1)
- cytokine production (1)
- dabrafenib (1)
- decafluoroazobezene (1)
- degradation of fatty acids (1)
- dehydration (1)
- deoxyhypusinhydroxylase (1)
- derivates (1)
- derivatisation (1)
- design of experiments (1)
- detector (1)
- device-related infections (1)
- diabetes (1)
- dicarbonyl (1)
- differentiation (1)
- diffusion constant (1)
- diketopiperazines (1)
- dimere Liganden (1)
- dimeric ligands (1)
- dimeric strychnine ligands (1)
- dioxins (1)
- discovery (1)
- dissolution (1)
- dissolution rates (1)
- distillation books (1)
- dose individualization (1)
- dose linearity (1)
- dried bilberries (1)
- drug formulation (1)
- drug impurities (1)
- drug metabolism (1)
- drug monitoring (1)
- drug-delivery systems (1)
- dualsteric (1)
- dualsteric ligand (1)
- effector Treg (eTreg) (1)
- efflux pumps (1)
- elastic-plastic properties (1)
- elastischer Eindringmodul (1)
- electroactive (1)
- electrohydrodynamic (1)
- electrophoresis (1)
- electrospun fibers (1)
- emulsions oil-in-water (1)
- enantiodifferentiation (1)
- enantiomer (1)
- enantiomerenrein (1)
- enantiomers (1)
- enantiopure (1)
- enantioselectivity (1)
- encapsulation (1)
- endothelial cell (1)
- enoyl reductase (1)
- enoyl-ACP reductase inhibitors (1)
- enoyl-ACP-reductase (1)
- enterohepatic recirculation (1)
- enzyme kinetics (1)
- enzymes (1)
- ephedrine (1)
- epitope mapping (1)
- epoxides (1)
- erythromycin (1)
- esculentus (1)
- ester value (1)
- ethanol (1)
- ethanolaminphosphate (1)
- ethers (1)
- eugenyl cinnamate (1)
- evaporation based detectors (1)
- evaporationsbasierte Detektoren (1)
- ex vivo (1)
- ex vivo Modell (1)
- ex-chiral-pool synthesis (1)
- exchange reaction (1)
- excipient (1)
- excitotoxicity (1)
- experimental visceral leishmaniasis (1)
- expression (1)
- extra cellular matrix (1)
- extraction (1)
- fatty acid metabolism (1)
- fatty acid methyl ester (1)
- fatty acid synthesis II (1)
- fenoterol (1)
- fermentation (1)
- fermentation alcohols (1)
- field testing (1)
- flame retardants (1)
- flavonoid (1)
- flexibility (1)
- flow (1)
- flow properies (1)
- flow properties (1)
- flow-conditioners (1)
- fluidised bed granulation (1)
- fluorescence (1)
- fluorescence polarization (1)
- fluorescence resonance energy transfer (1)
- fluorescent ligands (1)
- fluorescent probes (1)
- fluorimetric assay (1)
- fluorine-18 (1)
- fluoroquinolone (1)
- fluoroquinolones (1)
- fluticasone propionate (1)
- flux (1)
- foamy virus (1)
- food (1)
- food safety (1)
- formaldehyde (1)
- forms (1)
- formulation development (1)
- fractal dimension (1)
- fractionation (1)
- fragment screening (1)
- fragment-based design (1)
- free energy calculations (1)
- free fatty acids (1)
- free radicals (1)
- fruit juice (1)
- funktionale Präpolymere (1)
- furan (1)
- furanone (1)
- gallotannins (1)
- gamma delta (1)
- gastrointestinal (1)
- gastrointestinal tract (1)
- genetic codon expansion (1)
- genetics (1)
- genotoxicity (1)
- gentamicin (1)
- gentamicin sulfate (1)
- germination (1)
- getrocknete Heidelbeeren (1)
- glidant (1)
- glucocorticoids (1)
- glucos metabolism (1)
- glucose (1)
- glucose lowering (1)
- glutamate receptors (1)
- glutamates (1)
- glycocalyx (1)
- glycolytic flux control (1)
- gprotein (1)
- gradient HPLC–UV (1)
- green coffee beans (1)
- green notes (1)
- gut microbiota; bioactivation; polyphenols; complex carbohydrates; tryptophan (1)
- hMSC-TERT (1)
- halo olefines (1)
- hardness (1)
- head and neck carcinoma (1)
- heart failure (1)
- heat shock response (1)
- hepatotoxicity (1)
- herbal books (1)
- high performance liquid chromatography (1)
- high throughput screening (1)
- high-resolution tandem mass spectrometry (1)
- high-throughput screening (1)
- histamine (1)
- history (1)
- homodimerization (1)
- homology modeling (1)
- honey (1)
- honeybee (1)
- honeybees (1)
- hplc (1)
- human African trypanosomiasis (1)
- human mesenchymal stem cells (1)
- human metabolism (1)
- human nutrition (1)
- human plasma (1)
- human receptor kinetics (1)
- humane mesenchymale Stammzellen (1)
- hybrid ligands (1)
- hybrid molecules (1)
- hydnocarpin (1)
- hydrogels (1)
- hydrogen bonding (1)
- hydrogen bonding mycobacterium tuberculosis (1)
- hydrolysis (1)
- hydroperoxides (1)
- hydrophile Interaktionschromatographie (1)
- hydrophilic interaction chromatography (1)
- hydroxy-dabrafenib (1)
- hypertension (1)
- hypoxia (1)
- hysterectomy (1)
- imaging (1)
- immunomodulatory (1)
- impurity profile (1)
- impurity test (1)
- in vitro dissolution methods (1)
- in vitro dissolution testing (1)
- in vitro-in vivo correlation (1)
- in vitro/in vivo Korrelation (1)
- in vitro/in vivo correlation (1)
- in vivo dissolution (1)
- in-vitro-assays (1)
- inclusion complex (1)
- infectious disease (1)
- influences of water (1)
- information technology (1)
- infusion solutions (1)
- inhibition (1)
- injectable protein formulation (1)
- innate immunity (1)
- interleukin-4 (1)
- intermolecular forces (1)
- intermolekulare Kräfte (1)
- internal transcribed spacer 2 (1)
- interparticular forces (1)
- interpartikuläre Haftkräfte (1)
- interpretable (1)
- interpretierbar (1)
- intestinal availability (1)
- intestinal mucus (1)
- intestinal permeability (1)
- intestinale Verfügbarkeit (1)
- intramolecular Michael addition (1)
- intranasal (1)
- intranasal corticosteroids (1)
- intrinsic metabolism (1)
- invasion (1)
- iodine value (1)
- ion-chromatography (1)
- ionic liquids (1)
- ipratropium bromide (1)
- irreversibel (1)
- irreversible (1)
- irreversible Inhibitoren (1)
- irreversible inhibitors (1)
- isocyanide multicomponent reactions (1)
- isoindolines (1)
- isolated reperfused lung (1)
- isolation (1)
- isomerization (1)
- isoprostaglandin (1)
- isosteviol sodium (1)
- isotopically labelled peptides (1)
- istotope discrimination (1)
- jaw bone (1)
- kappa-B activation (1)
- kasA (1)
- ketamine (1)
- kinase inhibitor (1)
- kinase inhibitors (1)
- konfokale Raman-Spektroskopie (1)
- kontinuierliche Ultrafiltration (1)
- kristallin (1)
- lactams (1)
- laser diffraction analysis (1)
- lattice forces (1)
- lead optimization (1)
- lead structure optimization (1)
- leaves (1)
- levodopa (1)
- ligandenselektive Konformationen (1)
- lignaselective conformations (1)
- linear discriminant analysis (1)
- lipid deterioration (1)
- lipid deterioration markers (1)
- liposomes (1)
- lipoxygenase <5-> (1)
- liquid chromatography electrospray ionization tandem mass spectrometry (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liquid chromatography-mass spectrometry (1)
- liver (1)
- liver impairment (1)
- lower urinary tract (1)
- lowering lattice forces (1)
- lung (1)
- lung perfusion model (1)
- mRNA level (1)
- mRNA-Spiegel (1)
- maceration (1)
- macroarray (1)
- macrophage (1)
- macrophage infectivity potentiator (1)
- macrophage infectivity potentiator protein (1)
- macrophages (1)
- magnesium stearate (1)
- mammary gland (1)
- mannich reaction (1)
- manufacturer (1)
- marine metagenomics (1)
- marine natural products (1)
- marine organisms (1)
- marine sponges (1)
- maritime pine bark extract (1)
- markers of exposure (1)
- mass balance (1)
- matrix metalloproteinases (1)
- measurement of humidity (1)
- meat (1)
- meat products (1)
- mechanistic drug-drug interactions (1)
- mechanistische Arzneistoffinteraktionen (1)
- mechanochemical degradation (1)
- medicine authentication tools (1)
- medieval (1)
- medieval herbal books (1)
- melanoma (1)
- melatonin (1)
- melatonin analogues (1)
- melatonin receptor ligands (1)
- membrane (1)
- metabolic glycoengineering (1)
- metabolic network (1)
- metabolic network model (1)
- metabolic syndrome (1)
- metabolisches Netzwerk (1)
- metabolite (1)
- metabonomics (1)
- metastasis (1)
- method development (1)
- methylanthranilate (1)
- micelles (1)
- microemulsion (1)
- microscopy (1)
- microspheres (1)
- mikroorganisms (1)
- mixed-mode chromatography (1)
- mixing conditions (1)
- mobile apps (1)
- model binding site (1)
- modelling (1)
- modelling of a spiral jet mill (1)
- modified monosaccharides (1)
- molecular biopharmaceutics (1)
- molecular dynamic (1)
- molecular dynamics simulations (1)
- molecular mechanics (1)
- molecular systematics (1)
- molekulares Modellieren (1)
- monoclonal antibodies (1)
- monocyte (1)
- monocytes (1)
- monoklonale Antikörper (1)
- mucin (1)
- multicomponent Ugi-type reaction (1)
- multicomponent drugs (1)
- multiple muyloma (1)
- muscarinic (1)
- muscarinic M1 receptor (1)
- muscarinic acetylcholine receptor (1)
- muscarinic acetylcholine receptors (1)
- mutagenicity (1)
- mutation frequency (1)
- mycobacterium tuberculosis (1)
- mycotoxins (1)
- nano-material (1)
- nanomaterials (1)
- nanoparticle synthesis (1)
- nanoparticles (1)
- naphthalenes (1)
- natural ligands (1)
- natural product (1)
- natural product hybrids (1)
- natürliche Liganden (1)
- nerve agent (1)
- network chain length (1)
- neue Inhibitorklasse (1)
- neue Verunreinigungen (1)
- neuroblastoma cell (1)
- neuroprotective (1)
- neuroprotectivity (1)
- new impurities (1)
- new inhibitor class (1)
- nichtpeptidische Inhibitoren (1)
- nicotinic receptors (1)
- non-chromophore analytes (1)
- non-peptidic inhibitors (1)
- non-racemic (1)
- nonhuman primates (1)
- novel nepetolactone derivative (1)
- nuclear cardiology (1)
- nuclear magnetic resonance spectroscopy (1)
- nucleobases (1)
- oak wood (1)
- oak wood extract (1)
- obtusifolia bertol (1)
- octopamine receptors (1)
- oleanane saponins (1)
- olive oil (1)
- online monitoring system (1)
- opioid ligands (1)
- opioid receptors (1)
- oral anticancer drugs (1)
- oral drug absorption (1)
- oral lyophilisate (1)
- oral microbiome (1)
- orale Bioverfügbarkeit (1)
- ortho-Phthaldialdehyd (1)
- ortho-phthaldialdehyd (1)
- osimertinib (1)
- osteochondral implant (1)
- osteoprosis (1)
- oxidative Stressmarker (1)
- oxidative stress (1)
- oxidative stress marker (1)
- oxime (1)
- oxygen (1)
- oxytosis/ferroptosis (1)
- p-Glykoprotein (1)
- paraffins (1)
- parasite (1)
- parasitic (1)
- parasitär (1)
- paromomycin (1)
- particle (1)
- particle surface (1)
- patch clamp recording (1)
- pectins (1)
- pefloxacin (1)
- pentacyclic triterpene (1)
- peptide sensors (1)
- peptide stapling (1)
- peptidomimetic (1)
- peptidomimetisch (1)
- perfluoroarylation (1)
- peri-implant disease (1)
- permeation (1)
- personalized antimicrobial therapy (1)
- pharmaceutical care (1)
- pharmacodynamic (1)
- pharmacological evaluation (1)
- pharmacology (1)
- pharmacometrics (1)
- pharmacy (1)
- phase-solubility (1)
- phenolic acids (1)
- phenylethylamine (1)
- phosphoantigens (1)
- phosphoglycolate phosphatase (1)
- phosphorus (1)
- phosphorylation (1)
- photocontrol (1)
- photopharmacology (1)
- phylogenetic analysis (1)
- phylogenetic tree (1)
- phylogeny (1)
- phytochemicals (1)
- phytochemistry (1)
- phytomedicine (1)
- phytoneering (1)
- phytopathogens (1)
- pig (1)
- pig-caecum-model (1)
- pipecolic acid derivatives (1)
- piperacillin/tazobactam (1)
- piperidin alcaloids (1)
- piperidines (1)
- pitot tube (1)
- plant extracts (1)
- plants (1)
- plasma protein binding (1)
- plasma proteins (1)
- podophyllotoxin (1)
- pollen (1)
- poly(2-ethyl-2-oxazoline) (1)
- poly(dimethylsiloxane) (1)
- polyamine pathway (1)
- polychlorinated biphenyls (1)
- polyethylenglykole (1)
- polylactid (1)
- polymer drug interaction (1)
- polymer processing (1)
- polymers (1)
- polysorbate 80 (1)
- poor water-soluble drugs (1)
- poorly water soluble (1)
- poorly water soluble drugs (1)
- posaconazole (1)
- positron-emission-tomography (1)
- post-operative recovery (1)
- post-surgery recovery (1)
- postsurgical adhesion (1)
- posttranscriptional modification (1)
- posttranskriptionale Modifikation (1)
- powder (1)
- premix (1)
- pressure (1)
- pressurized microwave‐assisted extraction (1)
- prevention (1)
- principal component analysis (1)
- pro-inflammatory cytokines (1)
- process of solution (1)
- procyanidines (1)
- procyanidins (1)
- profiles (1)
- proliferation (1)
- propionate (1)
- protease inhibition (1)
- protease-sensitive release (1)
- proteasome system (1)
- protein (1)
- protein engineering (1)
- protein ligand interactions (1)
- protein modification (1)
- protein nebulization (1)
- protein therapeutics (1)
- pseudodistomine C (1)
- psidium guajava; (1)
- pulmonal (1)
- pulmonary absorption (1)
- purification (1)
- purity control (1)
- pyridine (1)
- pyridobenzodiazepine (1)
- pyroglutamic acid (1)
- pyrrolizidine alkaloid N-oxide (1)
- pyrrolizidine alkaloids (1)
- qPCR (1)
- quality evaluation (1)
- quantification (1)
- quantitativ (1)
- quantitative (1)
- quantitative 1H NMR (1)
- quantitative NMR spectroscopy (1)
- quantitative analysis (1)
- quantum mechanics (1)
- quercetin (1)
- quercetin glucuronides (1)
- quinolones (1)
- quinone oxidoreductase (1)
- radiosynthesis (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- randomized controlled study (1)
- rat study (1)
- reactive metabolites (1)
- reaktive Metabolite (1)
- receptor (1)
- receptors (1)
- recovery aroma (1)
- red blood cells (1)
- red fruit oil (1)
- relation (1)
- relaxation (1)
- remodeling (1)
- renal cell carcinoma (1)
- renin-angiotensin system (1)
- replica-exchange molecular dynamics (1)
- required hydrophilic–lipophilic balance (1)
- residence time (1)
- resistance (1)
- response surface (1)
- ribosomal RNA (1)
- roast coffee (1)
- rocket salad (1)
- ruxolitinib (1)
- sacha inchi oil (1)
- saponification Value (1)
- saturation transfer difference NMR (1)
- scanner (1)
- scar revision surgery (1)
- schistosmiasis (1)
- schistosoma (1)
- schistosomula (1)
- schwefelhaltige Aromastoffe (1)
- schwer wasserlöslich (1)
- scoring functions (1)
- secondary structure (1)
- secreted aspartic proteases (1)
- secretion (1)
- sekretorische Aspartatproteasen (1)
- sensor (1)
- sensory chewing gums (1)
- serjanic acid (1)
- serum (1)
- shellac (1)
- short-range order (1)
- silk fibroin (1)
- silybin (1)
- simple (1)
- simulated intestinal fluid (1)
- single-molecule microscopy (1)
- sisomicin (1)
- site-specific protein modification (1)
- skin whitening (1)
- smooth muscle (1)
- soil-transmitted helminthiases (1)
- solid dispersion (1)
- solid state NMR spectroscopy (1)
- solid-state NMR spectroscopy (1)
- sorbitol-fermenters (1)
- spectrofluorimetry (1)
- sphingomonads (1)
- spice extracts (1)
- spices (1)
- spiropiperidines (1)
- spray (1)
- squalene (1)
- stability (1)
- steered molecular dynamics (1)
- stereoselective (1)
- sterubin (1)
- strawberry (1)
- streptomyces (1)
- structural elucidation (1)
- structure-based drug design (1)
- structure–activity relationships (1)
- strychnine (1)
- subcutaneous fat layer (1)
- substandard and falsified medicines (1)
- subtractive-methods (1)
- subtype selectivity (1)
- sugar phosphate (1)
- sulfoxidation (1)
- sulfur containing flavour compounds (1)
- sun screening (1)
- surface coverage (1)
- surface functionalization (1)
- surface roughness (1)
- synovial fluid (1)
- system (1)
- tablets (1)
- tacrine (1)
- tandem mass spectrometry (1)
- tandem-Wittig-1 (1)
- tensile strength tester (1)
- tensile strengths (1)
- terphenyl derivatives (1)
- tetromycin (1)
- thalidomide (1)
- therapeutic gases (1)
- therapeutic strategy (1)
- therapeutisches Target (1)
- thermodynamic (1)
- thermodynamics (1)
- thin-layer chromatography (1)
- thymyl cinnamate (1)
- timololmaleate (1)
- tofacitinib (1)
- toll-like receptors (1)
- tongue (1)
- topical treatment (1)
- total synthesis (1)
- toxicity (1)
- track and trace (1)
- trametinib (1)
- transcriptome (1)
- transglutaminase (1)
- translationally and rotationally invariant (1)
- translations- und rotationsinvariant (1)
- transport (1)
- treatment regimens (1)
- triacylglycerides (1)
- tropische Infektionskrankheiten (1)
- trypanosoma cruzi (1)
- tuberculosis (1)
- tumor suppressor gene (1)
- two-dimensional (1)
- type 2 diabetes (1)
- tyrosinase (1)
- underutilized legumes (1)
- unnatural amino acid (1)
- unsaturated fatty acids (1)
- unterer Harntrakt (1)
- urolithins (1)
- ursolic acid (1)
- vacuoles (1)
- valsartan (1)
- valtrates (1)
- vascularized fat construct (1)
- velocity (1)
- veterinarians (1)
- veterinary medicine (1)
- vif (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- volumetric absorptive microsampling (1)
- watersolubility (1)
- young’s modulus (1)
- zweidimensional (1)
- HILIC (1)
- Ölsäure (1)
- ß-Carbolinalkaloide, 7-Alkyloxycumarine, Clopidogrel, Paracetamol (1)
- ß-Carboline (1)
- ß-carboline alkaloids, 7-alkyloxycoumarins, clopidogrel, acetaminophen (1)
- ß-carbolines (1)
- β2 - Agonisten (1)
- β2 - agonist (1)
Institute
- Institut für Pharmazie und Lebensmittelchemie (403) (remove)
Sonstige beteiligte Institutionen
- Universität Belgrad, Serbien (2)
- ACC GmbH Analytical Clinical Concepts (1)
- Apotheke, Universitätsklinikum Würzburg (1)
- Bayer AG, Research & Development, Pharmaceuticals, Investigational Toxicology (1)
- Bundesinstitut für Arzneimittel und Medizinprodukte (1)
- Friedrich-Schiller-Universität Jena (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-9708 Wuerzburg, Germany (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-97080 Wuerzburg, Germany (1)
- IBMP - Institut für Biomedizinische und Pharmazeutische Forschung in Nürnberg-Heroldsberg (1)
- Johns Hopkins School of Medicine (1)
EU-Project number / Contract (GA) number
- 26230120009 (1)
- 296679 (1)
- 311932 (1)
- 314911 (1)
- 701983 (1)
Dietary fatty acids serve as objective biomarkers for the estimation of habitual diet mainly because biomarkers are free of memory bias or inaccuracies of food databases. The aim of the present work encompassed the implementation of a gas chromatographical method coupled with a mass spectrometrical and flame-ionization detector for analysis of fatty acid biomarkers in human biospecimens, their analytical determination and statistical evaluation in two different study populations and different biospecimens as well as the elaboration of adverse reactions to food ingredients with special focus on food allergies and food intolerances in the context of a possible implementation into an application for consumer health. The first aim was the identification of potential influence of fatty acid biomarkers on desaturase and elongase indexes (Δ9DI, Δ6DI, Δ5DI and ELOVLI5), which are factors in type 2 diabetes risk, in breast adipose tissue from healthy women. Influence of further variables on respective indexes was also investigated. 40 samples were investigated and potential variables were either collected by questionnaire or determined. Principle component analysis was applied for fatty acid biomarkers (PCdiet1, PCdiet2 and PCdiet3 representative for the dietary intake of vegetable oils/nuts, fish and partially hydrogenated vegetable oils), endogenous estrogens (PCE1) and oxysterols (PCOxy1). Multiple linear regression models were applied. Δ9DI and Δ6DI were influenced non-significantly and significantly negatively by PCdiet2 supporting a putative beneficial effect of vegetable oils and nuts on type 2 diabetes risk factors. ELOVLI5 and Δ5DI were influenced significantly and non-significantly positively by PCdiet1 supporting a putative beneficial effect of fish consumption on type 2 diabetes risk factors. On the other hand, PCdiet1 also significantly and non-significantly positively influenced Δ9DI and Δ6DI supporting a putative adverse effect of fish biomarkers on type 2 diabetes risk factors. The opposing influences of PCdiet1 suggesting an ambivalent role of dietary intake of fish on investigated indexes. Δ6DI was significantly positively influenced by PCdiet3 and number of pregnancies supporting a putative adverse effect of partially hydrogenated vegetable oils and pregnancies on type 2 diabetes risk factors. Lifestyle factors like smoking significantly and non-significantly influenced Δ9DI and Δ6DI putatively adversely. Δ5DI was influenced significantly positively by estrogen active drugs suggesting a putative beneficial effect on type 2 diabetes risk factors. It must be considered that a variation coefficient of up to 0.44 only explained 44% of variance of the respective indexes, suggesting other influencing factors might play a role. The second aim was the implementation of a gas chromatographical method coupled with a mass spectrometrical and flame-ionization detector for analysis of fatty acid biomarkers in human biospecimens. The method was optimized for separation and detection of 40 fatty acids. Mean recovery for tridecanoic acid was x(tridecanoic acid) = 90.51% and for nonadecanoic acid x(nonadecanoic acid) = 96.21%. Thus, there was no significant loss of fatty acids with shorter and longer carbon chains over the extraction process to be expected. Limit of detections were calculated in adipose tissue samples and ranged from 0.007 to 0.077% of the proportion of the respective fatty acid to total fatty acids. The third aim was the investigation if differentiation between breast glandular and adipose tissue had a relevant impact on the analysis of dietary fatty acid biomarkers or if contamination of breast glandular with breast adipose tissue and vice versa was neglectable for the analysis of dietary fatty acid biomarkers. No statistical significant differences were observed for all investigated fatty acid biomarkers (pentadecanoic-, heptadecanoic-, trans palmitoleic-, eicosapentaenoic-, docosahexaenoic-, linoleic and α-linolenic acid) between breast glandular and adipose tissue. Thus, differentiation between breast glandular and adipose tissue seems not to be necessary for the analysis of fatty acids serving as biomarkers for the intake of specific food groups. Potential influence of mixed breast tissue on fatty acid biomarkers analysis seems to be neglectable. The fourth aim was the determination of fatty acid biomarkers in adipose tissue in another study population from healthy participants. 27 adipose tissue samples were analyzed. Milk and ruminant fat biomarkers exhibited proportions of 0.47% for pentadecanoic acid, 0.34% for heptadecanoic acid and 0.25% for trans palmitoleic acid. Fish fatty acid biomarkers revealed proportions of 0.034% for eicosapentaenoic acid and 0.061% for docosahexaenoic acid. The mean proportion of vegetable oils and nuts biomarkers were 9.58% for linoleic acid and 0.48% for α-linolenic acid in all adipose tissues. Principle component analysis was applied for the fatty acid biomarkers to provide objective markers of habitual diet for this study population. PCdiet1 was mainly characterized by pentadecanoic acid, heptadecanoic acid and trans palmitoleic acid and therefore served as a principle component for the dietary intake of milk and ruminant fat. PCdiet2 and PCdiet3 only exhibited pattern for ω3 and ω6 fatty acids but not for dietary intake of specific food groups and could therefore not used as objective marker. PCdiet1, 2 and 3 explained 82.76% of variance. The last aim of this thesis was the elaboration of adverse reactions to food ingredients with special focus on food allergies and food intolerances in the context of a possible implementation into an application for consumer health. Scientific information on adverse reactions to food ingredients and trigger substances was provided in this thesis and possible implementation strategies were evaluated. For food allergens, which have regulatory requirements in the context of labelling, a strategy was elaborated, where it is necessary to provide information on the list of ingredients, the nexus ’contain’ and the respective food allergen as well as information on the name of the product. For food intolerances, which do not have regulatory requirements, limits were shown in the context of the application. If the elaborated food intolerances shall be implemented into the application, a professional dietary concept has to be developed for every food intolerance because of the complexity of the implementation.
The aim of this study was to determine the potential of some Ghanaian underutilized legumes in helping to reduce the problems of poverty, hunger and malnutrition among the vulnerable group of the Ghanaian population. The study looked into the functional properties, fat and fatty acid distribution, raffinose, sucrose, glucose, fructose, calcium, magnesium, sodium, potassium, iron, copper, manganese, zinc, cyanide and isoflavone contents of raw and processed seed flours of Cajanus cajan, Canavalia ensiformis, Canavalia gladiata, Mucuna pruriens, Parkia biglobosa, Phaseolus lunatus and Vigna subterranea. The parameters mentioned above were also determined for raw fruit flour of Dialium guineense. In addition to these, the study also looked into the crude protein and starch contents of the raw and processed seed flours of Canavalia gladiata, Parkia biglobosa and Vigna subterranea. The obtained results suggest that the legumes may have untapped potential, which may be exploited to help assist in reducing hunger, malnutrition and poverty in Ghana. Results of the functional properties reveal that the legumes may serve useful roles in various food products. For instance, velvet tamarind (Dialium guineense) flour may be useful in infant food formulations because of it high solubility and low bulk density. African Locust bean (Parkia biglobosa) flour had the highest fat content among the studied flours, recording a fat content of approximately 14%. It may therefore be economical to express the oil and use the oil as an edible oil or for industrial applications for products such as soaps, shampoos, paints, etc. This means the properties of the oil of African Locust bean flour need to be studied to know the uses of the oil. Unsaturated fatty acids in the cis configuration formed more than 50% of the fatty acids in all the legumes. This observation coupled with the low sodium content of all the legumes suggest that these legumes may be suitable for consumption to prevent cardiovascular diseases. The daily nutrient needs of individuals can be met by the consumption of the appropriate amounts of these legumes. For example, 375.25 g of processed velvet beans (Mucuna pruriens) flour may be able to meet the adequate intake (AI) of 350 mg/day magnesium for adult males.
Schimmelpilze können in Abhängigkeit des Immunstatus und der Vorerkrankungen betroffener Patienten unterschiedliche Krankheitsbilder wie Hypersensitivitäts-erkrankungen oder lebensbedrohliche invasive Infektionen hervorrufen. Da die Diagnosestellung dieser Erkrankungen mitunter komplex und insensitiv ist, sollten im Rahmen dieser Arbeit unterschiedliche Ansätze neuer diagnostischer Assays untersucht werden.
In den letzten Jahren wurden Assays entwickelt, die auf Basis durchflusszytometrisch quantifizierter Pilz-spezifischer T-Zellen aus peripherem Blut einen supportiven Biomarker zur Diagnostik invasiver Mykosen liefern könnten. Da die hierfür isolierten T-Zellen anfällig gegenüber präanalytischer Lagerzeiten und immunsuppressiver Medikation sind, wurden hier Protokolloptimierungen vorgenommen, um anhand eines Vollblut-basierten Assays mit zusätzlicher CD49d-Kostimulation diesen Limitationen entgegen zu wirken. In einer Studie an gesunden Probanden konnte dabei gezeigt werden, dass die Kombination der Durchflusszytometrie mit ausgewählten Zytokin-Messungen (IL-5, IL-10 und IL-17) zu einer verbesserten Erkennung vermehrt Schimmelpilz-exponierter Personen beitragen könnte. Neben Infektionen könnten dabei im umwelt- und arbeitsmedizinischen Kontext Polarisationen der T-Zell-Populationen detektiert werden, welche mit Sensibilisierungen und Hypersensitivität assoziiert werden.
Zusätzlich wurde ein in vitro Transwell® Alveolarmodell zur Simulation pulmonaler Pilzinfektionen für Erreger der Ordnung Mucorales adaptiert, durch Reproduktion wichtiger Merkmale der Pathogenese von Mucormykosen validiert, und für Untersuchungen der Immunpathologie und Erreger-Invasion verwendet. Das Modell wurde anschließend zur in vitro Evaluation von radioaktiv markiertem Amphotericin B mit 99mTc oder 68Ga als nuklearmedizinischen Tracer verwendet. Die untersuchten Schimmelpilze zeigten dabei eine zeit- und dosis-abhängige Aufnahme der Tracer, während bakteriell infizierte Proben nicht detektiert wurden. Die erhobenen Daten dokumentieren ein vielversprechendes Potenzial von Amphotericin B-basierten Tracer, das in zukünftigen in vivo Studien weiter evaluiert werden sollte.
Microbial, mammalian and plant cells produce and contain secondary metabolites, which typically are soluble in water to prevent cell damage by crystallization. The formation of ion pairs, e.g. with carboxylic acids or mineral acids, is a natural blueprint to keep basic metabolites in solution. It was aimed at showing whether the mostly large carboxylates form soluble protic ionic liquids (PILs) with basic natural products resulting in enhanced aqueous solubility. Furthermore, their supramolecular pattern in aqueous solution was studied. Thereby, naturally occurring carboxylic acids were identified being appropriate counterions for natural basic compounds and facilitate the formation of PILs with their beneficial characteristics, like improved dissolution rate and enhanced apparent solubility.
Bile solubilization plays a major role in the absorption of poorly water-soluble drugs. Excipients used in oral drug formulations impact bile-colloidal properties and their molecular interactions. Polymer-induced changes of bile colloids, e.g., by Eudragit E, reduced the flux of the bile interacting drug Perphenazine whereas bile non-interacting Metoprolol was not impacted. This study corroborates these in vitro findings in rats. Eudragit E significantly reduced systemic availability of Perphenazine but not Metoprolol compared to the oral administrations without polymer. This study confirms the necessity to carefully select polymers for bile interacting drugs whereas non-bile interacting drugs are more robust in terms of excipient choice for formulation. The perspective of bile interaction may introduce interesting biopharmaceutical leverage for better performing oral formulations of tomorrow.
Poorly water-soluble drugs frequently solubilize into bile colloids and this natural mechanism is key for efficient bioavailability. We tested the impact of pharmaceutical polymers on this solubilization interplay using proton nuclear magnetic resonance spectroscopy, dynamic light scattering, and by assessing the flux across model membranes. Eudragit E, Soluplus, and a therapeutically used model polymer, Colesevelam, impacted the bile-colloidal geometry and molecular interaction. These polymer-induced changes reduced the flux of poorly water-soluble and bile interacting drugs (Perphenazine, Imatinib) but did not impact the flux of bile non-interacting Metoprolol. Non-bile interacting polymers (Kollidon VA 64, HPMC-AS) neither impacted the flux of colloid-interacting nor colloid-non-interacting drugs. These insights into the drug substance/polymer/bile colloid interplay potentially point towards a practical optimization parameter steering formulations to efficient bile-solubilization by rational polymer selection.
Polymer-Biokonjugationen, vornehmlich mit dem Goldstandard PEG, führen zu einer verbesserten Pharmakokinetik, beeinflussen aber auch die konformative Stabilität von Proteinen. Bisherige Mutationsstudien, in denen überwiegend (Asn)PEG4 -Konjugate der Beta-faltblattstrukturreichen, humanen Pin 1 WW-Domäne untersucht wurden, postulieren auf einer Proteindesolvatation beruhende Stabilisierungsmechanismen: eine Stärkung intramolekularer Salzbrücken und NH-pi-Bindungen, sowie entropisch günstige Wasserverdrängungen um apolare Aminosäuren und Hydroxylgruppen. Ziel dieser Arbeit ist es, die Protein-Polymer-Dynamik auf molekularer Ebene zu charakterisieren, um damit rationale Ansätze zum Design neuer Biokonjugate voranzutreiben und mögliche PEG-Alternativen zu etablieren. Hierzu wurde eine Vielzahl an Deskriptoren mittels Molekulardynamik-Simulationen der WW-Konjugate gewonnen und mit publizierten Stabilitätsdaten in multivariaten Regressions- und logistischen Klassifikationsmodellen korreliert. Die gewonnenen QSPR-Modelle decken im Vergleich zu einer bereits publizierten, kristallstrukturbasierten Richtlinie einen größeren und strukturell vielfältigeren Datensatz an Konjugaten ab und zeigen gleichzeitig, auch für ein Konjugat der Src SH3-Domäne, eine deutlich verbesserte Leistung. Die Modelldeskriptoren beschreiben sowohl eine Modulation der Solvatation als auch Protein-Polymer-Interaktionen. Metadynamik-Simulationen zeigten zudem die Polymerdynamik während einer partiellen Proteinentfaltung auf. Mithilfe weiterer Simulationen von Konjugaten des alpha-helikalen Her2-Affibodys wurde die Dynamik von PEG und verschiedener Alternativen (LPG, PEtOx, PMeOx) systematisch studiert. PEG interagierte mit positiv geladenen Lysinen und Argininen in der Nähe hydrophober Aminosäuren. LPG zeigte zusätzliche Wechselwirkungen der Hydroxylgruppen mit Aspartaten und Glutamaten. POx-Polymere interagierten mit Phenylalaninen, Tyrosinen und über Carbonylgruppen mit HB-Donatoren. Größere Konjugate (10 - 50 kDa PEG/LPG/PEtOx) des antiviralen Biologikums Interferon-alpha2a wurden mittels gaußbeschleunigter MDs und einer CG-Simulation analysiert. Charakteristische Wechselwirkungspartner stimmten mit den Beobachtungen zu Oligomer-Konjugaten überein. In Einklang mit experimentellen Daten der Kooperationspartner zu den 10-kDa-Varianten deuteten zusätzliche Constrained-Network-Analysen, welche die Proteinflexibilität evaluieren, auf eine thermische Destabilisierung hin. Die Bioaktivität der untersuchten Konjugate wurde weiterhin erfolgreich mit den Gyrationsdurchmessern der modellierten Strukturen korreliert.
Exposure-efficacy and/or exposure-toxicity relationships have been identified for up to 80% of oral anticancer drugs (OADs). Usually, OADs are administered at fixed doses despite their high interindividual pharmacokinetic variability resulting in large differences in drug exposure. Consequently, a substantial proportion of patients receive a suboptimal dose. Therapeutic Drug Monitoring (TDM), i.e., dosing based on measured drug concentrations, may be used to improve treatment outcomes. The prospective, multicenter, non-interventional ON-TARGET study (DRKS00025325) aims to investigate the potential of routine TDM to reduce adverse drug reactions in renal cell carcinoma patients receiving axitinib or cabozantinib. Furthermore, the feasibility of using volumetric absorptive microsampling (VAMS), a minimally invasive and easy to handle blood sampling technique, for sample collection is examined. During routine visits, blood samples are collected and sent to bioanalytical laboratories. Venous and VAMS blood samples are collected in the first study phase to facilitate home-based capillary blood sampling in the second study phase. Within one week, the drug plasma concentrations are measured, interpreted, and reported back to the physician. Patients report their drug intake and toxicity using PRO-CTCAE-based questionnaires in dedicated diaries. Ultimately, the ON-TARGET study aims to develop a nationwide infrastructure for TDM for oral anticancer drugs.
Chimeric antigen receptors (CARs) are able to specifically direct T cells to tumor antigens and therapy with anti-CD19 CARs has already cured cancer patients with B-cell lymphomas who have undergone long-term therapy non-successful. Despite this impressive result, the therapy is currently only approved as a last treatment option for blood cancers due to its life-threatening deficiencies. For patient safety and to enable additional application such as the treatment of solid tumors, CAR-T cells must be controllable, e. g. by chemically programmable CARs (cpCARs) regulated by hapten-like compounds.
This thesis reports the synthesis and characterization of such hapten-like compounds. In the first step, seven different warheads with two different spacers were bound to biotin in order to find a suitable warhead for programming the cpCAR.
In a second step, synthetic routes for the three pharmacophores folate, c(RGD), and an RGD peptidomimetic were developed. The routes allow the modification of the pharmacophores with one of the warheads from the first step. CuAAC was chosen as a bioorthogonal approach to link pharmacophores and warheads.
In total, three different pharmacophores were modified with the 1,3-diketone motif of compound 21 leading to 112, 113 and 128. Activation of the T-cell signaling cascade was tested after binding of these hapten-like compounds to the cpCAR in the presence of suitable target structures. For 112, only a slight, non-significant, activation of the T-cell signaling cascade was observed, whereas for 113 and 128, a significant activation of the T-cell signaling cascade was observed.
The poor solubility of the folate compounds led to alternative strategies. Folic acid was exchanged by pteroic acid and the bifunctional, linear compounds were enlarged to trifunctional dendrimers.
Besides the reported regioisomer in 112, a second one, which was not reported to date, occurred by the cyclization of the linear RGD pentapeptide leading to 113.
After the reported synthesis of an RGD peptidomimetic analogous to 128 could not be reproduced, a new synthetic route was developed. It also consists of 17 steps, but reduces the number of linear steps from 13 to 10. Moreover, the developed route contains an asymmetric hydrogenation step and is, compared to the published one, more flexible by the use of the copper-catalyzed azide-alkyne cycloaddition (CuAAC). In addition, an unknown reaction was observed. Instead of the formation of a Schiff base in the reductive amination of 129, an insertion of propargylamine occurred forming 131. The reaction is almost quantitative and in high purity. After requiring no purification, it could be predestined for industrial purposes, such as the synthesis of N-functionalized 1,2-dihydroquinolines or as a building block with various orthogonal functional groups.
Besides the sulfonamide 16, the diketone (21, 27, 31) and lactam compounds (39 – 41), experiments on adapter molecules with further warheads were performed. In the synthesis of a proadapter approach, in which the warhead is formed only after the retro-aldol reaction catalyzed by the mAb, 6 of 10 steps were successfully performed. A newly developed synthesis to keto-sulfonyl and keto-sulfoxide compounds could not be completed but was performed on a small scale to the point of keto-sulfonyl and keto-sulfoxide. Furthermore, a universal synthesis route was designed to allow the introduction of the warhead at the end of the synthesis by acylation. Thus, after 5 shared steps, 3 of them in quantitative yield, different warheads may be introduced. Moreover, this also facilitates the purification and the analysis of the compounds by the absence of tautomerism or labile groups. However, the acylation experiments were not successful with either the acid cyanide or the Weinreb amide.
In summary, this thesis has proven that the 1,3-diketone motif is a suitable warhead for programming the cpCAR, which was developed by Hudecek et al. (unpublished data). The hapten-like compounds 112, 113 and 128 simultaneously bind to integrin ${\alpha}_v{\beta}_3$ and the cpCAR activating the T-cell signaling cascade. The modular synthesis strategy and the use of the bioorthogonal CuAAC allow straightforward access to these valuable immunotherapeutics but revealed the need for an additional purification step to remove copper ions.
Purpose
Knowledge on Ruxolitinib exposure in patients with graft versus host disease (GvHD) is scarce. The purpose of this prospective study was to analyze Ruxolitinib concentrations of GvHD patients and to investigate effects of CYP3A4 and CYP2C9 inhibitors and other covariates as well as concentration-dependent effects.
Methods
262 blood samples of 29 patients with acute or chronic GvHD who were administered Ruxolitinib during clinical routine were analyzed. A population pharmacokinetic model obtained from myelofibrosis patients was adapted to our population and was used to identify relevant pharmacokinetic properties and covariates on drug exposure. Relationships between Ruxolitinib exposure and adverse events were assessed.
Results
Median of individual mean trough serum concentrations was 39.9 ng/mL at 10 mg twice daily (IQR 27.1 ng/mL, range 5.6-99.8 ng/mL). Applying a population pharmacokinetic model revealed that concentrations in our cohort were significantly higher compared to myelofibrosis patients receiving the same daily dose (p < 0.001). Increased Ruxolitinib exposure was caused by a significant reduction in Ruxolitinib clearance by approximately 50%. Additional comedication with at least one strong CYP3A4 or CYP2C9 inhibitor led to a further reduction by 15% (p < 0.05). No other covariate affected pharmacokinetics significantly. Mean trough concentrations of patients requiring dose reduction related to adverse events were significantly elevated (p < 0.05).
Conclusion
Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors. Elevated Ruxolitinib trough concentrations might be a surrogate for toxicity.
Breast cancer etiology is associated with both proliferation and DNA damage induced by estrogens. Breast cancer risk factors (BCRF) such as body mass index (BMI), smoking, and intake of estrogen-active drugs were recently shown to influence intratissue estrogen levels. Thus, the aim of the present study was to investigate the influence of BCRF on estrogen-induced proliferation and DNA damage in 41 well-characterized breast glandular tissues derived from women without breast cancer. Influence of intramammary estrogen levels and BCRF on estrogen receptor (ESR) activation, ESR-related proliferation (indicated by levels of marker transcripts), oxidative stress (indicated by levels of GCLC transcript and oxidative derivatives of cholesterol), and levels of transcripts encoding enzymes involved in estrogen biotransformation was identified by multiple linear regression models. Metabolic fluxes to adducts of estrogens with DNA (E-DNA) were assessed by a metabolic network model (MNM) which was validated by comparison of calculated fluxes with data on methoxylated and glucuronidated estrogens determined by GC- and UHPLC-MS/MS. Intratissue estrogen levels significantly influenced ESR activation and fluxes to E-DNA within the MNM. Likewise, all BCRF directly and/or indirectly influenced ESR activation, proliferation, and key flux constraints influencing E-DNA (i.e., levels of estrogens, CYP1B1, SULT1A1, SULT1A2, and GSTP1). However, no unambiguous total effect of BCRF on proliferation became apparent. Furthermore, BMI was the only BCRF to indeed influence fluxes to E-DNA (via congruent adverse influence on levels of estrogens, CYP1B1 and SULT1A2).
Estrogens, namely 17β-estradiol (E2) and estrone (E1) are considered to play an important role in the initiation and promotion of breast cancer (summarized in Raftogianis et al., 2000), a malignancy responsible for around 500,000 deaths per year (summarized in Ghislain et al., 2016). Two major mechanisms have been postulated to explain the carcinogenic effects of estrogens: (1) the estrogen receptor-mediated stimulation of breast cell proliferation with a concomitant enhanced rate of mutations and (2) the metabolism of hydroxylated estrogens to quinone derivatives which can react with the DNA (Russo and Russo, 2006, summarized in Yager and Davidson, 2006). Nevertheless, as a detoxifying mechanism, E1, E2, and their hydroxylated and methoxylated metabolites are reversibly conjugated into sulfates and glucuronides devoid of biological activity (summarized in Guillemette et al., 2004). Yet, despite the key detoxifying function of these conjugates, the study of their circulating levels face some significant problems: (1) analysis by techniques such as radioimmunoassay lack specificity and accuracy and requires enzymatic/chemical hydrolysis before analysis, being unable to differentiate between sulfates and glucuronides (summarized in Stanczyk et al., 2007, summarized in Wang et al., 2016), (2) very little knowledge in healthy women, which has been identified as a barrier to advance in breast cancer research (summarized in Liu, 2000), and (3) far fewer studies in pre- than in postmenopausal women (summarized in Samavat and Kurzer, 2015). Therefore, to get more insights into the research of breast cancer etiology and prevention, the analysis of circulating levels of estrogens (including metabolites and conjugates) in women without breast cancer through reliable analytical techniques, is required.
Purpose
A neuropathological hallmark of Alzheimer's disease (AD) is the presence of amyloid-β (Aβ) plaques in the brain, which are observed in a significant number of cognitively normal, older adults as well. In AD, butyrylcholinesterase (BChE) becomes associated with A\(_{β}\) aggregates, making it a promising target for imaging probes to support diagnosis of AD. In this study, we present the synthesis, radiochemistry, in vitro and preliminary ex and in vivo investigations of a selective, reversible BChE inhibitor as PET-tracer for evaluation as an AD diagnostic.
Procedures
Radiolabeling of the inhibitor was achieved by fluorination of a respective tosylated precursor using K[\(^{18}\)F]. IC\(_{50}\) values of the fluorinated compound were obtained in a colorimetric assay using recombinant, human (h) BChE. Dissociation constants were determined by measuring hBChE activity in the presence of different concentrations of inhibitor.
Results
Radiofluorination of the tosylate precursor gave the desired radiotracer in an average radiochemical yield of 20 ± 3 %. Identity and > 95.5 % radiochemical purity were confirmed by HPLC and TLC autoradiography. The inhibitory potency determined in Ellman's assay gave an IC\(_{50}\) value of 118.3 ± 19.6 nM. Dissociation constants measured in kinetic experiments revealed lower affinity of the inhibitor for binding to the acylated enzyme (K2 = 68.0 nM) in comparison to the free enzyme (K\(_{1}\) = 32.9 nM).
Conclusions
The reversibly acting, selective radiotracer is synthetically easily accessible and retains promising activity and binding potential on hBChE. Radiosynthesis with \(^{18}\)F labeling of tosylates was feasible in a reasonable time frame and good radiochemical yield.
The GABA\(_{B}\) receptor agonist baclofen is a medication commonly used for the treatment of muscle spasticity. It is an amino acid and related to the neurotransmitter GABA. In this study, we developed a new, gradient high-performance liquid chromatography (HPLC) method for the impurity assessment of baclofen, which is appropriate for pharmacopoeial purposes. Since the impurities related to the synthesis pathway are acids, zwitterionic, or neutral, the method development is challenging. However, the separation of all components was achieved on a C18 stationary phase using a water–acetonitrile–trifluoroacetic acid gradient. A limit of detection (LOD) of at least 0.02% was registered for all specified impurities. Additionally, CAD detection was performed to detect potential impurities lacking off a chromophore. The baclofen batches analyzed are far more pure than expected. All impurities were found below the specification limit, and thus, they can be regarded as unspecified. Moreover, the required runtime could be significantly reduced compared to the current USP or Ph. Eur. method.
Spectroscopic methods were established decades ago in a wide variety of fields. This also applies to the pharmaceutical field, although they initially were mostly used for identity testing or structure elucidation only. Technical developments, such as miniaturization (NMR benchtop devices), Fourier transformations (for NMR, MIR spectroscopy) or the combination with chemometric evaluation (e.g., in Process Analytical Technology, PAT), have further increased their importance and opened up new applications. The aim of this work was to investigate further new approaches and to find new applications for already established methods and to show their benefits.
By means of MIR, NIR and NMR data and their chemometric evaluation (principal component analysis, PCA; hierarchical cluster analysis, HCA; linear discriminant analysis, LDA), possibilities were presented to successfully determine the manufacturer or the pharmaceutical company of various paracetamol preparations. In the course of this, various similarities and correlations between the preparations of individual companies could also be identified. For this purpose, a suitable sample preparation was developed for each spectroscopic method, and suitable measurement parameters in order to obtain reproducible spectra for the chemometric evaluation were determined. Furthermore, the results of the two unsupervised methods (HCA, PCA) were compared with each other. The HCA was able to confirm those of the PCA for the very most part. Additionally, through these methods it was possible to characterize many of the preparations based on clusters formed by comparable tablet compositions.
In order to be able to measure unmortared, whole tablets using the NIR spectrometer, an attachment was developed and manufactured using 3D printing. Its functionality was demonstrated by measuring and analyzing the tablets of two different batches of nine paracetamol preparations. The batches were clearly distinguished on the basis of a PCA and a significant difference was also demonstrated by means of statistical tests.
For NMR spectroscopy, a method was developed to obtain optimized "fingerprint" spectra of drug formulations. For this purpose, a 1D DOSY measurement was elaborated, in which the signals of the active ingredient could be filtered out by the appropriate choice of measurement parameters. The chemometric evaluation can thus focus on the remaining signals of the excipients, on the basis of which the preparations of the same API can be distinguished. Especially in the case of formulations that consist largely of active ingredient, data pre processing of the spectra can thus be simplified and greater importance can be assigned to the originally very small excipient signals.
A quantitative 1H NMR method was developed for the comparison of a high field spectrometer (400 MHz) with a benchtop spectrometer (80 MHz) for two finished drugs. It was shown that it is possible to obtain comparable results with both instruments, but that the influence of the excipients on the signals and the lower resolution of the benchtop instrument must be taken into account. Therefore, it was not possible to obtain comparable results without further optimization of the method for one of the active ingredients.
In the investigation of various reactions between APIs and excipients using DOSY, its usefulness as a screening method in stability testing was demonstrated. For this purpose, three different APIs and excipients were stressed together and the reaction mixtures were subsequently measured using DOSY. Based on the translational diffusion coefficient, the reaction products could be identified and distinguished from the active ingredients and the excipients used. The importance of thoughtful processing could also be demonstrated. If all peak heights are selected when evaluating signals split by direct spin spin coupling, this allows the detection of hidden signals as long as not all signals have the same diffusion coefficient. The selective selection of individual peak heights in the case of split signals also enables the evaluation of signals that overlap slightly. However, the limitations of this method were also shown when two signals overlap too much and differ too little in their diffusion coefficients.
Hence, it has been successfully demonstrated in the various projects that the new chemometric approaches, as well as the new applications of already established methods, enable in depth findings and thus have a clear added value.
Analysis of Drug Impurities by Means of Chromatographic Methods: Targeted and Untargeted Approaches
(2022)
The presented works aimed on the analysis of new impurities in APIs and medicinal products. Different subtypes of LC were coupled to suitable detection methods, i.e. UV and various MS techniques, depending on the chemical natures of the analytes and the analytical task.
Unexpected impurities in medicinal products and APIs caused several scandals in the past, concomitant with fatalities or severe side effects in human and veterinary patients. The detection of nitrosamines in sartans led to the discovery of nitrosamines in various other drugs, of which the antibiotic rifampicin was analyzed in this work. An examination of the synthesis of rifampicin revealed a high potential for the formation of 4-methyl-1-nitrosopiperazine (MeNP). An LC-MS/HRMS method suitable for the quantification of MeNP was applied in the analysis of drugs collected from Brazil, Comoros, India, Nepal, and Tanzania, where a single dose of rifampicin is used in the post-exposure prophylaxis of leprosy. All batches were contaminated with MeNP, ranging from 0.7-5.1 ppm. However, application of rifampicin containing up to 5 ppm MeNP was recommended by the regulatory authorities for the post-exposure prophylaxis of leprosy.
In the 1990s the aminoglycoside antibiotic gentamicin attracted attention after causing fatalities in the USA, but the causative agent was never identified unequivocally. The related substance sisomicin was recognized as a lead impurity by the Holzgrabe lab at the University of Würzburg: sisomicin was accompanied by a variety of other impurities and batches containing sisomicin had caused the fatalities. In 2016, anaphylactic reactions were reported after application of gentamicin. A contamination of the medicinal products with histamine, an impurity of the raw material fish peptone used upon the production, could be identified as the cause of the adverse effects. Batches of gentamicin sulfate, which had been stored at the University of Würzburg since the earlier investigations, were analyzed regarding their contamination with histamine to determine whether the biogenic amine was responsible for the 1990s fatalities as well. Furthermore, a correlation with the lead impurity sisomicin was checked. Histamine could be detected in all analyzed batches, but at a lower level than in the batches responsible for the anaphylactic reactions. Moreover, there is no correlation of histamine with the lead impurity sisomicin. Hence, the causative agent for the 1990s fatalities was not histamine and remains unknown.
Another source of impurities is the reaction of APIs with excipients, e.g. the esterification of naproxen with PEG 600 in soft gel capsules. The influence of the formulation’s composition on this reaction was investigated by means of LC-UV. Therefore, the impurity naproxen-PEG-ester (NPEG) was synthesized and used for the development of a method suitable for the analysis of soft gel capsule formulations. Different formulations were stressed for 7 d at 60 °C and the relative amount of NPEG was determined. The formation of NPEG was influenced by the concentrations of water and lactic acid, the pH, and the drug load of the formulation, which can easily be explained by the chemistry behind esterification reactions.
Keeping in mind the huge variety of sources of impurities, it might be impossible to predict all potential impurities of a drug substance/product. Targeted and untargeted approaches were combined in the impurity profiling of bisoprolol fumarate. Eight versions of an LC-HRMS method were developed to enable the detection of a maximum number of impurities: an acidic and a basic buffered LC was coupled to MS detection applying ESI and APCI, both in positive in negative mode. MS and MS/MS data were acquired simultaneously by information dependent acquisition. In the targeted approach, potential impurities were derived from a reaction matrix based on the synthesis route of the API, while the untargeted part was based on general unknown comparative screening to identify additional signals. 18 and 17 impurities were detected in the targeted and the untargeted approach, respectively. The molecular formulae were assessed based on the exact mass and the isotope pattern. Theoretical fragment spectra generated by in silico fragmentation were matched with experimental data to estimate the plausibility of proposed/elucidated structures. Moreover, the detected impurities were quantified with respect to an internal standard.
Plant extracts from Cecropia genus have been used by Latin-American traditional medicine to treat metabolic disorders and diabetes. Previous reports have shown that roots of Cecropia telenitida that contains serjanic acid as one of the most prominent and representative pentacyclic triterpenes. The study aimed to isolate serjanic acid and evaluate its effect in a prediabetic murine model by oral administration. A semi-pilot scale extraction was established and serjanic acid purification was followed using direct MALDI-TOF analysis. A diet induced obesity mouse model was used to determine the impact of serjanic acid over selected immunometabolic markers. Mice treated with serjanic acid showed decreased levels of cholesterol and triacylglycerols, increased blood insulin levels, decreased fasting blood glucose and improved glucose tolerance, and insulin sensitivity. At transcriptional level, the reduction of inflammation markers related to adipocyte differentiation is reported.
Hysterectomy has a variety of medical indications and improves pre-operative symptoms but might compromise the quality of life during recovery due to symptoms such as fatigue, headache, nausea, depression, or pain. The aim of the present study was to determine the effect of a standardized extract from French oak wood (Quercus robur) containing at least 40% polyphenols of the ellagitannins class, Robuvit\(^®\), on convalescence and oxidative stress of women after hysterectomy. Recovery status was monitored with the SF-36 questionnaire. The supplementation with Robuvit\(^®\) (300 mg/day) during 4 weeks significantly improved general and mental health, while under placebo some items significantly deteriorated. Oxidative stress and enhancement of MMP–9 activity was significantly reduced by Robuvit\(^®\) versus placebo. After 8 weeks of intervention, the patients’ condition improved independently of the intervention. Our results suggest that the use of Robuvit\(^®\) as a natural supplement relieves post-operative symptoms of patients after hysterectomy and reduces oxidative stress. The study was registered with ID ISRCTN 11457040 (13/09/2019).
Background
Even though the international combat against Neglected Tropical Diseases such as schistosomiasis or soil-transmitted helminthiases depends on reliable therapeutics, anthelminthic pharmacovigilance has been neglected on many national African drug markets. Therefore, quality and composition of Albendazole, Mebendazole and Praziquantel locally collected in Burkina Faso, Côte d’Ivoire, Ghana and Tanzania were analysed.
Methods
Samples of 88 different batches were obtained from randomly selected facilities. Sampling took place in Northwest Tanzania, Western Burkina Faso, Southeast Côte d’Ivoire and Southwest Ghana. Visual examination of both packaging and samples was performed according to the WHO ‘Be Aware’ tool. Products were then screened with the GPHF Minilab, consisting of tests of mass uniformity, disintegration times and thin-layer chromatography (TLC). Confirmatory tests were performed according to international pharmacopoeiae, applying assays for dissolution profiles and high-performance liquid chromatography (HPLC).
Findings
Despite minor irregularities, appearance of the products did not hint at falsified medicines. However, 19.6% of the brands collected in Ghana and Tanzania were not officially licensed for sale. Mass uniformity was confirmed in 53 out of 58 brands of tablets. 41 out of 56 products passed disintegration times; 10 out of the 15 failing products did not disintegrate at all. Evaluating TLC results, only 4 out of 83 batches narrowly missed specification limits, 18 batches slightly exceeded them. Not more than 46.3% (31 / 67) of the tablets assayed passed the respective pharmaceutical criteria for dissolution. HPLC findings confirmed TLC results despite shifted specification limits: 10 out of 83 tested batches contained less than 90%, none exceeded 110%.
Conclusion
In the four study countries, no falsified anthelminthic medicine was encountered. The active pharmaceutical ingredient was not found to either exceed or fall below specification limits. Galenic characteristics however, especially dissolution profiles, revealed great deficits.
The pharmacokinetics in patients with cystic fibrosis (CF) has long been thought to differ considerably from that in healthy volunteers. For highly protein bound β-lactams, profound pharmacokinetic differences were observed between comparatively morbid patients with CF and healthy volunteers. These differences could be explained by body weight and body composition for β-lactams with low protein binding. This study aimed to develop a novel population modeling approach to describe the pharmacokinetic differences between both subject groups by estimating protein binding. Eight patients with CF (lean body mass [LBM]: 39.8 ± 5.4kg) and six healthy volunteers (LBM: 53.1 ± 9.5kg) received 1027.5 mg cefotiam intravenously. Plasma concentrations and amounts in urine were simultaneously modelled. Unscaled total clearance and volume of distribution were 3% smaller in patients with CF compared to those in healthy volunteers. After allometric scaling by LBM to account for body size and composition, the remaining pharmacokinetic differences were explained by estimating the unbound fraction of cefotiam in plasma. The latter was fixed to 50% in male and estimated as 54.5% in female healthy volunteers as well as 56.3% in male and 74.4% in female patients with CF. This novel approach holds promise for characterizing the pharmacokinetics in special patient populations with altered protein binding.
Most drugs are no longer produced in their own countries by the pharmaceutical companies, but by contract manufacturers or at manufacturing sites in countries that can produce more cheaply. This not only makes it difficult to trace them back but also leaves room for criminal organizations to fake them unnoticed. For these reasons, it is becoming increasingly difficult to determine the exact origin of drugs. The goal of this work was to investigate how exactly this is possible by using different spectroscopic methods like nuclear magnetic resonance and near- and mid-infrared spectroscopy in combination with multivariate data analysis. As an example, 56 out of 64 different paracetamol preparations, collected from 19 countries around the world, were chosen to investigate whether it is possible to determine the pharmaceutical company, manufacturing site, or country of origin. By means of suitable pre-processing of the spectra and the different information contained in each method, principal component analysis was able to evaluate manufacturing relationships between individual companies and to differentiate between production sites or formulations. Linear discriminant analysis showed different results depending on the spectral method and purpose. For all spectroscopic methods, it was found that the classification of the preparations to their manufacturer achieves better results than the classification to their pharmaceutical company. The best results were obtained with nuclear magnetic resonance and near-infrared data, with 94.6%/99.6% and 98.7/100% of the spectra of the preparations correctly assigned to their pharmaceutical company or manufacturer.
The charged aerosol detector (CAD) is the latest representative of aerosol-based detectors that generate a response independent of the analytes' chemical structure. This study was aimed at accurately predicting the CAD response of homologous fatty acids under varying experimental conditions. Fatty acids from C12 to C18 were used as model substances due to semivolatile characterics that caused non-uniform CAD behaviour. Considering both experimental conditions and molecular descriptors, a mixed quantitative structure-property relationship (QSPR) modeling was performed using Gradient Boosted Trees (GBT). The ensemble of 10 decisions trees (learning rate set at 0.55, the maximal depth set at 5, and the sample rate set at 1.0) was able to explain approximately 99% (Q\(^2\): 0.987, RMSE: 0.051) of the observed variance in CAD responses. Validation using an external test compound confirmed the high predictive ability of the model established (R-2: 0.990, RMSEP: 0.050). With respect to the intrinsic attribute selection strategy, GBT used almost all independent variables during model building. Finally, it attributed the highest importance to the power function value, the flow rate of the mobile phase, evaporation temperature, the content of the organic solvent in the mobile phase and the molecular descriptors such as molecular weight (MW), Radial Distribution Function-080/weighted by mass (RDF080m) and average coefficient of the last eigenvector from distance/detour matrix (Ve2_D/Dt). The identification of the factors most relevant to the CAD responsiveness has contributed to a better understanding of the underlying mechanisms of signal generation. An increased CAD response that was obtained for acetone as organic modifier demonstrated its potential to replace the more expensive and environmentally harmful acetonitrile.
Naturally occurring compounds such as sesquiterpenes and sesquiterpenoids (SQTs) have been shown to modulate GABA\(_{A}\) receptors (GABA\(_{A}\)Rs). In this study, the modulatory potential of 11 SQTs at GABA\(_{A}\)Rs was analyzed to characterize their potential neurotropic activity. Transfected HEK293 cells and primary hippocampal neurons were functionally investigated using electrophysiological whole-cell recordings. Significantly different effects of β-caryophyllene and α-humulene, as well as their respective derivatives β-caryolanol and humulol, were observed in the HEK293 cell system. In neurons, the concomitant presence of phasic and tonic GABA\(_{A}\)R configurations accounts for differences in receptor modulation by SQTs. The in vivo presence of the γ\(_{2}\) and δ subunits is important for SQT modulation. While phasic GABA\(_{A}\) receptors in hippocampal neurons exhibited significantly altered GABA-evoked current amplitudes in the presence of humulol and guaiol, negative allosteric potential at recombinantly expressed α\(_{1}\)β\(_{2}\)γ\(_{2}\) receptors was only verified for humolol. Modeling and docking studies provided support for the binding of SQTs to the neurosteroid-binding site of the GABA\(_{A}\)R localized between transmembrane segments 1 and 3 at the (\(^{+}\)α)-(\(^{-}\)α) interface. In sum, differences in the modulation of GABA\(_{A}\)R isoforms between SQTs were identified. Another finding is that our results provide an indication that nutritional digestion affects the neurotropic potential of natural compounds.
Poly(vinylidene fluoride-co-trifluoroethylene) (P(VDF-co-TrFE)) is an electroactive polymer with growing interest for applications in biomedical materials and flexible electronics. In this study, a solvent-free additive manufacturing technique called melt electrowriting (MEW) has been utilized to fabricate well-defined microperiodic structures of the copolymer (P(VDF-co-TrFE)). MEW of the highly viscous polymer melt was initiated using a heated collector at temperatures above 120 °C and required remarkably slow collector speeds below 100 mm min\(^{-1}\). The fiber surface morphology was affected by the collector speed and an increase in β-phase was observed for scaffolds compared to the unprocessed powder. Videography shows vibrations of the P(VDF-co-TrFE) jet previously unseen during MEW, probably due to repeated charge buildup and discharge. Furthermore, piezo-force microscopy measurements demonstrated the electromechanical response of MEW-fabricated fibers. This research therefore achieves the melt electrohydrodynamic processing of fibers with micrometer resolution into defined structures with an important electroactive polymer.
Background
Reproducibility of reported antibacterial activities of plant extracts has long remained questionable. Although plant-related factors should be well considered in serious pharmacognostic research, they are often not addressed in many research papers. Here we highlight the challenges in reproducing antibacterial activities of plant extracts.
Methods
Plants with reported antibacterial activities of interest were obtained from a literature review. Antibacterial activities against Escherichia coli and Klebsiella pneumoniae were tested using extracts’ solutions in 10% DMSO and acetone. Compositions of working solutions from both solvents were established using LC-MS analysis. Moreover, the availability of details likely to affect reproducibility was evaluated in articles which reported antibacterial activities of studied plants.
Results
Inhibition of bacterial growth at MIC of 256–1024 μg/mL was observed in only 15.4% of identical plant species. These values were 4–16-fold higher than those reported earlier. Further, 18.2% of related plant species had MICs of 128–256 μg/mL. Besides, 29.2% and 95.8% of the extracts were soluble to sparingly soluble in 10% DMSO and acetone, respectively. Extracts’ solutions in both solvents showed similar qualitative compositions, with differing quantities of corresponding phytochemicals. Details regarding seasons and growth state at collection were missing in 65% and 95% of evaluated articles, respectively. Likewise, solvents used to dissolve the extracts were lacking in 30% of the articles, whereas 40% of them used unidentified bacterial isolates.
Conclusion
Reproducibility of previously reported activities from plants’ extracts is a multi-factorial aspect. Thus, collective approaches are necessary in addressing the highlighted challenges.
Metabolic glycoengineering enables a directed modification of cell surfaces by introducing target molecules to surface proteins displaying new features. Biochemical pathways involving glycans differ in dependence on the cell type; therefore, this technique should be tailored for the best results. We characterized metabolic glycoengineering in telomerase-immortalized human mesenchymal stromal cells (hMSC-TERT) as a model for primary hMSC, to investigate its applicability in TERT-modified cell lines. The metabolic incorporation of N-azidoacetylmannosamine (Ac\(_4\)ManNAz) and N-alkyneacetylmannosamine (Ac\(_4\)ManNAl) into the glycocalyx as a first step in the glycoengineering process revealed no adverse effects on cell viability or gene expression, and the in vitro multipotency (osteogenic and adipogenic differentiation potential) was maintained under these adapted culture conditions. In the second step, glycoengineered cells were modified with fluorescent dyes using Cu-mediated click chemistry. In these analyses, the two mannose derivatives showed superior incorporation efficiencies compared to glucose and galactose isomers. In time-dependent experiments, the incorporation of Ac\(_4\)ManNAz was detectable for up to six days while Ac\(_4\)ManNAl-derived metabolites were absent after two days. Taken together, these findings demonstrate the successful metabolic glycoengineering of immortalized hMSC resulting in transient cell surface modifications, and thus present a useful model to address different scientific questions regarding glycosylation processes in skeletal precursors.
In 1998, the aminoglycoside antibiotic gentamicin sulfate caused several cases of deaths in the United States, after the switch from twice- to once-daily application. Endotoxins were discussed as the cause for the adverse effects and sisomicin was identified as the lead impurity; batches containing sisomicin were contaminated with more impurities and were responsible for the fatalities. In 2016, anaphylactic reactions in horses, and later in humans with one fatality, were observed after application of gentamicin sulfate contaminated with histamine. To determine whether histamine was responsible for the 1990s death cases as well, histamine was quantified by means of liquid chromatography–tandem mass spectrometry (LC-MS/MS) in 30 samples of gentamicin sulfate analyzed in previous studies. Furthermore, a relative quantification of sisomicin was performed to check for a correlation between histamine and the lead impurity. A maximum amount of 11.52 ppm histamine was detected, which is below the limit for anaphylactic reactions of 16 ppm, and no correlation of the two impurities was observed. However, the European Medicines Agency recommends a stricter limit with regard to the maximum single dose of gentamicin sulfate to reach a greater gap between the maximum histamine exposition of 4.3 µg and the quantity known to cause hypotension of 7 µg. The low amounts of histamine and the fact that there is no connection with the contamination with sisomicin showed that histamine was not the cause for the death cases in the United States in 1998, and endotoxins remain the most probable explanation.
The enzyme butyrylcholinesterase (BChE) represents a promising target for imaging probes to potentially enable early diagnosis of neurodegenerative diseases like Alzheimer's disease (AD) and to monitor disease progression in some forms of cancer. In this study, we present the design, facile synthesis, in vitro and preliminary ex vivo and in vivo evaluation of a morpholine‐based, selective inhibitor of human BChE as a positron emission tomography (PET) tracer with a pseudo‐irreversible binding mode. We demonstrate a novel protecting group strategy for 18F radiolabeling of carbamate precursors and show that the inhibitory potency as well as kinetic properties of our unlabeled reference compound were retained in comparison to the parent compound. In particular, the prolonged duration of enzyme inhibition of such a morpholinocarbamate motivated us to design a PET tracer, possibly enabling a precise mapping of BChE distribution.
Die Permeabilität von Substanzen über Biomembranen erfolgt auf Basis ihrer Größe und Lipophilie, wird jedoch auch zu einem großen Anteil vom aktiven Transport bestimmt. Speziell im menschlichen Verdauungstrakt ist dieser Transportmechanismus neben seinen essentiellen physiologischen Aufgaben, wie den Transport von Nährstoffen, an einer Resistenz gegen exogene Stoffe und Xenobiotika beteiligt, der die Aufnahme in den Organismus über einen Rücktransport in das Darmlumen limitiert. Dabei hat die membranständige Effluxpumpe p-Glykoprotein (p-GP) als ein Baustein dieses Schutzmechanismus auch einen großen Einfluss auf die Arzneimitteltherapie. Über eine Modulierung der Pharmakokinetik von Arzneistoffen beschränkt sie die Aufnahme von Medikamenten und senkt dadurch deren Bioverfügbarkeit. Es wird auch für pflanzliche Inhaltsstoffe aus der Gruppe der Polyphenole ein möglicher Einfluss auf dieses Transportprotein diskutiert. Diese Beeinflussung kann sich entweder in einer Induktion oder einer Inhibition des Proteins äußern, was positive wie negative Effekte haben kann. Eine Hemmung des Transportproteins führt zu einer erhöhten Aufnahme einiger Arzneistoffe, die mit einer erhöhten Bioverfügbarkeit und einer potentiellen Dosissenkung einhergeht. Induziert man p-GP dagegen, so wird es beispielsweise ermöglicht, potentiell schädliche Xenobiotika noch intensiver auszuscheiden und nachteilige Plasmaspiegel zu verhindern. Im Rahmen der vorliegenden Arbeit sollte daher der Einfluss ausgewählter Polyphenole auf die Funktionalität und die Genexpression im CaCo-II-Zellkulturmodell näher untersucht, sowie vorab charakteristische Eigenschaften der pflanzlichen Inhaltsstoffe - Taxifolin, Silibinin, M1, Urolithin A, Urolithin B, Urolithin C, Isourolithin A, racemisches Hydnocarpin D, (+)-Hydnocarpin D, (-)-Hydnocarpin D - vergleichend bestimmt werden. Diese stoffspezifischen Charakteristika umfassten die Zytotoxizität, die Stabilität und die antioxidative Kapazität. Vor allem die Zytotoxizität und die Stabilität sind essentielle Parameter für aussagekräftige Resultate. Die Substanzen waren in der eingesetzten Konzentration von 50 µM mehrheitlich, mit Ausnahme des Hydnocarpins D, nicht-toxisch innerhalb der relevanten Versuchszeiträume, 4 h und 24 h, und den verwendeten Kulturmedien, DMEM-Pest und HBSS. Vor allem im Hinblick auf die Genexpressionsversuche war es die Basis für valide Ergebnisse, den Zeitraum bis 24 h als nicht-toxisch sicherstellen zu können. Hinsichtlich der Stabilität waren nur Taxifolin (27 % Restkonzentration) und der M1 (0 % Restkonzentration) nach 24 h in Zellkulturmedium kritisch. Auf Basis ihrer antioxidativen Kapazität werden pflanzlichen Inhaltsstoffen eine Reihe von gesundheitsförderlichen Merkmalen nachgesagt, weswegen dieser Aspekt für die Testsubstanzen zusätzlich vergleichend evaluiert wurde. Der Eintritt von Pathogenen kann Zusammenfassung 377 zum Beispiel durch oxidative Schädigung des Darmepithels erleichtert werden, was zusätzlich zu einem Effekt auf p-GP durch die Polyphenole unter Umständen positiv beeinflusst werden kann. Taxifolin, der M1 sowie die Urolithine A und C konnten so als antioxidativ aktive Stoffe erstmals vergleichend analysiert und die Resultate sinnvoll zu bestehenden Daten in Relation gesetzt werden. Sie konnten nach antioxidativer Potenz in der Reihenfolge Urolithin C > M1 > Taxifolin > Urolithin A geordnet werden. Zur Analyse des Einflusses der ausgewählten Polyphenole auf die Funktionalität von p-GP sollten Transportversuche über einen CaCo-II-Monolayer mit Rhodamin 123 als Markersubstanz durchgeführt werden. Diese Untersuchungen benötigen typischerweise eine vorbereitende Kulturzeit der Zellen von insgesamt drei Wochen, sodass sich eine Verkürzung dieser Zeitspanne aus Zeitersparnis- und Kostengründen positiv auf den Durchsatz der Versuche auswirken würde. In einem umfassenden Ansatz mit kombinierter Bestimmung der Qualifizierung der Zellschichten im Hinblick auf Qualität des Monolayers (TEER-Messung, Lucifer-Yellow-Transportrate, Fluoreszenzfärbung der Tight-junctions) sowie der Funktionalität und Expression von p-GP gelang der Nachweis, dass 14 Tage hinreichend und sinnvoll waren. Zentraler Bestandteil war in der vorliegenden Arbeit die Identifizierung der Effekte der Urolithine auf sowohl p-GP direkt, als auch auf die Genexpression dieses Transportproteins. Diese Polyphenole werden im menschlichen Verdauungstrakt über einen bakteriellen Metabolismus aus Ellagtanninen und Ellagsäure hergestellt und sind aufgrund ihrer vielfältigen gesundheitsförderlichen Charakteristiken in der Forschung von steigendem Interesse. Hierfür konnten nach unserem Kenntnisstand mit den gewählten Versuchsansätzen neue Erkenntnisse gewonnen werden. In den Transportversuchen mit Rhodamin 123 als Modellsubstrat von p-GP konnten die Urolithine den p-GP-vermittelten Transport positiv beeinflussen. Die Urolithine B (Papp-Ratio 1,98), C (Papp-Ratio 2,15) und das Isourolithin A (Papp-Ratio 1,63) steigerten den Rhodamintransport signifikant und lediglich für Urolithin A (Papp-Ratio 1,45) konnte keine Signifikanz belegt werden. Der Einfluss der Urolithine lag jeweils im Bereich des Modellinduktors Dexamethason. Ebenso konnte eine positive Modulierung der Genexpression nach 24 h detektiert werden. Die Hochregulierungen durch die Urolithine A (zwei- bis dreifach), B (1,4-fach) und C (1,8-fach) waren konsistent und statistisch signifikant. Urolithin A konnte hierbei als potentester Induktor charakterisiert werden, wohingegen sein Isomer Isourolithin A keinerlei signifikante Beeinflussung der Expression zeigte. In diesen Inkubationsversuchen wurde die Eigenschaft zur Erhöhung der Genexpression über den Einfluss auf den p-GP-vermittelten Rhodamintransport bestätigt. Die Urolithine A, B, C und Isourolithin A konnten nach einer Vorinkubation über 24 h und 48 h auch den Transport von Rhodamin 123 nochmals signifikanter zu den klassischen E Zusammenfassung 378 Transportversuchen ohne Vorinkubation steigern. Relevanz hierfür hatte der erste Zeitraum über 24 h, da hier ein deutlicher Anstieg der Rhodamintransportrate zu erkennen war. Nach 48 h stieg der Rhodamintransport nur noch geringfügig an oder ging sogar leicht zurück (Urolithin B). Hinsichtlich der Genexpression konnte nach 48 h nur noch Urolithin C p-GP signifikant hochregulieren, allerdings sind diese Erkenntnisse auf Basis der Zytotoxizität der Substanzen über diesen Zeitraum kritisch zu betrachten. In der Analyse des Effektes der weiteren Polyphenole auf die Genexpression von p-GP konnten für die meisten Stoffe nur zufällige Zusammenhänge hinsichtlich Hoch- und Herunterregulierung bestimmt werden. In den Transportversuchen konnte jedoch (+)-Hydnocarpin (Papp-Ratio 0,48) den Transport in gleichem Ausmaß wie der Modellinhibitor Verapamil (Papp-Ratio 0,48) hemmen. Durch Modifizierung des Versuchsmediums zur Annäherung an physiologischeren Bedingungen (Gallensäuren, pH 6) konnte für manche Substanzen ein deutlich verändertes Verhalten beobachtet werden. Die Rhodamintransportrate nahm unter Einfluss von Urolithin B, Isourolithin A und dem M1 signifikant nun ab und bei Urolithin C signifikant zu. Dies legt nahe, dass mit dem klassischen Transportversuchsmodell lediglich Tendenzen für die Substanzen bestimmt werden können. Weitere Untersuchungen näher an der Physiologie des Verdauungstraktes sind nötig, um ein genaueres Bild des Stoffeinflusses zu gewinnen. Die Frage nach zeitlichem Einsetzen beziehungsweise der Kontinuität des Effektes auf p� GP konnte mit den Urolithinen A, B und C sowie Dexamethason geklärt werden. Eine Substanzexposition von lediglich fünf Minuten war nicht ausreichend, um in den nachfolgenden zwei Stunden einen Effekt zu beobachten. Dies legt eine Reversibilität der zugrundeliegenden Mechanismen und eine notwendige dauerhafte Anwesenheit der Substanzen über die Versuchszeit nahe. Neben Rhodamin 123 wurden noch Transportversuche mit dem Fluorchinolonantibiotikum Ciprofloxacin als Modellsubstanz durchgeführt, da es aufgrund dessen Substratcharakters für p-GP von therapeutischer Relevanz sein kann, wenn das Transportverhalten durch Polyphenole beeinflusst wird. Im Gegensatz zu Rhodamin 123 wurde der Transport von Ciprofloxacin durch die vier Urolithine verringert, was für diese Metabolismusprodukte eine zusätzliche Wirkung auf weitere Transportproteine nahelegt, weil Ciprofloxacin unter anderem auch über BRCP transportiert wird. Mittels des bakteriellen Endotoxins LPS konnte eine Schädigung des CaCo-II-Monolayers erzeugt werden, welche sich über erniedrigte TEER-Werte und einen erhöhten Rhodamintransport nachweisen ließ. Eine Vorinkubation der vier Urolithine war nicht in der Lage, diese Schädigung abzumildern, jedoch nicht komplett zu verhindern. Die TEER- Zusammenfassung 379 Werte konnten zwar wieder etwas gesteigert werden, jedoch maskierte die starke Stimulation dieser Pflanzenstoffe auf p-GP und den damit verbundenen Transport von Rhodamin 123 mögliche positive Effekte auf diese oxidative Stresssituation. Zusammenfassend war es mit der vorliegenden Arbeit erstmals durch systematische vergleichende Untersuchung und Kombination von Charakterisierungsansätzen möglich, eine deutliche Beeinflussung der Genexpression und Funktionalität des p-Glykoproteins durch vor allem die Urolithine aufzuzeigen, was eine Relevanz sowohl des Mikrobioms als auch der Ernährung in der Arzneimitteltherapie nahelegt. Zudem gelang es den klassischen Transportassay durch Verkürzung um eine Woche zu verbessern.
The present thesis concerns the molecular imaging of opioid receptors and human butyrylcholinesterase with the aid of tailored probes, which are suitable for the respective applied imaging techniques. The first part focusses on imaging of opioid receptors with selective probes using total internal reflection- and single molecule fluorescence microscopy. Design and synthesis of the ligands are presented and their pharmacological characterization and application in microscopy experiments are shown. The second part of this thesis focused on the development of 18F-labeled, selective radiotracers for imaging of butyrylcholinesterase via positron emission tomography. The design and synthesis of each a reversible and pseudoirreversible 18F-labeled tracer are presented. After evaluation of the binding properties of each tracer, their initial application in ex vivo autoradiography- and preliminary in vivo microPET studies is described and analyzed.
Many (poly‐)phenolic natural products, for example, curcumin and taxifolin, have been studied for their activity against specific hallmarks of neurodegeneration, such as amyloid‐β 42 (Aβ42) aggregation and neuroinflammation. Due to their drawbacks, arising from poor pharmacokinetics, rapid metabolism, and even instability in aqueous medium, the biological activity of azobenzene compounds carrying a pharmacophoric catechol group, which have been designed as bioisoteres of curcumin has been examined. Molecular simulations reveal the ability of these compounds to form a hydrophobic cluster with Aβ42, which adopts different folds, affecting the propensity to populate fibril‐like conformations. Furthermore, the curcumin bioisosteres exceeded the parent compound in activity against Aβ42 aggregation inhibition, glutamate‐induced intracellular oxidative stress in HT22 cells, and neuroinflammation in microglial BV‐2 cells. The most active compound prevented apoptosis of HT22 cells at a concentration of 2.5 μm (83 % cell survival), whereas curcumin only showed very low protection at 10 μm (21 % cell survival).
Chronic inflammatory diseases such as rheumatoid arthritis, type 2 diabetes and cardiovascular diseases, are associated with the homeostatic imbalance of one of several physiological systems combined with the lack of spontaneous remission, which causes the disease to persevere throughout patients’ lives. The inflammatory response relies mainly on tissue-resident, pro-inflammatory M1 type macrophages and, consequently, a chance for therapeutic intervention lies in driving macrophage polarization towards the anti-inflammatory M2 phenotype. Therefore, anti-inflammatory cytokines that promote M2 polarization, including interleukin-4 (IL4), have promising therapeutic potential. Unfortunately, their systemic use is hampered by a short serum half-life and dose-limiting toxicity. On the way towards cytokine therapies with superior safety and efficacy, this thesis is focused on designing bioresponsive delivery systems for the anti-inflammatory cytokine IL4.
Chapter 1 describes how anti-inflammatory cytokines are tightly regulated in chronic, systemic inflammation as in rheumatoid arthritis but also in acute, local inflammation as in myocardial infarction. Both diseases show a characteristic progression during which anti-inflammatory cytokine delivery is of variable benefit. A conventional, passive drug delivery system is unlikely to release the cytokines such that the delivery matches the dynamic course of the (patho-)physiological progress. This chapter presents a blueprint for active drug delivery systems equipped with a 24/7 inflammation detector that continuously senses for matrix metalloproteinases (MMP) as surrogate markers of the disease progress and responds by releasing cytokines into the affected tissues at the right time and place. Because they are silent during phases of low disease activity, bioresponsive depots could be used to treat patients in asymptomatic states, as a preventive measure. The drug delivery system only gets activated during flares of inflammation, which are then immediately suppressed by the released cytokine drug and could prevent the steady damage of subclinical chronic inflammation, and therefore reduce hospitalization rates.
In a first proof of concept study on controlled cytokine delivery (chapter 2), we developed IL4-decorated particles aiming at sustained and localized cytokine activity. Genetic code expansion was deployed to generate muteins with the IL4’s lysine 42 replaced by two different unnatural amino acids bearing a side chain suitable for click chemistry modification. The new IL4 muteins were thoroughly characterized to ensure proper folding and full bioactivity. Both muteins showed cell-stimulating ability and binding affinity to IL4 receptor alpha similar to those of wild type IL4. Copper-catalyzed (CuAAC) and strain-promoted (SPAAC) azide–alkyne cycloadditions were used to site-selectively anchor IL4 to agarose particles. These particles had sustained IL4 activity, as demonstrated by the induction of TF-1 cell proliferation and anti-inflammatory M2 polarization of M-CSF-generated human macrophages. This approach of site-directed IL4 anchoring on particles demonstrates that cytokine-functionalized particles can provide sustained and spatially controlled immune-modulating stimuli.
The idea of a 24/7 sensing, MMP driven cytokine delivery system, as described in the introductory chapter, was applied in chapter 3. There, we simulated the natural process of cytokine storage in the extracellular matrix (ECM) by using an injectable solution of IL4 for depot formation by enzyme-catalyzed covalent attachment to ECM components such as fibronectin. The immobilized construct is meant to be cleaved from the ECM by matrix-metalloproteinases (MMPs) which are upregulated during flares of inflammation. These two functionalities are facilitated by a peptide containing two sequences: a protease-sensitive peptide linker (PSL) for MMP cleavage and a sequence for covalent attachment by activated human transglutaminase FXIIIa (TGase) included in the injection mix for co-administration. This peptide was site-selectively conjugated to the unnatural amino acid at IL4 position 42 allowing to preserve wild type bioactivity of IL4. In vitro experiments confirmed the anticipated MMP response towards the PSL and TGase-mediated construct attachment to fibronectin of the ECM. Furthermore, the IL4-peptide conjugates were able to reduce inflammation and protect non-load bearing cartilage along with the anterior cruciate ligament from degradation in an osteoarthritis model in rabbits. This represents the first step towards a minimally invasive treatment option using bioresponsive cytokine depots with potential clinical value for inflammatory conditions.
One of the challenges with this approach was the production of the cytokine conjugate, with incorporation of the unnatural amino acid into IL4 being the main bottleneck. Therefore, in chapter 4, we designed a simplified version of this depot system by genetically fusing the bifunctional peptide via a flexible peptide spacer to murine IL4. While human IL4 loses its activity upon C-terminal elongation, murine IL4 is not affected by this modification. The produced murine IL4 fusion protein could be effectively bound to in vitro grown extracellular matrix in presence of TGase. Moreover, the protease-sensitive linker was selectively recognized and cleaved by MMPs, liberating intact and active IL4, although at a slower rate than expected. Murine IL4 offers the advantage to evaluate the bioresponsive cytokine depot in many available mouse models, which was so far not possible with human IL4 due to species selectivity.
For murine IL4, the approach was further extended to systemic delivery in chapter 5. To increase the half-life and specifically target disease sites, we engineered a murine IL4 variant conjugated with a folate-bearing PEG chain for targeting of activated macrophages. The bioactive IL4 conjugate had a high serum stability and the PEGylation increased the half-life to 4 h in vivo. Surprisingly, the folate moiety did not improve targeting in an antigen-induced arthritis (AIA) mouse model. IL4-PEG performed better in targeting the inflamed joint, while IL4-PEG-folate showed stronger accumulation in the liver. Fortunately, the modular nature of the IL4 conjugate facilitates convenient adaption of PEG chain length and the targeting moiety to further improve the half-life and localization of the cytokine.
In summary, this thesis describes a platform technology for the controlled release of cytokines in response to inflammation. By restricting the release of the therapeutic to the site of inflammation, the benefit-risk ratio of this potent class of biologics can be positively influenced. Future research will help to deepen our understanding of how to perfectly combine cytokine, protease-sensitive linker and immobilization tag or targeting moiety to tackle different diseases.
The past decades have witnessed the development of new pharmaceutical compounds that modulate receptor function by targeting allosteric sites. Allosteric sites are, by definition, domains topographically distinct from the orthosteric binding pocket where the natural ligand binds. Exploring the possibilities of linking orthosteric and allosteric pharmacophores in one compound to yield ‘bitopic’ compounds is a strategy derived from the “message-address” concept by Schwyzer , first applied to GPCRs by Portoghese et al. This concept explicitly underlines the orthosteric/allosteric combination, in opposite to the more general umbrella term bivalent. The broad possibilities of bitopic ligands in the pharmaceutical field are under continuous study. Bitopic compounds are promising pharmaceutical tools for taking advantage of the allosteric binding to achieve subtype selectivity while preserving high affinity at the receptor. The development of bitopic ligands, based on the idea of combining high affinity (via orthosteric sites) with high selectivity (via allosteric sites), have led to the development of highly selective bivalent ligands for GPCRs , such as for the opioid receptors , muscarinic acetylcholine receptors (mAChRs), serotonin receptors, cannabinoid receptors, and gonadotropin-releasing hormone receptors. This concept has even been extended to other receptors, for examples nicotinic receptors and other proteins, such as acetylcholinesterases and the tyrosine kinase receptors TrkA and TrkC. The reasons to pursue a bitopic ligand approach are various. An improved affinity for the target GPCR and/or an improved selectivity either at the level of receptor subtype, or at the level of signaling pathway. Another advantage of bitopic ligands over purely allosteric ligands is that the former rely on the appropriate presence of endogenous agonist tone to mediate their effects, whereas a bitopic ligand would engage the orthosteric site irrespective of the presence or absence of endogenous tone. By way of introduction to the hybrid approach, a review of the concept of hybrids compounds targeting the cholinergic system is presented in section A of this thesis. Recent updates in hybrid molecule design as a strategy for selectively addressing multiple target proteins involved in Alzheimer's disease (AD) is here reported . This represents the potential and the growing interest in hybrid compound as pharmacological tools to achieve receptor subtype selectivity and/or, to study the overall functional activity of the receptor. Until now, muscarinic acetylcholine receptors (mAChRs) have proved to be a particularly fruitful receptor model for the development and characterization of bitopic ligands. In this thesis, several examples of new muscarinic bitopic approach are reported in the results section. A study of bipharmacophoric ligands composed of the muscarinic positive allosteric modulators (BQCAderived compounds) linked with chain of various lengths to different orthosteric building blocks is reported in the result part 1. Synthesis and examination of the potential pharmacological characteristic of Oxotremorine-BQCAd compounds and Xanomeline-BQCAd hybrid derivatives are described in results parts 2 and 4, respectively. Moreover, the bitopic concept has even been extended to other proteins, such as acetylcholinesterase. In the result part 5 an overview of the new Tacrine-Xanomeline hybrids aiming to improve the inhibitory potency of the acetylcholinesterase and simultaneously to increase the cholinergic tone, via the xanomelinic portion acting on the M1 receptor is given. A new trivalent approach is presented for the first time to deepen the study of the M1 muscarinic receptor in the result part 6. Moreover, the synthesis of a new series of iperoxo-derived alkane, bis(ammonio)alkane-type and rigidified chain ligands is given in the result part 7 together with some prospects for further research.
Inhibition of coronavirus (CoV)‐encoded papain‐like cysteine proteases (PL\(^{pro}\)) represents an attractive strategy to treat infections by these important human pathogens. Herein we report on structure‐activity relationships (SAR) of the noncovalent active‐site directed inhibitor (R)‐5‐amino‐2‐methyl‐N‐(1‐(naphthalen‐1‐yl)ethyl) benzamide (2 b), which is known to bind into the S3 and S4 pockets of the SARS‐CoV PL\(^{pro}\). Moreover, we report the discovery of isoindolines as a new class of potent PL\(^{pro}\) inhibitors. The studies also provide a deeper understanding of the binding modes of this inhibitor class. Importantly, the inhibitors were also confirmed to inhibit SARS‐CoV‐2 replication in cell culture suggesting that, due to the high structural similarities of the target proteases, inhibitors identified against SARS‐CoV PL\(^{pro}\) are valuable starting points for the development of new pan‐coronaviral inhibitors.
To diagnose diseases correctly requires not only trained and skilled personnel, but also cost-intensive and complex equipment. Rapid tests can help with the initial evaluation, but result generation can also take up to several hours, depending on the test system. At this point, novel bioresponsive diagnostic systems are used, responding to the disease related shift of biological processes. They monitor changes in the biological environment and can react to them e.g. with the release of substances. This can be used in drug delivery formulations but can also help to diagnose diseases occurring in the oral cavity and inform patients of their state of health. The tongue is herein used as a 24/7 available detector.
In section I of this work, the foundation for the development of these diagnostic systems was laid. A suitable flavoring agent was found, which is stable, can be coupled to the N-terminus of peptides and has a strongly conceivable taste. For the optimization of the protease-sensitive linker (PSL), an analytical system was established (PICS assay), which determines protease-specific cleavable amino acid sequences. In order to replace the PMMA particles previously required, an acetyl protecting group was introduced N-terminally as it protects peptides and proteins in the human body from degradation by human aminopeptidase. The new synthesized flavor was examined with a NIH cell line for cytotoxicity and with an electronic tongue setup for its bitterness.
Section II deals with the structure of a system which detects severe inflammations in the oral cavity, e.g. PA. The established PICS assay was used to confirm the previously used PSL sequence in its application. Using solid phase peptide synthesis, 3 linkers were synthesized which respond to the elevated MMP concentrations present in inflammation. The resulting peptides were acetylated and coupled with HATU/DIPEA to the modified denatonium. Cutting experiments with MMPs over different concentration and time ranges confirmed the response of the diagnostic sensor to these enzymes. The obtained construct was examined for cell toxicity by WST assay. The masked bitterness of the sensors was confirmed by an electronic tongue setup.
To address non-human proteases (and thereby infections), section III focuses on the establishment of detection system of a cysteine protease SpeB expressed by Streptococcus pyogenes. The in-house expression of SpeB using E. coli cells was established for this purpose. An analysis of the SpeB cleavage sites was performed using a PICS assay setup. Four constructs with different PSL were synthesized analogous to section II. Cleavage experiments with the expressed and purified SpeB showed a response of two constructs to the protease. In addition, a system was established to quantify the concentration of SpeB in human saliva using western blot technique with subsequent quantification.
In section IV a compound was synthesized which can now be coupled to a flavor. The final coupled construct is able to detect present NA activity specifically from influenza A and B. The market for existing influenza diagnostics was explored to determine the need for such a system. A neuraminic acid was modified in positions 4 and 7 and protected in such a way that subsequent coupling via the hydroxy-group in position 2 was selectively possible.
In summary, this results in a diagnostic platform that can be used anywhere, by anyone and at any time. This represents a new dimension in the rapid diagnosis of inflammations and bacterial or viral infections.
Investigation of isomerization of dexibuprofen in a ball mill using chiral capillary electrophoresis
(2021)
Besides the racemate, the S‐enantiomer of ibuprofen (Ibu) is used for the treatment of inflammation and pain. Since the configurational stability of S‐Ibu in solid state is of interest, it was studied by means of ball milling experiments. For the evaluation of the enantiomeric composition, a chiral CE method was developed and validated according to the ICH guideline Q2(R1). The addition of Mg\(^{2+}\), Ca\(^{2+}\), or Zn\(^{2+}\) ions to the background electrolyte (BGE) was found to improve Ibu enantioresolution. Chiral separation of Ibu enantiomers was achieved on a 60.2 cm (50.0 cm effective length) x 75 μm fused‐silica capillary using a background electrolyte (BGE) composed of 50 mM sodium acetate, 10 mM magnesium acetate tetrahydrate, and 35 mM heptakis‐(2,3,6‐tri‐O‐methyl)‐β‐cyclodextrin (TM‐β‐CD) as chiral selector. The quantification of R‐Ibu in the mixture was performed using the normalization procedure. Linearity was evaluated in the range of 0.68–5.49% R‐Ibu (R\(^{2}\) = 0.999), recovery was found to range between 97 and 103%, the RSD of intra‐ and interday precision below 2.5%, and the limit of quantification for R‐ in S‐Ibu was calculated to be 0.21% (extrapolated) and 0.15% (dilution of racemic ibuprofen), respectively. Isomerization of S‐Ibu was observed under basic conditions by applying long milling times and high milling frequencies.
Extraction is a key step in studying compounds from plants and other natural sources. The common use of high temperatures in pressurized microwave‐assisted extraction (PMAE) makes it unsuitable for the extraction of compounds with low or unknown thermal stability. This study aimed at determining the suitability of low‐temperature, short‐time PMAE in attaining yields comparable to those of prolonged maceration at room temperature. Additionally, we explored the phytochemical differences of the extracts from both techniques. Maceration at room temperature for 24 hr and PMAE at 40–45°C and 10 bar for 30 min were carried out on 18 samples from 14 plant species at a solvent‐to‐feeds ratio of 10. The PMAE yields of 16 out of 18 samples were within the proportions of 91–139.2% as compared with the respective extracts from maceration. Varying numbers of nonmatching peaks were noted in MS chromatograms of five extract pairs, indicating selective extraction of some compounds. Low‐temperature PMAE can attain reasonable extraction efficiency with the added value of sparing compounds of low thermal stability. The method can also enable the recovery of compounds distinct from those obtained by maceration.
Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3A4 and is susceptible for drug–drug interactions (DDI). The goal of this work was to develop a physiologically based pharmacokinetic (PBPK) model to investigate EHC, to simulate DDI with Rifampin and to simulate subjects with hepatic impairment. The model was established using PK-Sim® and six human clinical studies. The inclusion of an EHC process into the model led to the most accurate description of the pharmacokinetic behavior of CAB. The model was able to predict plasma concentrations with low bias and good precision. Ninety-seven percent of all simulated plasma concentrations fell within 2-fold of the corresponding concentration observed. Maximum plasma concentration (C\(_{max}\)) and area under the curve (AUC) were predicted correctly (predicted/observed ratio of 0.9–1.2 for AUC and 0.8–1.1 for C\(_{max}\)). DDI with Rifampin led to a reduction in predicted AUC by 77%. Several physiological parameters were adapted to simulate hepatic impairment correctly. This is the first CAB model used to simulate DDI with Rifampin and hepatic impairment including EHC, which can serve as a starting point for further simulations with regard to special populations.
For the quality assurance of substances for pharmaceutical use, a variety of analytical techniques are available to address specific analytical problems. In this field of application, liquid chromatography (LC) stands out as the gold standard in the pharmaceutical industry. Various detectors can be employed, which are e.g. based on UV/Vis spectroscopy for the examination of molecules with a chromophore, or mass spectrometry (MS) for structural elucidation of analytes. For the separation of enantiomers, the use of capillary electrophoresis (CE) may be more favorable due to the high separation efficiency and easy-to-use and comparatively inexpensive chiral selectors, in contrast to chiral columns for LC, which are usually very expensive and limited to a restricted number of analytes. For structure elucidation in impurity profiling, one- and multidimensional 1H NMR spectroscopy is a valuable tool as long as the analyte molecule has got nuclei that can be detected, which applies for the magnitude of organic pharmaceutical substances.
For the evaluation of the amount of mineral oil aromatic hydrocarbons (MOAH) in various paraffin samples from different suppliers, a straightforward method based on 1H NMR spectroscopy was elaborated. The MOAH/MOSH ratio was used to indicate the amount of MOAH of paraffins and to evaluate the extent of refining. In addition, a representative paraffin sample was measured without sample solvent at high temperatures (about 340 K) to avoid the interfering residual solvent signals in the spectral regions of interest. The results of both methods were in good accordance.
Moreover, the 1H NMR results were complemented with the UV measurements from the purity testing of paraffins according to the DAB 8. Correlations of the NMR and UV spectroscopic data indicated a linear relationship of both methods for the determination of MOAH in paraffins.
Finally, the 1H NMR data was evaluated by principal component analysis (PCA) to explore differences within the paraffin samples and the spectral regions in the 1H NMR spectrum which are responsible for the formation of groups. It could be found that most variation is due to the MOSH of the paraffins. The PCA model was capable of differentiating between soft, liquid and solid paraffins on the one hand and between natural and synthetic liquid paraffins on the other hand.
The impurity profiling of L-ascorbic acid 2-phosphate magnesium (A2PMg) was performed by means of one- and two-dimensional NMR spectroscopy. Several ethylated impurities could be detected, which were likely to be formed during synthesis of A2PMg. The structures of two of the ethylated impurities were identified as ascorbic acid 2-phosphate ethyl ester and ethanol, (residual solvent from synthesis). NMR spectroscopic studies of the fractions obtained from preparative HPLC of A2PMg revealed two additional impurities, which were identified as phosphorylated derivatives of ascorbic acid, ascorbic acid 3,5-phosphate and ascorbic acid 5-phosphate.
Solid state mechanochemistry as an alternative approach for stress testing was applied on the drug substances S-Ibuprofen (Ibu) and Clopidogrel (CLP) using a ball mill, in order to study their degradation profile:
First, the isomerization of S-Ibu was investigated, which was stressed in the solid state applying several milling frequencies and durations under basic, acidic and neutral conditions. For the separation of Ibu enantiomers, a chiral CE method was developed and validated according to ICH Q2(R1). It was found that S-Ibu is overall very stable to isomerization; it shows minor conversion into the R-enantiomer under basic environment applying long milling times and high frequencies.
Last, the degradation profile of clopidogrel hydrogen sulfate (CLP) was investigated, which was stressed in the solid state under various oxidative conditions. An already existing HPLC-UV method was adjusted to sufficiently separate the degradation products, which were characterized by means of UV and MS/(MS) detection. Most of the degradation products identified were already reported to result from conventional CLP stress tests. The degradation profile of CLP was mainly influenced by the material of the milling jar and the type of catalyst used.
The charged aerosol detector (CAD) is an aerosol-based detector employed in liquid chromatography which has become established in the field of pharmaceutical analysis due to its outstanding performance characteristics, e.g. the almost uniform response for nonvolatile analytes. Owing to its principle of detection, the response of the CAD depends on the volatility of a compound and is inherently nonlinear. However, the newly implemented instrumental settings evaporation temperature and power function value (PFV) are valuable tools to overcome some of these drawbacks and can even enhance the detector’s capabilities when adjusted properly.
This thesis aimed to evaluate the impact of the new instrumental settings on the CAD performance. Additionally, the influence of modern separation techniques for small polar compounds on the CAD was assessed and the applicability of hyphenated UV-CAD techniques explored. The optimization strategies derived from the evaluation procedures and the conjunction of the instrumental and chromatographic techniques investigated were utilized for the challenging impurity profiling of amino acids and amino acid-like drugs.
The results of the method validation procedures confirmed the broad applicability of the CAD in the pharmaceutical analysis of nonvolatile compounds, supported by satisfactory sensitivity and reproducibility for meeting the regulatory requirements with respect to the ICH guidelines Q2(R1) and Q3A(R2). The limits of applicability include the analysis of semivolatile compounds, and the method transfer between current and legacy CAD models. Further advances in the definition and standardization of allowed ranges for the instrumental settings and the establishment of general optimization procedures in the method development could lead to a more widespread use of the detection technique in compendial methods.
Considerable effort has previously been invested in a light‐controlled inhibition of the enzyme acetylcholinesterase (AChE). We found that a novel azobenzene‐based bistacrine AChE inhibitor switched faster than the known dithienylethene based bistacrine and inverted the photo‐controlled interactions of the photoisomers compared to its dithienylethene congener. Furthermore, we have optimized a previously described light‐controlled tacrine‐based AChE inhibitor. Isomerization upon irradiation with UV light of the novel inhibitor was observed in aqueous medium and showed no fatigue over several cycles. The cis‐enriched form showed an 8.4‐fold higher inhibition of hAChE compared with its trans‐enriched form and was about 30‐fold more active than the reference compound tacrine with a single‐digit nanomolar inhibition. We went beyond proof‐of‐concept to discover photoswitchable AChE inhibitors with pharmacologically desirable nanomolar inhibition, “cis‐on” effect, and pronounces differences between the photoisomers.
Alzheimer′s disease (AD) is a neurological disorder with still no preventive or curative treatment. Flavonoids are phytochemicals with potential therapeutic value. Previous studies described the flavanone sterubin isolated from the Californian plant Eriodictyon californicum as a potent neuroprotectant in several in vitro assays. Herein, the resolution of synthetic racemic sterubin (1) into its two enantiomers, (R)‐1 and (S)‐1, is described, which has been performed on a chiral chromatographic phase, and their stereochemical assignment online by HPLC‐ECD coupling. (R)‐1 and (S)‐1 showed comparable neuroprotection in vitro with no significant differences. While the pure stereoisomers were configurationally stable in methanol, fast racemization was observed in the presence of culture medium. We also established the occurrence of extracted sterubin as its pure (S)‐enantiomer. Moreover, the activity of sterubin (1) was investigated for the first time in vivo, in an AD mouse model. Sterubin (1) showed a significant positive impact on short‐ and long‐term memory at low dosages.
Opioid receptors (ORs) are classified among the oldest and best investigated drug targets due to their fundamental role in the treatment of pain and related disorders. ORs are divided in three conventional subtypes (μ, κ, δ) and the non‐classical nocicepetin receptor. All ORs are family A G protein‐coupled receptors (GPCRs), and are located on the cell surface. Modern biophysical methods use light to investigate physiological processes at organismal, cellular and subcellular level. Many of these methods rely on fluorescent ligands, thus highlighting their importance. This review addresses the advancements in the development of opioid fluorescent ligands and their use in biological, pharmacological and imaging applications.
Cell culture models are helpful tools to study inflammatory diseases, like rheumatoid arthritis (RA), osteoarthritis (OA), arteriosclerosis or asthma, which are linked to increased matrix metalloproteinase (MMP) activity. Such cell culture models often focus on the secretion of cytokines and growth factors or the direct effects of disease on tissue destruction. Even though the crucial role of MMPs in inflammatory diseases is known, the results of MMP studies are contradictious and the use of MMPs as biomarkers is inconsistent. MMPs play an important role in disease pathology, as they are involved in elastin degradation in the walls of alveoli in chronic obstructive pulmonary disease (COPD), tumor angiogenesis and metastasis and in cartilage and bone degradation in arthropathies. In RA and OA MMPs are secreted by osteocytes, synoviocytes, and by infiltrating immune cells in response to the increased concentration of inflammatory mediators, like growth factors and cytokines. MMPs are zinc and calcium-dependent proteinases and play an important role in physiological and pathological extracellular matrix (ECM) turn over. Their substrate specificity gives them the ability to degrade all major ECM components, like aggrecan, elastin, gelatin, fibronectin and all types of collagen even the triple helix of collagen monomers. The ECM consists of two large three-dimensional cross-linked macromolecule classes: one are fibrous proteins, like collagen and elastin fibers that are responsible for ECM’s structure, tensile strength, resiliency, reversible extensibility, and deformability and the second class is comprised of proteoglycans composed of glycosaminoglycan (GAG) chains covalently attached to protein cores that are multifunctionally involved in signaling pathways and cell interactions. ECM is present within all tissues and organs and changes in ECM structure contribute to pathogenesis, e.g. wounded and fibrotic tissue, COPD or tumours.
This thesis primarily focuses on the development of a diagnostic peptide system, that enables to gain information on MMP activity from ECM by deploying the isobaric mass encoding strategy. The core element of the developed system is an isotopically labelled peptide sequence (mass tag), that is released in response to elevated levels of MMPs and allows multiplexed detection in tandem mass spectrometry (LC-MS/MS). The mass reporters possess a modular structure with different functionalities. C-terminal either a transglutaminase (TG) recognition sequence or a high molecular weight polyethylene glycol (PEG) moiety was attached to immobilize the mass reporters covalently or physically at the injection site. The following matrix metalloproteinase substrate sequence (MSS) is incorporated in two different versions with different sensitivity to MMPs. The MSS were applied in pairs for relative quantification consisting of the cleavable version synthesized with natural L-amino acids and the non-cleavable D-amino acid variant. The mass tag was synthesized with isotopically labelled amino acids and is separated from the MSS by a UV light-sensitive molecule. N-terminal the mass tag is followed by a tobacco etch virus protease (TEV) sensitive sequence, that is responsible to separate the mass tag from the affinity tag, which was either the Strep-tag II sequence or biotin and were added for purification purposes.
Chapter 1 presents a step-by-step protocol on how to design a mass tag family allowing for multiplexed analysis by LC-MS/MS. The multiplexing is achieved by developing an isobar mass tag family with four family members, which are chromatographically indistinguishable, but due to the mass encoding principles they fragment in distinct y-type ions with a mass difference of 1 or 2 Da each in MS2. Furthermore, it is explained how to covalently attach the mass reporter peptides onto ECM by the activated calcium-catalyzed blood coagulation transglutaminase factor XIII (FXIIIa). The lysine of mass reporter’s TG sequence (D-domain of insulin-like growth factor-I (IGF-I)) and a glutamine in fibronectin are covalently crosslinked by FXIIIa and build an isopeptide bond. Elevated levels of MMP release the mass reporters from ECM by recognizing the inter-positioned MSS.
The designed mass reporters were able to monitor enzyme activity in an in vitro setting with cell-derived ECM, which was shown in Chapter 2. The modular structured mass reporters were investigated in a proof of concept study. First, the different modules were characterized in terms of their MMP responsiveness and their sensitivity to TEV protease and UV light. Then the FXIIIa-mediated coupling reaction was detailed and the successful coupling on ECM was visualized by an immunosorbent assay or confocal laser scanning microscopy. Finally, the immobilized mass reporters on ECM were incubated with MMP-9 to investigate their multiplexing ability of MMP activity. The cleaved mass reporter fragments were purified in three steps and mass tags were analyzed as mix of all four in LC-MS/MS.
Chapter 3 describes the change from an immobilizing system as seen in chapter 1 and 2 to a soluble enzyme activity monitoring system that was applied in an osteoarthritic mouse model. Instead of the immobilizing TG sequence the C-terminal MMS was extended with two amino acids where one holds an azide moiety to perform a strain-promoted azide-alkyne cycloaddition to a high molecular weight dibenzocyclooctyne-polyethylene glycol (DBCO-PEG), which was chosen to retain the mass reporters at the injection site. Furthermore, the N-terminal affinity tag was extended with a 2.5 kDa PEG chain to increase the half-life of the mass reporter peptides after MMP release. The systems biocompatibility was proved but its enzyme monitoring ability in an in vivo setting could not be analyzed as samples degraded during shipping resulting from the Chinese customs blocking transport to Germany.
In summary the diagnostic peptide system was developed in two variants. The immobilized version one from chapter 1 and 2 was designed to be covalently attached to ECM by the transglutaminase-mediated cross-linking reaction. In an in vitro setting the functionality of the mass reporter system for the detection of MMP activity was successfully verified. The second variant comprises of a soluble mass reporter system that was tested in an OA mouse model and showed biocompatibility. With these two designed systems this thesis provides a flexible platform based on multiplexed analysis with mass-encoded peptides to characterize cell culture models regarding their MMP activity, to deploy cell-derived ECM as endogenous depot scaffold and to develop a mass tag family that enables simultaneous detection of at least four mass tags.
Understanding intramammary estrogen homeostasis constitutes the basis of understanding the role of lifestyle factors in breast cancer etiology. Thus, the aim of the present study was to identify variables influencing levels of the estrogens present in normal breast glandular and adipose tissues (GLT and ADT, i.e., 17β-estradiol, estrone, estrone-3-sulfate, and 2-methoxy-estrone) by multiple linear regression models. Explanatory variables (exVARs) considered were (a) levels of metabolic precursors as well as levels of transcripts encoding proteins involved in estrogen (biotrans)formation, (b) data on breast cancer risk factors (i.e., body mass index, BMI, intake of estrogen-active drugs, and smoking) collected by questionnaire, and (c) tissue characteristics (i.e., mass percentage of oil, oil%, and lobule type of the GLT). Levels of estrogens in GLT and ADT were influenced by both extramammary production (menopausal status, intake of estrogen-active drugs, and BMI) thus showing that variables known to affect levels of circulating estrogens influence estrogen levels in breast tissues as well for the first time. Moreover, intratissue (biotrans)formation (by aromatase, hydroxysteroid-17beta-dehydrogenase 2, and beta-glucuronidase) influenced intratissue estrogen levels, as well. Distinct differences were observed between the exVARs exhibiting significant influence on (a) levels of specific estrogens and (b) the same dependent variables in GLT and ADT. Since oil% and lobule type of GLT influenced levels of some estrogens, these variables may be included in tissue characterization to prevent sample bias. In conclusion, evidence for the intracrine activity of the human breast supports biotransformation-based strategies for breast cancer prevention. The susceptibility of estrogen homeostasis to systemic and tissue-specific modulation renders both beneficial and adverse effects of further variables associated with lifestyle and the environment possible.
Antimikrobielle Resistenzen stellen eine weltweite Herausforderung dar und sind mit einer hohen Morbidität und Mortalität verbunden. Die Letalitätsrate durch multiresistente Keime steigt stetig an, weshalb die WHO im Jahr 2017 eine Prioritätenliste resistenter Keime erstellte, die die Entwicklung neuer Antibiotika vorantreiben soll. Diese umfasst vornehmlich
gramnegative Bakterien, da diese aufgrund ihres Zellaufbaus sowie diverser Resistenzmechanismen besonders widerstandsfähig gegenüber dem Angriff vieler Antibiotika sind. Einige grampositive Keime (z.B. S. aureus) stehen ebenfalls auf dieser Liste und stellen eine große Herausforderung für die Medizin dar. Infolgedessen ist die Entwicklung neuer Antiinfektiva mit neuen Angriffspunkten gegen resistente Pathogene zwingend nötig, um mit bisherigen Resistenzen umgehen zu können.
Die vorliegende Arbeit beschäftigt sich mit der Entwicklung und Synthese von kovalent (reversibel) bindenden Inhibitoren der Enoyl-ACP-Reduktase FabI (Staphylococcus aureus, Escherichia coli) und der Thiolase FadA5 (Mycobacterium tuberculosis). Beide Enzyme sind essenziell für das Überleben des jeweiligen Bakteriums.
FabI ist ein wichtiges und geschwindigkeitsbestimmendes Schlüsselenzym der Fettsäuresynthese Typ II diverser Bakterien. Hierbei werden wichtige Phospholipide hergestellt, die für den Aufbau der Zellmembran nötig sind. Schiebel et al. ist es gelungen, einen potenten Inhibitor für den Erreger S. aureus sowie E. coli zu entwickeln und zu charakterisieren. Ausgehend von dieser Verbindung wurde eine Substanzbibliothek mit verschiedenen „warheads“ hergestellt. Hierbei wurde die Verknüpfung zwischen dem Pyridon-Grundgerüst und der elektrophilen Gruppe sowie die über den Ether verknüpften aromatischen Ringsysteme variiert. Diese Verbindungen wurden hinsichtlich ihrer inhibitorischen Aktivität am jeweiligen Enzym getestet. Anschließend wurde von Verbindung 32 und 33, die jeweils eine gute Inhibition des Enzyms aufweisen, der IC50-Wert gemessen. Beide Verbindungen weisen eine 50-prozentige Reduktion der Enzymaktivität im mittleren nanomolaren Bereich auf. Zusätzlich wurde Verbindung 32 in einem sogenannten „jump-dilution“-Assay auf kovalente Inhibition getestet. Durch dieses Experiment konnte eine kovalente Inhibition des Enzyms ausgeschlossen werden.
Die Reaktivität der eingesetzten „warheads“ wurde gegenüber einem Tripeptid mittels eines LC/MS-Iontrap-Systems bestimmt. Die untersuchten Verbindungen zeigten keine signifikante Reaktion mit der im Tripeptid eingebauten nukleophilen Aminosäure Tyrosin, deren Nukleophilie bei dem pH-Wert des Tests (pH = 8.2 und 10.8) nicht hoch genug ist.
Um einen Einblick in den Bindemodus der Verbindungen zu erhalten, wurden ferner Kristallisationsversuche durchgeführt. Die erhaltenen Kristallstrukturen zeigen, dass die Verbindungen mit dem gewünschten Bindemodus am Zielenzym binden, aber eine kovalente Modifizierung des Tyrosins146 durch die eingesetzten „warheads“ aufgrund der großen Entfernung (6 Å zwischen elektrophiler Gruppe und Tyrosin146), unwahrscheinlich ist.
Zusätzlich wurden die physikochemischen Eigenschaften (Stabilität, Wasserlöslichkeit und logP) der Verbindung 32 sowie Verbindung 33 charakterisiert.
M. tuberculosis ist der Erreger der global verbreiteten Infektionskrankheit Tuberkulose (TB), die zu den zehn häufigsten Todesursachen weltweit gehört. Das Bakterium kann das im menschlichen Körper vorkommende Cholesterol metabolisieren und nutzt dessen Abbauprodukte als wichtige Kohlenstoffquelle. Die Thiolase FadA5 ist bei diesem Abbau ein wichtiges Enzym und konnte als potenzielles innovatives Target für neue Antibiotika definiert werden.
Durch Dockingstudien konnten zwei potenzielle Leitstrukturen als Inhibitoren der Thiolase FadA5 identifiziert werden. Im Rahmen dieser Arbeit wurden die vorgeschlagenen Strukturen mit dem gewünschten „warhead“ synthetisiert und hinsichtlich ihrer inhibitorischen Aktivität gegenüber dem Enzym untersucht. Die Zielverbindungen zeigen keine signifikante Hemmung sowie kovalente Bindung über die eingesetzten „warheads“ an die Thiolase FadA5.
A liquid chromatography tandem mass spectrometry method for the analysis of ten kinase inhibitors (afatinib, axitinib, bosutinib,cabozantinib, dabrafenib, lenvatinib, nilotinib, osimertinib, ruxolitinib, and trametinib) in human serum and plasma for theapplication in daily clinical routine has been developed and validated according to the US Food and Drug Administration andEuropean Medicines Agency validation guidelines for bioanalytical methods. After protein precipitation of plasma samples withacetonitrile, chromatographic separation was performed at ambient temperature using a Waters XBridge® Phenyl 3.5μm(2.1×50 mm) column. The mobile phases consisted of water-methanol (9:1, v/v) with 10 mM ammonium bicarbonate as phase A andmethanol-water (9:1, v/v) with 10 mM ammonium bicarbonate as phase B. Gradient elution was applied at a flow rate of 400μL/min. Analytes were detected and quantified using multiple reaction monitoring in electrospray ionization positive mode. Stableisotopically labeled compounds of each kinase inhibitor were used as internal standards. The acquisition time was 7.0 min perrun. All analytes and internal standards eluted within 3.0 min. The calibration curves were linear over the range of 2–500 ng/mLfor afatinib, axitinib, bosutinib, lenvatinib, ruxolitinib, and trametinib, and 6–1500 ng/mL for cabozantinib, dabrafenib, nilotinib,and osimertinib (coefficients of correlation≥0.99). Validation assays for accuracy and precision, matrix effect, recovery,carryover, and stability were appropriate according to regulatory agencies. The rapid and sensitive assay ensures high throughputand was successfully applied to monitor concentrations of kinase inhibitors in patients.
Microbial, mammalian, and plant cells produce and contain secondary metabolites, which typically are soluble in water to prevent cell damage by crystallization. The formation of ion pairs, for example, with carboxylic acids or mineral acids, is a natural blueprint to maintain basic metabolites in solution. Here, we aim at showing whether the mostly large carboxylates form soluble protic ionic liquids (PILs) with the basic natural product papaverine resulting in enhanced aqueous solubility. The obtained PILs were characterized by H-1-N-15 HMBC nuclear magnetic resonance (NMR) and in the solid state using X-ray powder diffraction, differential scanning calorimetry, and dissolution measurements. Furthermore, their supramolecular pattern in aqueous solution was studied by means of potentiometric and photometrical solubility, NMR aggregation assay, dynamic light scattering, zeta potential, and viscosity measurements. Thereby, we identified the naturally occurring carboxylic acids, citric acid, malic acid, and tartaric acid, as being appropriate counterions for papaverine and which will facilitate the formation of PILs with their beneficial characteristics, like the improved dissolution rate and enhanced apparent solubility.
Bioprinting has emerged as a valuable threedimensional (3D) biomanufacturing method to fabricate complex hierarchical cell-containing constructs. Spanning from basic research to clinical translation, sterile starting materials are crucial. In this study, we present pharmacopeia compendial sterilization methods for the commonly used bioink component alginate. Autoclaving (sterilization in saturated steam) and sterile filtration followed by lyophilization as well as the pharmacopeia non-compendial method, ultraviolet (UV)-irradiation for disinfection, were assessed. The impact of the sterilization methods and their effects on physicochemical and rheological properties, bioprinting outcome, and sterilization efficiency of alginate were detailed. Only sterile filtration followed by lyophilization as the sterilization method retained alginate's physicochemical properties and bioprinting behavior while resulting in a sterile outcome. This set of methods provides a blueprint for the analysis of sterilization effects on the rheological and physicochemical pattern of bioink components and is easily adjustable for other polymers used in the field of biofabrication in the future.
The muscarinic M\(_1\) acetylcholine receptor is an important drug target for the treatment of various neurological disorders. Designing M\(_1\) receptor-selective drugs has proven challenging, mainly due to the high conservation of the acetylcholine binding site among muscarinic receptor subtypes. Therefore, less conserved and topographically distinct allosteric binding sites have been explored to increase M\(_1\) receptor selectivity. In this line, bitopic ligands, which target orthosteric and allosteric binding sites simultaneously, may provide a promising strategy. Here, we explore the allosteric, M1-selective BQCAd scaffold derived from BQCA as a starting point for the design, synthesis, and pharmacological evaluation of a series of novel bitopic ligands in which the orthosteric moieties and linker lengths are systematically varied. Since β-arrestin recruitment seems to be favorable to therapeutic implication, all the compounds were investigated by G protein and β-arrestin assays. Some bitopic ligands are partial to full agonists for G protein activation, some activate β-arrestin recruitment, and the degree of β-arrestin recruitment varies according to the respective modification. The allosteric BQCAd scaffold controls the positioning of the orthosteric ammonium group of all ligands, suggesting that this interaction is essential for stimulating G protein activation. However, β-arrestin recruitment is not affected. The novel set of bitopic ligands may constitute a toolbox to study the requirements of β-arrestin recruitment during ligand design for therapeutic usage.
Ischemic stroke is one of the leading causes of death worldwide. It damages neurons and other supporting cellular elements in the brain. However, the impairment is not only confined to the region of assault but the surrounding area as well. Besides, it also brings about damage to the blood-brain barrier (BBB) which in turn leads to microvascular failure and edema. Hence, this necessitates an on-going, continuous search for intervention strategies and effective treatment. Of late, the natural sweetener stevioside proved to exhibit neuroprotective effects and therapeutic benefits against cerebral ischemia-induced injury. Its injectable formulation, isosteviol sodium (STVNA) also demonstrated favorable results. Nonetheless, its effects on the BBB have not yet been investigated to date. As such, this present study was designed to assess the effects of STVNA in our in vitro stroke model of the BBB.The integrity and permeability of the BBB are governed and maintained by tight junction proteins (TJPs) such as claudin-5 and occludin. Our data show increased claudin-5 and occludin expression in oxygen and glucose (OGD)-deprived murine brain capillary cerebellar endothelial cells (cerebEND) after STVNa treatment. Likewise, the upregulation of the transmembrane protein integrin-αv was also observed. Finally, cell volume was reduced with the simultaneous administration of STVNA and OGD in cerebEND cells. In neuropathologies such as stroke, the failure of cell volume control is a major feature leading to loss of cells in the penumbra as well as adverse outcomes. Our initial findings, therefore, point to the neuroprotective effects of STVNA at the BBB in vitro, which warrant further investigation for a possible future clinical intervention.
Marine natural products have achieved great success as an important source of new lead compounds for drug discovery. The Red Sea provides enormous diversity on the biological scale in all domains of life including micro- and macro-organisms. In this review, which covers the literature to the end of 2019, we summarize the diversity of bioactive secondary metabolites derived from Red Sea micro- and macro-organisms, and discuss their biological potential whenever applicable. Moreover, the diversity of the Red Sea organisms is highlighted as well as their genomic potential. This review is a comprehensive study that compares the natural products recovered from the Red Sea in terms of ecological role and pharmacological activities.
Drug-target kinetics enable time-dependent changes in target engagement to be quantified as a function of drug concentration. When coupled to drug pharmacokinetics (PK), drug-target kinetics can thus be used to predict in vivo pharmacodynamics (PD). Previously we described a mechanistic PK/PD model that successfully predicted the antibacterial activity of an LpxC inhibitor in a model of Pseudomonas aeruginosa infection. In the present work we demonstrate that the same approach can be used to predict the in vivo activity of an enoyl-ACP reductase (FabI) inhibitor in a model of methicillin-resistant Staphylococcus aureus (MRSA) infection. This is significant because the LpxC inhibitors are cidal, whereas the FabI inhibitors are static. In addition P. aeruginosa is a Gram-negative organism whereas MRSA is Gram-positive. Thus this study supports the general applicability of our modeling approach across antibacterial space.
Bestimmung der Plasmaproteinbindung von niedrig affinen Liganden am Beispiel der Ephedra-Alkaloide
(2021)
Zur Bestimmung der Bindungsaffinität von Liganden zu den Plasmaproteinen, insbesondere Albumin, wurden über die Jahre zahlreiche Methoden entwickelt. Die Grundlage dieser Arbeit war die Bestimmung der Plasmaproteinbindung der Ephedra-Alkaloide unter Verwendung einzelner dieser etablierten Methoden. Aufgrund ihres Anwendungsgebiets als Notfallmedikation bei Anästhesie-bedingter Hypotonie und den damit verbundenen Anforderungen an die Pharmakokinetik, sollten die Ephedra-Alkaloide niedrig-affine Liganden der Plasmaproteine darstellen. In der Literatur und in vorhergehenden Arbeiten wurden für die Ephedra-Alkaloide jedoch sehr unterschiedliche, teilweise der Indikation widersprechende Affinitäten bestimmt. Daher sollte im Rahmen dieser Arbeit das Ausmaß der Plasmaproteinbindung der Ephedra-Alkaloide weiter untersucht und die Affinität zu Albumin bzw. anderen Plasmaproteinen im humanen Serum bestimmt werden. Neben der Affinität sollte auch die Stereoselektivität der Bindung genauer betrachtet werden, die bei der Bindung vieler Wirkstoffe eine Rolle spielt. Als Referenzmethode diente die kontinuierliche Ultrafiltration, die auch schon bei Hörst verwendet wurde.
Folgende Schlussfolgerungen konnten aus den Ergebnissen dieser Arbeit gezogen werden:
1) Die Ergebnisse der kontinuierlichen Ultrafiltration zeigten, dass die Ephedra-Alkaloide, Ephedrin und Pseudoephedrin, ein nur geringes Ausmaß an Plasmaprotein-bindung von 4 – 9 % gegenüber bovinem und humanem Serumalbumin zeigen. Eine deutlich höhere Plasmaproteinbindung von 19 – 37 % konnte hingegen bei der Verwendung von humanem Serum bestimmt werden. Die Affinität von Pseudoephedrin war dabei jeweils geringer als die von Ephedrin.
2) Diese Ergebnisse mit humanem Serum und die Tatsache, dass Albumin vorwiegend saure Stoffe bindet, legen nahe, dass die Ephedra-Alkaloide vermehrt an andere Plasmaproteine in Serum binden. Erste Messergebnisse mit saurem α1 Glykoprotein bestätigen diese Vermutung.
3) Eine Stereoselektivität konnte nur in geringem Maß bei (+) Ephedrin beobachtet werden, wobei der Unterschied nur im Serum signifikant ist. Pseudoephedrin dagegen zeigte keinerlei Stereoselektivität. Diese Beobachtung passt zu den Schlussfolgerungen der Pfeiffer‘schen Regel zur Stereoselektivität einer Bindung.
4) Andere Sympathomimetika mit einer zusätzlichen Phenolgruppe im Molekül zeigen eine ähnlich niedrige Affinität zu Albumin von ca. 10 %. Eine zusätzliche Phenolgruppe scheint die sauren Eigenschaften des Liganden nicht ausreichend zu erhöhen, um die Affinität zu Albumin signifikant zu steigern.
5) Das tertiäre Kohlenstoffatom am Stickstoff des Ephedrins scheint in gewisser Weise an der Bindung zu Albumin beteiligt zu sein. Sympathomimetika mit einer zusätzlichen Methylgruppe an diesem Kohlenstoffatom, wie Ephedrin, Pseudoephedrin und Oxilofrin, zeigen eine größere Streuung der Messergebnisse. Eine zusätzliche Methylgruppe in dieser Position scheint die Bindung daher sterisch zu hindern.
6) Die Ergebnisse der diskontinuierlichen Ultrafiltration bestätigen weitestgehend die Ergebnisse der kontinuierlichen Ultrafiltration
7) Eine Bestimmung des Ausmaßes der Plasmaproteinbindung von niedrig-affinen Stoffen ist mit den anderen orthogonalen Methoden ACE, NMR und iTC nicht möglich. Diese drei verwendeten Methoden trennen nicht wie die klassischen Methoden den gebundenen vom ungebundenen Wirkstoff, sondern beruhen auf einer Veränderung bestimmter Messparameter: bei der ACE die Migrationszeit, bei der NMR-Spektroskopie die chemische Verschiebung der Signale bzw. der Diffusionskoeffizient und bei der iTC die frei werdende Bindungswärme. Bei allen drei Methoden war die Änderung der Messgröße aufgrund der niedrigen Plasmaproteinbindung zu gering, um auswertbar zu sein.
8) Eine Störgröße bei die orthogonalen Methoden war vielfach auch das Albumin selbst bzw. dessen Eigenschaften. Bei der Affinitäts-Kapillarelektrophorese sind physiologische HSA-Konzentrationen wegen des starken Basislinienrauschens nicht messbar. Zudem bewirkt der Albuminzusatz im Trennpuffer eine Viskositätsänderung, die den EOF verlangsamt und so die Messung stört. Bei der NMR-Spektroskopie können wegen der Überlagerung der Signale durch die breiten Albuminbanden weder Veränderungen in der chemischen Verschiebung noch des Diffusionskoeffizienten zuverlässig bestimmt werden. In der iTC erschwerte die Schaumbildung der Lösung, die durch die Oberflächenaktivität des Albumins verursacht wird, die Messung.
In dieser Arbeit konnte somit das Ausmaß der Plasmaproteinbindung der Ephedra-Alkaloide mit verschiedenen Methoden erfolgreich bestimmt werden. Damit bestätigte diese Arbeit, dass die Ephedra-Alkaloide, wie deren Indikation vermuten lässt, zu den niedrig affinen Liganden des Albumins zählen. Um genauer eingrenzen zu können durch welche Plasmaproteine im Blutserum die Ephedra-Alkaloide transportiert werden, sollten die Untersuchungen zum sauren α1-Glykoprotein fortgesetzt und gegebenenfalls durch weitere Bestimmungen mit anderen Plasmaproteinen ergänzt werden.
Die Ergebnisse dieser Arbeit haben auch gezeigt, dass viele der unzähligen Methoden zur Untersuchung der Plasmaproteinbindung bei der Bestimmung von niedrig affinen Liganden ihre Grenzen haben. Nach wie vor sind zur Bestimmung einer niedrigen Bindungsaffinität weiterhin die klassischen Methoden, wie die kontinuierliche Ultrafiltration, Mittel der Wahl. Nicht zuletzt deshalb erfreuen sich diese Methoden auch heute noch großer Beliebtheit.
High-resolution nuclear magnetic resonance (NMR) spectroscopy is used in structure elucidation and qualitative as well as quantitative examination of product components. Despite the worldwide development of numerous innovative NMR spectroscopic methods, several official methods that analyze specific substances and do not represent a holistic analysis, are still in use for the quality control of drugs, food and chemicals. Thus, counterfeit or contaminated products of inferior quality can be brought onto the market and distributed despite previous quality controls. To prevent this, three NMR spectroscopic methods have been developed within the scope of this work (1) to study the peroxide value in vegetable and animal oils, (2) for the qualitative and quantitative analysis of metal cations and (3) to determine the enantiomeric excess in chiral alcohols. In oil analysis, titration methods are used to determine the bulk quality parameters such as peroxide value, which represents the concentration of peroxides. Titrations show several drawbacks, such as the need of a large amount of sample and solvents, cross reactions and the low robustness. Thus, an alternative NMR spectroscopic method was developed to improve the peroxide analysis by using triphenylphosphine as a derivatization reagent, which reacts with peroxides in a stoichiometric ratio of 1:1 forming triphenylphosphine oxide. In the 1H-31P decoupled NMR spectrum, the signals of the unreacted triphenylphosphine and the reacted triphenylphosphine oxide are detected at 7.4 ppm and 7.8 ppm, respectively. The ratio of the two signals is used for the calculation of the peroxide concentration. 108 oil samples with a peroxide value between 1 meq/kg and 150 meq/kg were examined using the developed method. Oils with a very low peroxide value of less than 3 meq/kg showed a relative standard deviation of 4.9%, highly oxidized oils with a peroxide value of 150 meq/kg of 0.2%. The NMR method was demonstrated as a powerful technique for the analysis of vegetable and krill oils. Another 1H NMR spectroscopic method was developed for the qualitative determination of Be2+, Sr2+ and Cd2+, and for the qualitative and quantitative determination of Ca2+, Mg2+, Hg2+, Sn2+, Pb2+ and Zn2+ by using ethylenediamine tetraacetate (EDTA) as complexing agent. EDTA is a hexadentate ligand that forms stable chelate complexes with divalent cations. The known amount of added EDTA and the signal ratio of free and complexed EDTA are used to calculate the concentrations of the divalent cations, which makes the use of an internal standard obsolete. The use of EDTA with Be2+, Sr2+, Cd2+, Ca2+, Mg2+, Hg2+, Sn2+, Pb2+ and Zn2+ result in complexes whose signals are pH-independent, showing cation-specific chemical shifts and couplings in the 1H NMR spectrum that are used for identification and quantification. In the presented NMR method, the limit of quantification of the cations Ca2+, Mg2+, Hg2+, Sn2+, Pb2+, and Zn2+ was determined with 5-22 μg/mL. This method is applicable in the food and drug sectors. The third NMR spectroscopic method introduced an alternative determination of the enantiomer excess (ee) of the chiral alcohols menthol, borneol, 1-phenylethanol and linalool using phosgene as a derivatizing reagent. Phosgene reacts with a chiral alcohol to form carboxylic acid diesters, made of two identical (RR, SS) or two different enantiomers (RS, SR). These two different types of diastereomers can be examined by the difference of their chemical shifts. In the presented method, the integration values of the carbonyl signals in the 13C NMR spectrum are used for the determination of the enantiomer excess. The limit of quantification depends, among others, on the sample and on the non-labelled or 13C-labelled phosgene used for the analysis. In the case of menthol, a quantification limit of ee=99.1% was determined using non-labelled phosgene and ee=99.9% using 13C-labelled phosgene. The 13C NMR method was also applied for the quality control of the enantiomeric purity of borneol, 1-phenylethanol and linalool. The developed 13C NMR method represents a powerful alternative to Mosher’s reagent for investigating the enantiomeric excess in chiral alcohols. This work demonstrates the variety of possibilities of applications for the quantitative nuclear magnetic resonance spectroscopy in the chemical analysis of drugs, food and chemicals using tagging reactions such as derivatizations and complexations. The nuclear resonance spectroscopic methods developed in this research work represent powerful alternatives to the previously used quality control techniques.
Salt formation is a routinely used strategy for poorly water-soluble drugs and traditionally performed with small inorganic counterions. High energy crystal lattices as well as effects on the local pH within the aqueous boundary layer during dissolution drive the increased dissolution rate and apparent solubility. Ionic liquids however, by definition low melting ionic salts with often large organic counterions, combine an increased dissolution rate with solubilization of the drug by the counterion itself. Long lasting supersaturation profiles of increased kinetic solubility were reported for several drugs formulated as ionic liquids increasing their overall bioavailability. Furthermore, aggregation and micellization between highly lipophilic compounds and amphiphilic bile acids was described before, demonstrating the capabilities of the human body itself to utilize solubilization of poorly water-soluble compounds. Development of novel counterions not only tailoring the desired physicochemical properties e.g. dissolution rate of the parent drug but adding – in a best-case scenario synergistic – pharmacological activity has been driven forward in the last years. However, salt formation can only be applied for ionizable i.e. acidic or basic compounds. While co-crystals can be used as a nonionized alternative, their formation is not always successful leading to an urgent need for other formulation strategies. In these lines, development of 2D and 3D printing techniques has been ongoing for the last decades and their pharmaceutical application has been demonstrated. The versatile nature and commercial availability allow a decentralized production further elaborating this technique for a highly flexible and patient-oriented supply with medication.
This thesis focuses on the theoretical background and potential application of salt formation in the pharmaceutical development of a drug candidate. The first section presents the current knowledge and state of the art in preparation of low melting ionic liquids i.e. salts and is translated to the in vitro investigation of molecular interaction between the poorly water-soluble drug imatinib and components of the human intestinal fluid in the second section. Development of novel antibiotic counterions and assessment of their potential use in pharmaceutical formulations with fluoroquinolones is described in the last two sections.
Chapter I describes the application of low melting ionic liquids in pharmaceutical formulation and details their development in the last two decades from versatile organic solvents in chemical synthesis towards amorphous strategies for drug delivery. The chapter gives a general overview on molecular structure and physicochemical properties of several drug containing ionic liquids and details the mechanisms which attribute to a typically fast dissolution, increased aqueous solubility as well as enhanced permeation which was reported in several publications.
Chapter II translates the increased aqueous solubility of drugs by an organic counterion to the human gastrointestinal tract with taurocholate and lecithin as main drivers for the solubilization of highly lipophilic and poorly water-soluble drugs. Investigation of the interaction of imatinib – a poorly water-soluble weak base – with fasted- and fed state simulated intestinal fluids revealed a complex interplay between the components of the intestinal fluid and the drug. Mixed vesicles and micelles were observed in concentration dependent aggregation assays and revealed differences in their size, molecular arrangement as well as composition, depending on the tested drug concentration. Overall, the study outlines the effective interaction of weakly basic drugs with taurocholate and lecithin to minimize recrystallization during intestine passage finally leading to favorable supersaturation profiles.
Chapter III focuses on the development of novel antibiotic counterions which potentially move the evolution of ionic liquids from a pharmaceutical salt with tailored physicochemical properties to a synergistic combination of two active pharmaceutical ingredients. The natural occurring anacardic acid derived from the cashew nut shell inspired a series of antibacterial active acidic compounds with increasing alkyl chain length. Their physicochemical properties, antibacterial activity, bacterial biofilm inhibition and cytotoxicity were detailed and in vivo activity in a Galleria mellonella model was assessed. This group of anacardic acid derivatives is synthetically accessible, easily modifiable and yielded two compounds with favorable activity and physicochemical profile for further drug development.
Chapter IV outlines the potential application of anacardic acid derivatives in pharmaceutical formulations by salt formation with fluoroquinolone antibiotics as well as novel techniques such as 2D/3D printing for preparation of drug imprinted products. Despite anacardic acid derivatives demonstrated promising physicochemical properties, salt formation with fluoroquinolone antibiotics was not feasible. However, 2D/3D printed samples with anacardic acid derivative alone or in combination with ciprofloxacin demonstrated physical compatibility between drug and matrix as well as antibacterial activity against three S. aureus strains in an agar diffusion assay. Conclusively, drug printing can be applied for the herein tested compounds, but further process development is necessary.
In summary, preparation of low melting ionic liquids, salts or co-crystals is an appropriate strategy to increase the aqueous solubility of poorly water-soluble drugs and tailor physicochemical properties. The counterion itself solubilizes the drug and furthermore potentially interferes with the complex micellar environment in the human intestine. However, salt formation as routinely used formulation strategy is not feasible in every case and development of alternative techniques is crucial to hurdle challenges related to unfavorable physicochemical properties. The outlined techniques for 2D/3D drug printing provide versatile production of drug products while extending the design space for novel drug development.
Detaillierte Einblicke in die Struktur von mit Wirkstoffen beladenen Polymermizellen sind rar, aber wichtig um gezielt optimierte Transportsysteme entwickeln zu können. Wir konnten beobachten, dass eine Erhöhung der Curcumin‐Beladung von Triblockcopolymeren auf Basis von Poly(2‐oxazolinen) und Poly(2‐oxazinen) schlechtere Auflösungseigenschaften nach sich zieht. Mitthilfe von Festkörper‐NMR‐Spektroskopie und komplementären Techniken ist es möglich, ein ladungsabhängiges Strukturmodell auf molekularer Ebene zu erstellen, das eine Erklärung für die beobachteten Unterschiede liefert. Dabei belegen die Änderungen der chemischen Verschiebungen und Kreuzsignale in 2D‐NMR‐Experimenten die Beteiligung des hydrophoben Polymerblocks an der Koordination der Curcumin‐Moleküle, während bei höherer Beladung auch eine zunehmende Wechselwirkung mit dem hydrophilen Polymerblock beobachtet wird. Letztere könnte elementar für die Stabilisierung von ultrahochbeladenen Polymermizellen sowie das Design von verbesserten Wirkstofftransportsystemen sein.
Sacha inchi oil is a premier raw material with highly nutritional and functional features for the foodstuff, pharmaceutical, beauty, and personal care industries. One of the most important facts about this oil is the huge chemical content of unsaturated and polyunsaturated fatty acids. However, the current available information on the characterization of the triglyceride composition and the advance physicochemical parameters relevant to emulsion development is limited. Therefore, this research focused on providing a detailed description of the lipid composition using high-resolution tandem mass spectrometry and thorough physicochemical characterization to find the value of the required hydrophilic–lipophilic balance (HLB). For this, a study in the interfacial tension was evaluated, followed by the assessment of different parameters such as creaming index, droplet size, viscosity, zeta potential, pH, and electrical conductivity for a series emulsified at thermal stress condition. The results show that fatty acids are arranged into glycerolipids and the required HLB to achieve the maximum physical stability is around 8.
A series of photoactivatable CO‐releasing molecules (PhotoCORMs) was prepared from manganese pentacarbonyl bromide and 1H‐benzimidazol‐2‐ylmethyl‐(N‐phenyl)amine ligands (L) bearing different electron‐donating and electron‐withdrawing groups R = H, 4‐CH\(_3\), 4‐OCH\(_3\), 4‐Cl, 4‐NO\(_2\), 2‐, 3‐, and 4‐COOCH\(_3\) on the phenyl substituent to give octahedral manganese(I) complexes of the general formula [MnBr(CO)\(_3\)(L)]. Aerated DMSO solutions of the compounds are stable in the dark for 16 h with no CO release. However, the compounds rapidly release CO upon illumination at 412–525 nm, depending on the substitution pattern. Its influence on the photophysical and photochemical properties was systematically explored using UV/Vis spectroscopy and CO release measurements with a commercial gas sensor system. In the nitro‐substituted compound, the electronically excited state switched from benzimidazole‐ to phenyl‐centered, leading to a markedly different photochemical behavior of this visible‐light activated PhotoCORM.
μ‐Opioid receptors (μ‐ORs) play a critical role in the modulation of pain and mediate the effects of the most powerful analgesic drugs. Despite extensive efforts, it remains insufficiently understood how μ‐ORs produce specific effects in living cells. We developed new fluorescent ligands based on the μ‐OR antagonist E‐p‐nitrocinnamoylamino‐dihydrocodeinone (CACO), that display high affinity, long residence time and pronounced selectivity. Using these ligands, we achieved single‐molecule imaging of μ‐ORs on the surface of living cells at physiological expression levels. Our results reveal a high heterogeneity in the diffusion of μ‐ORs, with a relevant immobile fraction. Using a pair of fluorescent ligands of different color, we provide evidence that μ‐ORs interact with each other to form short‐lived homodimers on the plasma membrane. This approach provides a new strategy to investigate μ‐OR pharmacology at single‐molecule level.
Detailed insight into the internal structure of drug‐loaded polymeric micelles is scarce, but important for developing optimized delivery systems. We observed that an increase in the curcumin loading of triblock copolymers based on poly(2‐oxazolines) and poly(2‐oxazines) results in poorer dissolution properties. Using solid‐state NMR spectroscopy and complementary tools we propose a loading‐dependent structural model on the molecular level that provides an explanation for these pronounced differences. Changes in the chemical shifts and cross‐peaks in 2D NMR experiments give evidence for the involvement of the hydrophobic polymer block in the curcumin coordination at low loadings, while at higher loadings an increase in the interaction with the hydrophilic polymer blocks is observed. The involvement of the hydrophilic compartment may be critical for ultrahigh‐loaded polymer micelles and can help to rationalize specific polymer modifications to improve the performance of similar drug delivery systems.
Ellagitannins are signature constituents of oak wood and their consumption has been associated with various health benefits. In vivo, they undergo metabolic degradation including gut microbial metabolism yielding urolithins. Only limited data is available about compounds being present in blood after intake of an extract from French oak wood, Robuvit®. In the course of a randomized, double-blind, controlled clinical investigation, 66 patients undergoing hysterectomy received placebo or 300 mg Robuvit® per day before and over 8 weeks after surgery. Serum and blood cell samples were analyzed by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). The number of urolithin producers and the urolithin levels increased after intake of Robuvit®. In serum samples, the median concentration of urolithin A was 14.0 ng/ml [interquartile range (IQR) 57.4] after 8 weeks. Urolithin B was determined at 22.3 ng/ml (IQR 12.6), urolithin C at 2.66 ng/ml (IQR 2.08). In blood cells, lower concentrations and only urolithins A and B were detected. A statistically significant association of lower post-surgical pain scores with metabotype A was detected (p < 0.05). To conclude, supplementation with French oak wood extract raised urolithin generation in patients and suggested health advantages for urolithin-producers.
Quinolone antibiotics present an attractive oral treatment option in patients with cystic fibrosis (CF). Prior studies have reported comparable clearances and volumes of distribution in patients with CF and healthy volunteers for primarily renally cleared quinolones. We aimed to provide the first pharmacokinetic comparison for pefloxacin as a predominantly nonrenally cleared quinolone and its two metabolites between both subject groups. Eight patients with CF (fat-free mass [FFM]: 36.3 ± 6.9 kg, average ± SD) and ten healthy volunteers (FFM: 51.7 ± 9.9 kg) received 400 mg pefloxacin as a 30 min intravenous infusion and orally in a randomized, two-way crossover study. All plasma and urine data were simultaneously modelled. Bioavailability was complete in both subject groups. Pefloxacin excretion into urine was approximately 74% higher in patients with CF compared to that in healthy volunteers, whereas the urinary excretion of metabolites was only slightly higher in patients with CF. After accounting for body size and composition via allometric scaling by FFM, pharmacokinetic parameter estimates in patients with CF divided by those in healthy volunteers were 0.912 for total clearance, 0.861 for nonrenal clearance, 1.53 for renal clearance, and 0.916 for volume of distribution. Nonrenal clearance accounted for approximately 90% of total pefloxacin clearance. Overall, bioavailability and disposition were comparable between both subject groups.
The cholinergic hypothesis has been reported first being the cause of memory dysfunction in the Alzheimer’s disease. Researchers around the globe have focused their attention on understanding the mechanisms of how this complicated system contributes to processes such as learning, memory, disorientation, linguistic problems, and behavioral issues in the indicated chronic neurodegenerative disease. The present review reports recent updates in hybrid molecule design as a strategy for selectively addressing multiple target proteins involved in Alzheimer’s disease (AD) and the study of their therapeutic relevance. The rationale and the design of the bifunctional compounds will be discussed in order to understand their potential as tools to investigate the role of the cholinergic system in AD.
Die Detektion Arzneimittel-induzierter Leberschädigung (engl. DILI – Drug induced liver injury) stellt eine Herausforderung in der präklinischen Entwicklung von Arzneistoffen dar. Die zur Verfügung stehenden konventionellen klinisch-chemischen Marker, wie Alanin-Aminotransferase (ALAT), Aspartat-Aminotransferase (ASAT) und Alkalische Phosphatase (APh), zeigen z. B. bei minimaler bis leichter Leberpathologie keine Veränderungen im Serum an und besitzen somit nur eine geringe Sensitivität für den frühzeitigen Nachweis einer Lebertoxizität. Des Weiteren besitzen klinisch-chemische Serummarker gleichzeitig eine geringe Spezifität und sind somit für die Differenzierung unterschiedlicher Lebertoxizitäten nur limitiert geeignet. Neben den beschriebenen diagnostischen Herausforderungen können u. a. auch histopathologische Befunde in der Leber, ohne eine Veränderung der klinisch-chemischen Serummarker auftreten und umgekehrt. Die Histopathologie ist als Goldstandard zwar spezifisch, als invasive Technik für eine Verlaufskontrolle in toxikologischen und klinischen Studien aber ungeeignet. In den vergangenen Jahren lieferten Studien zum Gallensäure-Profiling mittels Flüssigkeitschromatographie-Tandem-Massenspektrometrie (LC-MS/MS) mit Modellsubstanzen, die unterschiedliche Formen einer Lebertoxizität in Ratten induzierten Hinweise, dass individuelle Gallensäuren ein diagnostisches Potential für die Bewertung einer Leberschädigung besitzen. Ziel dieser Arbeit ist es, dass Gallensäure-Profiling in die vorgeschriebene Diagnostik der Lebertoxizität in der präklinischen Arzneimittelentwicklung zu implementieren und zu bewerten, ob diese Marker einen wertvollen Beitrag zur Charakterisierung einer Lebertoxizität leisten können.
Hierzu wurde eine quantitative LC-MS/MS-Methode etabliert und validiert, die es ermöglicht, 20 verschiedene endogene Gallensäuren in Ratten zu analysieren. Die quantitative Analytik ermöglichte eine selektive Bestimmung von primären, konjugierten und sekundären Gallensäuren. Für die Quantifizierung der individuellen Gallensäuren wurden 2 MRM-Übergänge bestimmt. Zur Bestimmung des Arbeitsbereiches wurden 20 Referenzstandards von Gallensäuren verwendet. Eine Kalibrierung mit sieben Kalibrierpunkten in aufsteigender Konzentration wurde für die Bestimmung der endogenen Konzentrationen genutzt. Zur Kompensation des Matrixeffektes wurden 10 isotopenmarkierte interne Standards in die Analytik eingefügt. Die Reproduzierbarkeit laufender Messungen wurde durch eingefügte Qualitätskontrollen (QCs) in drei verschiedenen Konzentrationsbereichen überwacht.
Es wurde ein Gallensäure-Profiling mittels LC-MS/MS im Plasma und Lebergewebe von Ratten, die mit verschiedenen Arzneimitteln behandelt wurden, durchgeführt. Histopathologische
Zusammenfassung
Untersuchungen konnten aufzeigen, dass sich in den Lebern von männlichen Ratten, die mit dem Arzneimittel Amitriptylin über 14 Tage behandelt wurden, eine makrovesikuläre Steatose in der Leber manifestierte. Die klassischen Serummarker, wie ALAT, ASAT und Gamma-Glutamyltransferase (γGT), konnten diese Art des Leberschadens nicht detektieren. Dagegen erhöhten sich die Konzentrationen Glycin-konjugierter Gallensäuren mit parallel absinkenden Konzentrationen von Taurin-konjugierten Gallensäuren im Lebergewebe behandelter Ratten. Gleichzeitig ergaben sich signifikant erhöhte Konzentrationen der primären Gallensäuren CA und CDCA im Plasma behandelter Ratten.
Andere Gallensäure-Profile konnten nach einer Methapyrilen-induzierten Leberzellnekrose mit hepatobiliärer Schädigung beobachtet werden. Nach einer 14-tägigen Behandlungsphase mit 80 mg/kg KG Methapyrilen, erhöhten sich die Konzentrationen von 11 Gallensäuren im Lebergewebe behandelter Tiere. Gleichzeitig stiegen die Konzentrationen von allen 20 individuellen Gallensäuren im Plasma behandelter Ratten an.
Zusätzlich zur quantitativen Analyse von Gallensäuren mittels LC-MS/MS wurde die Expression von Genen der Gallensäure-Biosynthese, des Gallensäure-Transports und die Regulation der Gallensäure-Homöostase mittels Multiplex-Analyse untersucht. Die erhöhte Expression von Genen für Efflux-Transporter der Multidrug Resistance-Related Protein (MRP)-Familie deutet auf einen gesteigerten Abtransport von Gallensäuren ins Blut hin und korrespondierte mit erhöhten Gallensäure-Konzentrationen im Plasma der behandelten Ratten.
Des Weiteren wurden die Erkenntnisse der Gallensäure-Profile aus den tierexperimentellen Studien als Grundlage genutzt, um Arzneimittel-induzierte Lebertoxizität auf ein zellbiologisches In-vitro-System zu übertragen. Es wurden In-vitro-Experimente mit primären Rattenhepatozyten zwischen zwei Kollagenmatrices (Sandwich-Kultivierung) durchgeführt. Dieses etablierte System wird u. a. für Untersuchungen an hepatobiliären Transportsystemen (z. B. Bile Salt Export Pump, BSEP) genutzt. Das Gallensäure-Profiling in den Zellkulturüberständen belegt, dass die primären Hepatozyten konjugierte Gallensäuren bilden, dass sie bei einer Inkubation mit primären Gallensäuren diese verstoffwechseln und dadurch, neben den bereits vorhandenen Gallensäuren, weitere konjugierte Gallensäuren produzieren. Eine Exposition mit den Hepatotoxinen Troglitazon und Methapyrilen führte zu Veränderungen in der Gallensäure-Homöostase der Hepatozyten.
In den In-vivo-Experimenten wurde eine Methapyrilen-induzierte Nekrose mit hepatobiliärer Schädigung in den behandelten Ratten festgestellt. Bei der Behandlung mit Methapyrilen ergaben sich starke Konzentrationsanstiege der Gallensäuren im Plasma (u. a. von GCA und TCA), die mit den histopathologischen Befunden korrelierten. Anhand dieser Daten und der
Zusammenfassung
pharmakokinetischen Eigenschaften von Methapyrilen wurde ein Studiendesign für Rattenhepatozyten in Sandwich-Kulturen entwickelt, um eine initiale Abschätzung der Konzentrationsveränderungen von Gallensäuren im In-vitro-Testsystem durchzuführen. Ab Tag 8 der Behandlung kam es zu einem erhöhten Anstieg der GCA- und TCA-Konzentrationen im Zellkulturmedium. Daher besitzt das In-vitro-Testsystem möglicherweise das Potential, tierexperimentelle Studien bei der Bewertung einer Hepatotoxizität zu unterstützen oder sogar zu reduzieren.
Insgesamt zeigen diese Ergebnisse aus dieser Arbeit, dass Gallensäure-Profiling in männlichen und weiblichen Ratten eine geeignete Methode zur Detektion und Differenzierung von Leberschäden ist. Die Technologie ist flexibel einsetzbar und kann bereits etablierte Testverfahren, wie die Bestimmung von Serummarkern in der Klinischen Chemie und die Histopathologie unterstützen. Damit besitzt das Gallensäure-Profiling das Potential, die Bewertung beim Nachweis und bei der Charakterisierung einer Lebertoxizität im Rahmen der Evaluierung von präklinischen Arzneimittelkandidaten zu verbessern.
Alzheimer's disease (AD) is a multifactorial disease and the most common form of dementia. There are no treatments to cure, prevent or slow down the progression of the disease. Natural products hold considerable interest for the development of preventive neuroprotectants to treat neurodegenerative disorders like AD, due to their low toxicity and general beneficial effects on human health with their anti-inflammatory and antioxidant features. In this work we describe regioselective synthesis of 7-O-ester hybrids of the flavonoid taxifolin with the phenolic acids cinnamic and ferulic acid, namely 7-O-cinnamoyltaxifolin and 7-O-feruloyltaxifolin. The compounds show pronounced overadditive neuroprotective effects against oxytosis, ferroptosis and ATP depletion in the murine hippocampal neuron HT22 cell model. Furthermore, 7-O-cinnamoyltaxifolin and 7-O-feruloyltaxifolin reduced LPS-induced neuroinflammation in BV-2 microglia cells as assessed by effects on the levels of NO, IL6 and TNFα. In all in vitro assays the 7-O-esters of taxifolin and ferulic or cinnamic acid showed strong overadditive activity, significantly exceeding the effects of the individual components and the equimolar mixtures thereof, which were almost inactive in all of the assays at the tested concentrations. In vivo studies confirmed this overadditive effect. Treatment of an AD mouse model based on the injection of oligomerized Aβ\(_{25-35}\) peptide into the brain to cause neurotoxicity and subsequently memory deficits with 7-O-cinnamoyltaxifolin or 7-O-feruloyltaxifolin resulted in improved performance in an assay for short-term memory as compared to vehicle and mice treated with the respective equimolar mixtures. These results highlight the benefits of natural product hybrids as a novel compound class with potential use for drug discovery in neurodegenerative diseases due to their pharmacological profile that is distinct from the individual natural components.
Liquid chromatography has become the gold standard for modern quality control and purity analytics since its establishment in the 1930s. However, some analytical questions remain very challenging even today. Several molecules and impurities do not possess a suitable chromophore for the application of UV detection or cannot be retained well on regular RP columns. Possible solutions are found in derivatization procedures, but they are time consuming and can be prone to errors. In order to detect non chromophore molecules underivatized, the concept of aerosol based universal detection was established with the introduction of the evaporative light scattering detector (ELSD) in the 1970s and the charged aerosol detector (CAD) followed in 2002. These two challenging fields – polar and non chromophore molecules – are tackled in this thesis.
An overview of applications of the CAD in the literature and a comparison to its aerosol based competitors and MS is presented, emphasizing on its high sensitivity and robustness. Parameters and techniques to overcome the drawbacks of CAD, such as the use of gradient compensation or adjusted evaporation temperatures are discussed. A consideration of aspects and drawbacks of data transformation such as the integrated power function value (PFV) in the GMP environment is performed.
A method for the fatty acid analysis in polysorbate 80 that was developed on HPLC CAD was transferred to UHPLC CAD. Time and eluent savings of over 75% and 40%, respectively, as well as ways to determine the optimal CAD parameters resulted from this investigation. The evaporation temperature was determined as the most crucial setting, which has to be adjusted with care. Optimal signal to noise ratios are found at a compromise between maintaining analyte signal and reducing background noise. The incorporation of semi volatile short chain fatty acids enabled the observation of differences based on volatility of the analyte. E.g. for semi volatiles, an improved linearity by means of adjusting the PFV is achieved at values below 1.0 instead of at elevated PFVs.
Using sugars and sugar related antibiotics, a proof-of-concept was given that artificial neural networks can describe correlations between the structure and physicochemical properties of molecules and their response in CAD. Quantitative structure property relationships obtained by design of experiment approaches were able to predict the response of unseen substances and yielded insights on the response generation of the detector, which heavily relies on the formed surface area of the dried particle. Further work can substantiate upon these findings, eventually building a library of diverse eluent compositions, analytes and settings.
In order to cope with a chromatographically challenging substances, the application of ion pairing reversed phase chromatography coupled to low wavelength UV detection has been shown as a possible approach for the amino acid L asparagine. A method capable of compendial purity analysis in one single HPLC approach, thus making the utilization of the semi quantitative TLC-ninhydrin analysis obsolete, resulted from this. One cyclic dipeptide impurity (diketoasparagine) that was formerly not assessed, could be identified in several batches and added to the monograph of the Ph.Eur.
Studying ibandronate sodium with CAD and ELSD, it was found that randomly occurring spike peaks represent a major flaw of the ELSD when high sample load is present. The research with this non chromophore bisphosphonate drug furthermore shed light on possible drawbacks of mixed mode chromatography methods and ways to overcome these issues. Due to strong adsorption of the analyte onto the column, over ten injections of the highly concentrated test solution were found to be necessary to ensure reproducible peak areas. Preconditioning steps should thus be evaluated for mixed mode approaches during method development and validation.
Last, using a ternary mixed mode stationary phase coupled to CAD, a method for the impurity profiling of pamidronate disodium, also applicable to the assessment of phosphate and phosphite in four other bisphosphonate drugs, has been developed. This represents a major advantage over the Ph.Eur. impurity profiling of pamidronate, which requires two different methods, one of which is only a semi quantitative TLC approach.
Polyphenols exert beneficial effects in type 2 diabetes mellitus (T2DM). However, their mechanism of action remains largely unknown. Endothelial Akt-kinase plays a key role in the pathogenesis of cardiovascular complications in T2DM and therefore the modulation of its activity is of interest. This work aimed to characterize effects of structurally different polyphenols on Akt-phosphorylation (pAkt) in endothelial cells (Ea.hy926) and to describe structure-activity features. A comprehensive screening via ELISA quantified the effects of 44 polyphenols (10 µM) on pAkt Ser473. The most pronounced inhibitors were luteolin (44 ± 18%), quercetin (36 ± 8%), urolithin A (35 ± 12%), apigenin, fisetin, and resveratrol; (p < 0.01). The results were confirmed by Western blotting and complemented with corresponding experiments in HUVEC cells. A strong positive and statistically significant correlation between the mean inhibitory effects of the tested polyphenols on both Akt-residues Ser473 and Thr308 (r = 0.9478, p = 0.0003) was determined by immunoblotting. Interestingly, the structural characteristics favoring pAkt inhibition partially differed from structural features enhancing the compounds’ antioxidant activity. The present study is the first to quantitatively compare the influence of polyphenols from nine different structural subclasses on pAkt in endothelial cells. These effects might be advantageous in certain T2DM-complications involving over-activation of the Akt-pathway. The suggested molecular mode of action of polyphenols involving Akt-inhibition contributes to understanding their effects on the cellular level.
The stability of Trp in pure solutions and in parenteral AA formulations was evaluated with regard to typically used manufacturing processes, storage conditions and primary packaging. Therefore, thorough stability studies on Trp solutions were conducted beforehand. The applied stressing method, i.e. steam sterilization by autoclave, are chemically seen relatively mild but showed to be efficient to induce Trp degradation in the presence of oxygen. Subsequent identification, separation and characterization were challenging due to similar substance properties, numerous stereoisomers and pairs of diastereomers found amongst them. However, the identified o-aminoacetophenone compounds, Kyn and NFK, are associated with photo reactivity and have photo-oxidizing properties. Thus, best possible protection from UV-light, together with strict oxygen expulsion, are the most important criteria to impede Trp degradation after autoclaving.
The identification of Trp degradation products was assisted by the compilation of a substance library, which included manifold reported and chemically plausible Trp degradation substances. The substances were classified for priority and their early or late-stage occurrence. The large number of possible substances and stereoisomers was narrowed down with the information retrieved from LC-UV/MS experiments. However, final identification was achieved by the synthesis of proposed substances as references. The following eight substances were characterized as Trp degradation substances: Kyn, NFK and three pairs of diastereomers R,R/R,S DiOia, R,R/R,S Oia and cis/trans PIC. Fig. 33 shows the proposed degradation pathway and demonstrates the close chemical relationship, which may be an explanation for the conversion of some substances into each other during the storage period. The proposed pathway brings together the results of different Trp stability and stressing studies, respectively [89, 94, 97, 98, 103, 133]. To our knowledge, the simultaneous formation of the identified degradation substances has not been reported before and especially not under the stressing conditions applied.
The application of a traditional RP-HPLC method was compared to two developed IP-HPLC methods and a RP-HPLC methods using a modified perfluorinated column. Orthogonal analyses methods and especially the combination of UV and MS detection are necessary in order to indicate potentially undetected degradation substances. Main evaluation criteria were the separation performance, analyses time, reproducibility and feasibility. The best results upon assessment of all Trp degradation products, in both; pure Trp solutions and pharmaceutical formulations, were obtained by a traditional RP-HPLC. The optimized method was validated according to ICH guidelines Q2(R1) and meets the criteria of a stability-indicating HPLC-UV method. The validated method has a sufficient separation performance with an adequate selectivity indicating the Trp degradation substances next to each other and next to other AAs in finished pharmaceutical formulations.
The detailed knowledge of Trp degradation and the method presented may be transferred practically to the pharmaceutical industry processing Trp-containing products. In general, the findings might contribute to the quality management of such pharmaceutical products during
manufacturing and storage. Additionally, the study results provide basic information for the establishment of an impurity consideration following the ICH guidelines Q3B (R2) (impurities in new drug products) for products containing Trp. However, further development of the method applying more sophisticated detectors or more potent HPLC techniques like e.g. UHPLC and the implication of more sensitive (MS) detectors like ToF-MS would be advantageous with regard to economic and practical aspects.
Articular cartilage lesions that occur upon intensive sport, trauma or degenerative disease represent a severe therapeutic problem. At present, osteoarthritis is the most common joint disease worldwide, affecting around 10% of men and 18% of women over 60 years of age (302). The poor self-regeneration capacity of cartilage and the lack of efficient therapeutic treatment options to regenerate durable articular cartilage tissue, provide the rationale for the development of new treatment options based on cartilage tissue engineering approaches (281). The integrated use of cells, biomaterials and growth factors to guide tissue development has the potential to provide functional substitutes of lost or damaged tissues (2,3). For the regeneration of cartilage, the availability of mesenchymal stromal cells (MSCs) or their recruitment into the defect site is fundamental (281). Due to their high proliferation capacity, the possibility to differentiate into chondrocytes and their potential to attract other progenitor cells into the defect site, bone marrow-derived mesenchymal stromal cells (BMSCs) are still regarded as an attractive cell source for cartilage tissue engineering (80). However, in order to successfully engineer cartilage tissue, a better understanding of basic principles of developmental processes and microenvironmental cues that guide chondrogenesis is required.
In the „Position Paper of the Division of Clinical Pharmacy of the German Pharmaceutical Society (DPhG)” clinical pharmacy is defined as the science and practice of the rational use of drugs1, which includes the individualization of drug therapy. Clinical pharmacists therefore need a profound knowledge of the pharmacokinetic properties of relevant drugs, and clinical factors that are influencing these properties.
Against the background of individualizing drug therapy, pharmacokinetic and clinical factors are studied in this thesis.
In order to obtain an overview of the existing data on the pharmacokinetics of imipenem / cilastatin and meropenem in critically ill patients, a literature review for each of these carbapenem antibiotics was performed. These reviews included studies in critically ill patients as well as studies in healthy volunteers. While the reported results of studies in healthy volunteers had a small variability, studies in critically ill patients show significant differences in the resulting pharmacokinetics. These differences were not only between, but also within these studies, resulting in a high variability of the pharmacokinetic parameters of the carbapenems in critically ill patients. Furthermore, the results of studies in critically ill patients indicate that clinical factors and in particular renal function have different effects on the pharmacokinetics of imipenem and cilastatin.
A therapeutic drug monitoring (TDM) program for antibiotics was initiated in an intensive care unit. The calculation of the pharmacokinetics of imipenem / cilastatin and meropenem was carried out with a population pharmacokinetic approach (POP-PK) and in addition with a non-compartmental approach (NCA).
The POP-PK analysis showed that the pharmacokinetics of imipenem and cilastatin could be described adequately with a 1-compartment model. The resulting mean total body clearance (CL) of imipenem and cilastatin was 11.6 L/h (4.24 to 27.5) and 6.14 L/h (0.520 to 26.6 L/h). The nonrenal clearance was estimated to be 5.30 L / h (24.9% CV) for imipenem and 0.138 L / h (33.3% CV) for cilastatin.
The results of the NCA were in good agreement with the results of the POP-PK approach, as the NCA resulted in an imipenem clearance of 15.5 ± 7.3 L / hr and cilastatin clearance of 10.1 ± 9.9 L / h. The individual clearances resulting from the different pharmacokinetic approaches were in good correlation showing correlation coefficients (r) of 0.882 (p <0.001) and 0.908 (p <0.001) for imipenem and cilastatin.
In summary, this study identified and quantified significant differences between the individual clearance mechanisms of imipenem and cilastatin. This is particularly true for patients with impaired renal function and sepsis. As imipenem / cilastatin is only available in a fixed dose combination, those patients might be treated inadequately with this combination. The great variability in the pharmacokinetics of imipenem and cilastatin in septic patients underscores the importance of a TDM program of both substances.
For meropenem, a PK/PD model was developed that predicts the concentration gradients of meropenem, serum creatinine, C-reactive protein and procalcitonin simultaneously. A non-linear relationship between the clearance of creatinine and meropenem was identified and the resulting equation for the calculation of the total body clearance of meropenem (for a 70 kg patient) was: 0.480 L/h + 9.86 L/h. (CLCR/6L/h)0.593, with 0.480 L/h representing the nonrenal clearance of meropenem.
The resulting mean meropenem clearance of the NCA was 11.9 ± 8.7 L/h. The individual clearances resulting from the different pharmacokinetic approaches were poorly correlated showing a correlation coefficient (r) of 0.502 (p <0.001).
In summary, this study showed a non-linear relationship of meropenem clearance and creatinine clearance. The model shows that the renal function may change rapidly and to a significant extent in patients with sepsis and septic shock, which in turn, underscores that creatinine concentrations are not in steady state in these patients. Conversely, dose adjustment based on creatinine values might lead to inappropriate therapy. This underlines the importance of a TDM program for meropenem in critically ill patients.
The two most important considerations when choosing an antibiotic for the prophylaxis of postoperative bone infections are its activity against the whole spectrum of bacteria, which might be involved in bone infections, and its ability to penetrate bone tissue and thus to achieve concentrations above the minimum inhibitory concentration (MIC) of the corresponding pathogens.
In order to gain information on this data, a study was conducted which investigated the pharmacokinetics of ampicillin / sulbactam in plasma, cortical and cancellous bone. Pharmacokinetic parameters in plasma were determined using NCA. The bone penetration represents the ratio of the concentration in the bone tissue to plasma concentration at the time of bone removal. The resulting half-life of ampicillin and sulbactam in plasma was 1.60 0.37 h and 1.70 0.42 h. The elimination of both substances was in a good correlation with creatinine clearance and resulted in correlation coefficients (r) of 0.729 (p = 0.003) for ampicillin and 0.699 (p = 0.005) for sulbactam. The mean clearance and the mean volume of distribution of ampicillin and sulbactam were 10.7 3.9 and 10.3 3.3 L/h, and 23.9 7.9 and 24.3 6.8 L. The mean concentrations of ampicillin in the cortical and cancellous bone were 6.60 4.22 and 10.15 7.40 µg/g, resulting in bone penetration ratios of 9.1 5.7 and 16.2 16.9 %. For sulbactam the corresponding concentrations were 3.91 2.52 and 5.73 4.20 µg/g, resulting in bone penetration ratios of 10.6 6.3 and 17.5 16.1 %.
In summary, this study shows that the bone penetration of both substances is on average rather unsatisfactory and has a high variability, which can lead to inadequate bone concentrations for the prophylaxis of bone infections. One factor that could be identified for the penetration of both substances into cancellous bone was the period between the application of the drug and the removal of the bone. Therefore, a time interval between the administration of the antibiotic and the incision should be considered.
Immunosuppression is a risk factor for the development of various malignancies, including hematologic diseases. While the relationship between the use of immunosuppressive therapy with methotrexate and the development of an Epstein-Barr virus (EBV) associated lymphoproliferative disease (LPD) has been well established, this connection is less evident for immunosuppressive therapy with azathioprine.
The patient presented by us was immunosuppressed with azathioprine for autoimmune hepatitis. The development of an EBV-associated Hodgkin-like lymphoma under this immunosuppressive therapy and especially the regression of the lymphoma after cessation of azathioprine confirms the relationship between this immunosuppressant, EBV-infection and the development of Hodgkin-like lymphoma. Therefore, albeit in rare cases, azathioprine-related lymphomas may respond to mere cessation of immunosuppressive therapy without need for chemotherapy.
Apart from viral infections, drugs are a major cause of acute liver failure. Due to the lack of specific symptoms or tests, it is difficult to diagnose a drug-induced liver injury. We report a case of a young patient in whom different antibiotics, the analgesic and antipyretic acetaminophen or a combination of these drugs may have led to DILI resulting in life-threatening ALF. Based on this case report, we describe a procedure to exclude non-drug related causes and discuss the hepatotoxic potential of the involved drugs in this case.
Our ability of screening broad communities for clinically asymptomatic diseases critically drives population health. Sensory chewing gums are presented targeting the tongue as 24/7 detector allowing diagnosis by “anyone, anywhere, anytime”. The chewing gum contains peptide sensors consisting of a protease cleavable linker in between a bitter substance and a microparticle. Matrix metalloproteinases in the oral cavity, as upregulated in peri-implant disease, specifically target the protease cleavable linker while chewing the gum, thereby generating bitterness for detection by the tongue. The peptide sensors prove significant success in discriminating saliva collected from patients with peri-implant disease versus clinically asymptomatic volunteers. Superior outcome is demonstrated over commercially available protease-based tests in saliva. “Anyone, anywhere, anytime” diagnostics are within reach for oral inflammation. Expanding this platform technology to other diseases in the future features this diagnostic as a massive screening tool potentially maximizing impact on population health.
Lokalisation und Bedeutung der NO-sensitiven Guanylyl-Cyclase bei der Leberfibrose in der Maus
(2019)
Mittels der im Rahmen dieser Arbeit behandelten Untersuchungen konnten neue Erkenntnisse über die Rolle der NO-GC bei der Pathogenese der Lungen- und der Leberfibrose gewonnen wer- den. Infolge einer Fibrose in Lunge und Leber kommt es zu einer übermäßigen Akkumulation von EZM, die zum Organversagen führen kann. Bis jetzt existieren nur wenige Therapiemöglichkeiten, die zur Behandlung von Organfibrose dienen. Jedoch konnte bereits gezeigt werden, dass durch den Einsatz von NO-GC-Stimulatoren/Aktivatoren es zu Verbesserung/Heilung bei verschiedenen Organfibrosen kommt. Deshalb wird vermutet, dass die NO-GC eine modulatorische Rolle bei der Entwicklung einer Organfibrose einnimmt. Die Effektorzellen sind bisher unbekannt.
Im ersten Teil dieser Arbeit sollten die Effektorzellen der Lunge in vitro untersucht werden. Da bekannt ist, dass in der Lunge Perizyten NO-GC exprimieren, wurde ein Protokoll etabliert, das es ermöglichte, Perizyten spezifisch aus der Lunge zu isolieren und in Kultur zu bringen. Durch den Einsatz von verschiedenen Markern wurden im Anschluss diese isolierten Perizyten weiter charakterisiert. Zum einen konnte festgestellt werden, dass die NO-GC in diesen isolierten Zellen exprimiert wird. Zum anderen stellte sich heraus, dass die Perizyten auch durch einen Marker (SM/MHC) identifiziert werden können, der eigentlich als VSMC-Marker gilt. Diese Daten waren analog zu den In-vivo-Daten von Aue et al. Zusätzlich sollte untersucht werden, ob diese NO-GC- exprimierenden Perizyten in Kultur zu Myofibroblasten differenziert werden können. Dies gelang jedoch nicht durch Stimulation mit TGF-β1.
Im zweiten Teil dieser Arbeit sollte herausgefunden werden, in welchen Zellen in der Leber die NO-GC exprimiert wird. Es konnte in vivo gezeigt werden, dass die NO-GC in der Leber in den HSC exprimiert wird. Da bekannt ist, dass die NO-GC Einfluss auf die Organfibrose nimmt, sollte die NO-GC-Expression in der Leberfibrose untersucht werden. Dabei konnte festgestellt werden, dass es zu einer gesteigerten NO-GC-Expression in der CCl4-induzierten Leberfibrose kommt. Diese war vor allem in den Myofibroblasten lokalisiert – den Zellen, die wahrscheinlich für den übermäßigen Einbau der EZM sorgen. Um den Einfluss der NO-GC auf die Leberfibrose genau- er zu untersuchen, wurde die Fibrose zwischen WT- und GCKO-Tieren verglichen. Dabei konnte beobachtet werden, dass es in den GCKO-Tieren zu einer stärkeren Fibrose als in WT-Tieren kam, die sich durch eine vermehrte Einlagerung von Kollagen und einer erhöhten Expression von TGF-β1 auszeichnete. Damit konnte nachgewiesen werden, dass die NO-GC eine wahrschein- lich protektive Rolle in der Leberfibrose einnimmt.
Im dritten Teil dieser Arbeit wurde die Rolle der HSC in der Leberfibrose genauer untersucht. Dabei konnte zum ersten mal festgestellt werden, dass sich die HSC in Subpopulation unter- teilen lassen. Durch den Einsatz von Reportermäusen, bei denen unter dem SM/MHC- oder PDGFRβ-Promotor das Flurophor tdTomato exprimiert wurde, ließen sich die HSC in 3 Subpo- pulationen einteilen: (1) SM/MHC-Tomato− und PDGFRβ-Tomato−; (2) SM/MHC-Tomato− und PDGFRβ-Tomato+ und (3) SM/MHC-Tomato+ und PDGFRβ-Tomato−. Durch Lineage-Tracing- Versuche konnte den beschriebenen Subpopulationen Aufgaben in der Leberfibrose und in deren Auflösung zugeordnet werden. Die Subpopulation 1 ist in der gesunden Leber hauptsächlich in den Zonen 2 und 3 des Leberazinus lokalisiert. In der Fibrose wandern diese Zellen zu den fibrotischen Regionen und differenzieren dort zu Myofibroblasten. In der Auflösung der Fibrose verschwinden diese Zellen durch Apoptose aus der Leber. Die HSC-Subpopulation 2 befindet sich in der gesunden Leber in der Zone 1 des Leberazinus. Auch in und nach Auflösung der Leberfibrose verweilen diese Zellen dort. Zwar befindet sich die HSC-Subpopulation 3 in der ge- sunden Leber ebenfalls nur in Zone 1 des Leberazinus, jedoch wandern die Zellen in der Fibrose in die Zone 2 und 3 und ersetzen dort die HSC-Subpopulation 1, die in die fibrotische Region gewandert ist. Nach Auflösung der Leberfibrose hat die HSC-Subpopulation 3 die Population 1 vollständig ersetzt.
Nach Identifizierung der HSC-Subpopulationen stellte sich die Frage, ob ein spezifischer Aus- schnitt der NO-GC zu einer veränderten Leberfibrose führt im Vergleich zum WT. Dazu wurde unter dem SM/MHC- und PDGFRβ-Promotor die NO-GC deletiert und die Fibrose in diesen Knockouts untersucht. Während bei der Deletion der NO-GC unter dem PDGFRβ-Promotor kein Unterschied im Vergleich zum WT gesehen werden konnte, ließ sich beim SM/MHC-GCKO Unterschiede feststellen. Durch den Ausschnitt der NO-GC in den Zellen der HSC-Subpopulation 3 kam es zu einer verringerten Expression von PPARγ in der gesunden Leber. Da PPARγ als Gegenspieler von TGF-β1 fungiert, konnte eine erhöhte TGF-β1-Expression in der gesunden und fibrotischen Leber des SM/MHC-GCKO im Vergleich zum WT-Tier gesehen werden. Diese Ergebnisse sprechen dafür, dass die NO-GC über die Steuerung des PPARγ ihren protektiven Effekt auf die Leberfibrose ausübt.
Molecular Effects of Polyphenols in Experimental Type 2 Diabetes Mellitus and Metabolic Syndrome
(2019)
The growing prevalence of type 2 diabetes mellitus (T2DM) demands novel therapeutic and adjuvant strategies. Polyphenols (PPs) are plant secondary metabolites. Epidemiological studies demonstrate an inverse relationship between their increased intake and the risk of development of T2DM and cardiovascular complications. However, the PPs’ mechanism of action remains largely unknown. The present work aimed to expand knowledge regarding the effects of PPs on diabetes relevant molecular targets.
Pycnogenol® (PYC) is a standardized pine bark extract which consists of oligomeric and monomeric PPs. Its anti-diabetic effects have been demonstrated in clinical trials. As a part of a human study involving 20 healthy volunteers, the extract’s effects on dipeptidyl peptidase IV (DPP IV) were investigated. This protease terminates the insulin secretagogue action of incretins. Its inhibition is a promising strategy in T2DM treatment. This study uncovered that PYC-intake of 100 mg daily over 14 days statistically significantly reduced DPP IV serum concentrations by 8.2 % (n= 38, p= 0.032). Contrary to expectations, this decrease was not paralleled by a reduction in the serum DPP IV enzymatic activity. To the best of our knowledge, the present study was the first investigating the effects of PPs on DPP IV serum concentrations and activities in humans. The finding that PYC is capable of reducing DPP IV serum concentrations might be important with regard to diabetes, where DPP IV levels are increased.
Screenings for PPs’ in vitro effects on DPP IV activity were performed employing a purified enzyme. The effects of tested PPs (among which PYC ingredients) at a physiologically relevant concentration of 5 µM were weak (< 10 %) and too small compared to the reference compound sitagliptin, and thus not likely to be clinically relevant. This result is in discordance with some published data, but consistent with the outcome from the present human study. In addition, fluorescence interactions with the experimental setup were registered: under certain conditions urolithin B exhibited an autofluorescence which might mask eventual inhibitory activity. Quercetin quenched the fluorescence slightly which might contribute to false positive results. No statistically significant effects of selected constituents and metabolites of PYC on the total DPP IV protein expression were observed in 3T3-L1 adipocytes. Thus, the lower DPP IV in vivo concentrations after intake of PYC cannot be explained with down-regulation of the DPP IV expression in adipocytes.
Akt kinase is responsible for the transmission of insulin signals and its dysregulation is related to insulin resistance and plays an important role in development of cardiovascular complications in T2DM. Thus, the modulation of the phosphorylation status of endothelial Akt-kinase, respectively its activity, might be a promising strategy in the management of these pathologies. This work aimed to uncover the effects of PPs from different structural subclasses on Akt-phosphorylation (pAkt) in endothelial cells (Ea.hy926). Short-term effects (5 – 30 min) were investigated at a concentration of 10 µM. In a pilot study two model PPs induced a moderate, but reproducible inhibition of pAkt Ser473 of 52.37 ± 21.01 % (quercetin; p= 0.006, n= 3) and 37.79 ± 7.14 % (resveratrol; p= 0.021, n= 4) compared to the negative control. A primary screening with Western blot analysis investigated the effects of eight compounds from different subclasses on pAkt Ser473 and Thr308 to reveal whether the observed inhibition PPs a group effect or specific to certain compounds. In addition to resveratrol and quercetin, statistically significant inhibitions of pAkt Ser473 were induced by luteolin (29.96 ± 11.06 %, p< 0.01, n= 6) and apigenin (22.57 ± 10.30 %, p< 0.01, n= 6). In contrast, genistein, 3,4,5-trimethoxystilbene, taxifolin and (+)-catechin caused no inhibition. A strong positive and statistically significant correlation between the mean inhibitory effects of the tested PPs on both Akt-residues Ser473 and Thr308 (r= 0.9478, p= 0.0003) was determined. A comprehensive secondary screening via ELISA involving 44 compounds from nine structural groups quantified the effects of PPs on pAkt Ser473 to uncover potential structure-activity features. The most potent inhibitors were luteolin (44.31 ± 17.95 %), quercetin (35.71 ± 8.33 %), urolithin A (35.28 ± 11.80 %), apigenin (31.79 ± 6.16 %), fisetin (28.09 ± 9.09 %), and resveratrol (26.04 ± 5.58 %). These effects were statistically significant (p< 0.01, n= 3 to 6). Further lead structure optimization might be based on the fact that the effects of luteolin and resveratrol also differed statistically significantly from each other (p= 0.008).
To the best of our knowledge, the present study is the first to compare quantitatively the short term effects of PPs from different subclasses on pAkt in endothelial cells. Basic structure-activity relationships revealed that for flavones and flavonols the presence of a C2=C3 double bond (ring C) was essential for inhibitory activity and hydroxylation on the m- and p- positions in the ring B contributed to it. For stilbenoids, three free OH-groups appeared to be optimal. The comparison of the inhibitory potentials of ellagic acid and its microbial metabolites showed that urolithin A was statistically significantly more effective than its progenitor compound. Despite their structural similarities, the only active compound among all urolithins tested was urolithin A, hydroxylated at the C3 and C8 positions. This suggested a specific effect for urolithin A. Based on the common structural determinants and molecular geometry of the most active PPs a pharmacophore model regarding Akt-inhibition was proposed.
In summary, the effects of a wide variety of PPs from diverse structural subclasses on the in vitro phosphorylation of endothelial Akt were quantitatively analyzed for the first time, the effects of previously undescribed compounds were determined and structure activity relationships were elucidated. The inhibitory potential of individual PPs might be beneficial in cases of sustained over-activation of Akt-kinase and its substrates such as S6 kinase as reported for certain T2DM-related pathological states, such as insulin resistance, endothelial dysfunction, excessive angiogenesis, vascular calcification, and insulin triggered DNA-damage. The results of the present work suggest potential molecular mechanisms of action of PP involving Akt-inhibition and DPP IV-down-regulation and thus contribute to the understanding of anti-diabetic effects of these compounds on the molecular level.
Bakterielle und parasitäre MIP-Proteine stellen wichtige Virulenzfaktoren dar, deren Inhibition das Überleben der Erreger sowie deren Penetration in menschliche Zellen stark einschränken kann. In dieser Arbeit standen die MIP-Proteine von Burkholderia pseudomallei (Auslöser der Melioidose) und Legionella pneumophila (Legionärskrankheit) im Fokus. Außerdem wurde das MIP-Protein von Trypanosoma cruzi (Chagas-Krankheit) untersucht. Die strukturverwandten humanen FKB-Proteine FKBP12 und FKBP52 sind relevante „off-targets“, wie Experimente mit Knockout-Mäusen gezeigt haben.
Ziel dieser Arbeit war die Verbesserung von bekannten MIP-Inhibitoren im Hinblick auf ihre Affinität und Selektivität für MIP-Proteine gegenüber den beiden genannten FKB-Proteinen bei gleichzeitig verbesserter Löslichkeit, mit Hilfe von in silico Methoden. Ausgangspunkt waren hierbei zwei von Dr. Christina Juli und Dr. Florian Seufert entwickelte Leitstrukturen, welche ein Pipecolinsäuregrundgerüst aufweisen. Diese Referenzliganden beinhalten einen 3,4,5-Trimethoxyphenylring (TMPR, vgl. Ref_t) bzw. einen Pyridinylring (Ref_p).
Beim Vergleich von insgesamt 32 MIP- und FKB-Proteinen konnten in zwei Loop-Bereichen, welche 50er bzw. 80er Loop genannt werden, relevante Unterschiede in der Aminosäuresequenz identifiziert werden. Die Nummerierung bezieht sich stets auf FKBP12. Diese Unterschiede ließen sich zum Design von vergleichsweise selektiv an MIP-Proteine bindenden Molekülen nutzen.
Der 50er Loop ist in nahezu allen MIP-Proteinen (jedoch nicht in BpsMIP) im Vergleich zu den FKB-Proteinen um zwei Aminosäuren verkürzt. Dadurch befindet sich das Proteinrückgrat von LpnMIP (Gln49) und TcrMIP (Arg49) näher am Zentrum der Bindetasche (definiert als Ile56, welches durch die Pipecolinsäureesterfunktion der Liganden adressiert wird). MD-Simulationen der beiden Apoproteine belegten, dass die geringere Distanz nicht durch Artefakte beim Modellieren der Strukturen bedingt ist. Aufbauend auf dieser Erkenntnis wurde gezeigt, dass der Pyridinylring von Ref_p eine Wasserstoffbrücke zu Gln49 ausbildet. Experimentell wurde dieser Befund durch eine entsprechende chemische Verschiebung der Aminosäure im NMR-Experiment von Dr. Kristian Schweimer bestätigt. Durch Überbrückung des Pipecolinsäurerings (Ligand 6bp) konnte die Wasserstoffbrücke in MD-Simulationen weiter stabilisiert werden. Durch Rechnungen zur Abschätzung der freien Bindungsenthalpien (mittels LIE und MM/GBSA) wurde eine erhöhte Affinität von 6bp im Vergleich zu Ref_p in LpnMIP ermittelt.
Im Laufe der Arbeit wurde anhand von pIC50-Werten, welche von Dr. Mathias Weiwad bestimmt wurden, erkannt, dass Liganden mit Pyridinylring oftmals eine bessere Affinität in LpnMIP aufweisen als die entsprechenden Liganden mit TMPR. Durch MD Simulationen wurde nachgewiesen, dass der TMPR in LpnMIP nur schwer an der in den anderen Proteinen bevorzugten Position binden kann. Grund hierfür ist die Mutation einer Aminosäure (zu Pro57) in diesem Bereich von LpnMIP: Diese verfügt über eine wenig flexible Seiten-kette, an welche sich der TMPR auf Grund seiner Rigidität nicht anpassen kann, was die Interaktion zwischen Protein und Ligand stört. Der Pyridinylring von Ref_p ist hiervon nicht betroffen, da er bevorzugt an einer anderen Stelle (Gln49, s. o.) bindet.
Der 80er Loop weist in vielen MIP-Proteinen deutlich hydrophobere Aminosäuren auf als in FKB-Proteinen. Von besonderem Interesse ist die Position 90, da hier in BpsMIP und LpnMIP sterisch weniger anspruchsvolle Aminosäuren (Val, Pro) vorliegen als in den bei-den FKB-Proteinen (Ile, Lys). Dieser Unterschied wurde mit kleinen hydrophoben Substituenten am Phenylring der Liganden adressiert. Bereits im Docking zeigten sich die positiven Effekte der para-Substitution durch Halogenatome oder eine Methylgruppe. Die von Dr. Mathias Weiwad und Dr. Mirella Vivoli ermittelten pIC50- bzw. pKi-Werte bestätigten diesen Trend. Zugleich nahm die Affinität zu FKBP12 deutlich ab. Bei der Untersuchung der Referenzliganden sowie deren Chlor- und Bromderivate in MD-Simulationen zeigte sich, dass der Phenylring der Liganden in den MIP-Proteinen bevorzugt in Richtung des 80er Loops orientiert ist; in den FKB-Proteinen liegt er hingegen um etwa 110° gedreht vor und kann somit schlechter mit der Bindetasche interagieren. Besonders ausgeprägt ist dieser Effekt in FKBP12. Basierend auf diesen Ergebnissen wurde der Phenylring durch einen 4-Bromo-1H-imidazol-2-ylsubstituenten ersetzt (Ligand 8ap). Dieser ist in der Lage, in der erwarteten Orientierung im Bereich des 80er Loops von BpsMIP zu binden und gleichzeitig eine stabile Wasserstoffbrücke zu Asp37 auszubilden. Hieraus resultiert für den Liganden eine deutlich höhere Affinität in LIE- und MM/GBSA-Rechnungen; in FKBP12 blieb sie auf Grund der dort instabilen Interaktion unverändert.
Die berechneten Energien können unmittelbar für einen relativen Vergleich verschiedener Liganden in einer Bindetasche verwendet werden. Für die Vorhersage von pKi- bzw. pIC50-Werten in den verschiedenen Proteinen ist eine Kalibrierung gegen die gemessenen Affinitäten erforderlich. Dies wurde für BpsMIP durchgeführt, indem eine lineare Korrelation zwischen den pKi- bzw. pIC50-Werten und den mit MM/GBSA ermittelten Energien aufgestellt wurde. Für LIE wurde auf publizierte Werte von Lamb et al. zurückgegriffen. Die berechneten Affinitäten stimmen für die bereits getesteten Inhibitoren gut mit den experimentellen pKi- und pIC50-Werten überein. Anhand der Modelle werden für 8ap Werte vorhergesagt, die besser als die experimentellen Affinitäten bekannter Liganden sind.
Idealerweise können auch aus den Scores, die durch Docking erhalten werden, bereits Rückschlüsse auf die Affinitäten der Liganden gezogen werden. Für die untersuchten Proteine war dies, auf Grund des engen Bereichs der experimentell ermittelten pKi- und pIC50-Werte, nicht mit hinreichender Richtigkeit möglich. Um die Scores dennoch für die Beurteilung neuer Liganden verwenden zu können, wurden logistische Regressionsmodelle erstellt. Anhand dieser kann abgeschätzt werden, ob ein Molekül in BpsMIP submikromolare Affinität aufweist. Die Richtigkeit dieser Vorhersagemodelle konnte durch die Berücksichtigung dreier weiterer Deskriptoren (Konfiguration am Stereozentrum der Pipecolinsäure, Molekulargewicht und logD-Wert) deutlich verbessert werden, wobei die AUC der entsprechenden ROC-Kurven Werte bis zu 0.9 erreichte. Diese Modelle können für die Postprozessierung eines Dockings angewendet werden, um die vielversprechendsten Kandidaten zu identifizieren und anschließend in rechnerisch anspruchsvolleren MD-Simulationen genauer zu untersuchen.
Mit dieser Arbeit wurde zur Weiterentwicklung der Leitstrukturen Ref_t und Ref_p beigetragen. Viele der getesteten Derivate wiesen deutlich verbesserte Löslichkeit bei gleichbleibender Affinität auf. Ferner wurden erstmalig detailliert die Unterschiede in den Bindetaschen zwischen 32 MIP- und FKB-Proteinen evaluiert. Hiervon wurden fünf in MD-Simulationen als Apoprotein und im Komplex mit verschiedenen Inhibitoren verglichen. Anhand dieser Simulationen wurde nachgewiesen, dass jeweils eine Aminosäure in BpsMIP und LpnMIP im Vergleich zum wichtigsten „off-target“ FKBP12 selektiv durch eine Wasserstoffbrücke adressiert werden kann. Durch LIE- und MM/GBSA-Rechnungen konnte gezeigt werden, dass in diesen hochkonservierten Bindetaschen eine bedeutende Modulation der Affinität zugunsten von BpsMIP möglich ist.
The number of active pharmaceutical ingredients (APIs) exhibiting a low solubility in aqueous media or a slow dissolution rate kept rising over the past years urging formulation scientists to explore new ways to tackle poor solubility and to enable oral absorption from such compounds. Bioavailability of poorly water-soluble compounds can be improved by increasing the dissolution rate and/or by increasing the gastro intestinal concentration through transient supersaturation. The dissolution rate of the API can be typically modified by the choice of the physical form, the polymorphic form, the powder surface area, and the local pH, while a transient supersaturation can be extended mainly by nucleation or crystallization inhibiting effects. In the present thesis, three strategies were explored to tailor the dissolution rate, the supersaturation and the hydrotropic solubilization of APIs, weak bases, respectively.
The first part of this thesis followed a bioinspired approach to extend the kinetic solubility of salts and co-crystals. API salts and co-crystals are high energy forms that can generate supersaturated solutions with respect to any more stable form, typically the most stable API form in physiological environment. The transient kinetic stabilization of supersaturated states, also termed “parachute effect”, is considered to improve bioavailability and is one aspect of the formulation that can be tailored. Inspiration from plants, which store high concentrations of aromatic bases in their vacuoles via complexation with polyphenols, sparked the evaluation to use hydroxybenzoic acid derivatives for salt or co-crystal engineering. Imatinib was chosen as the model compound for this investigation as its aromaticity and flat molecular architecture could favor interactions with hydroxybenzoic acid derivatives. One 1:1 Imatinib syringate co-crystal (I-SYA (1:1)) and one 1:2 Imatinib syringate co-crystal salt (I-SYA (1:2)) were obtained. Their dissolution assays in simulated intestinal fluid (SIF; a 50 mM phosphate buffer of pH 6.8) revealed that they formed stable solutions for several hours and days, respectively, in contrast to the marketed Imatinib mesylate salt (approx. 1h). This kinetic stability in solution was linked to the nucleation inhibition of the less soluble Imatinib hydrate by syringic acid (SYA). In solution 1H-NMR studies evidenced the aggregation of Imatinib and SYA. The amphiphilic nature of both Imatinib and SYA is considered to drive their association in solution, additionally, multiple intermolecular interactions such as hydrogen bonds and π-π stacking are likely to contribute. The association in solution enabled a phase of extended supersaturation, i.e., a parachute against desupersaturation, while no negative impact of aggregation on the permeability of both Imatinib and SYA was observed.
A prerequisite to reach supersaturation is a rapid dissolution and release of the API from the formulation. Accordingly, the second and third part of this thesis is focused on the so-called “spring effect” of amorphous solid dispersions (ASDs). The addition of a hydrotropic agent, meaning a molecule that can solubilize poorly water-soluble APIs in aqueous solutions (well-known examples of hydrotropes are benzoic acid and nicotinamide) into an amorphous Ciprofloxacin-polymer matrix led to ternary systems with a significantly faster release and higher concentration of the API in SIF as compared to binary ASDs consisting of Ciprofloxacin (CPX) and polymer only. The stronger spring could be rationalized by an improved wetting of the ASD, or/and by a hydrotropic solubilization effect, although these hypotheses need further investigation. Marked differences in the dissolution profiles of binary ASDs were observed in biorelevant fasted simulated intestinal fluid (FaSSIF; a medium containing Na taurocholate (3 mM) and lecithin (0.75 mM) at pH 6.5) as compared to SIF. In FaSSIF, API release from binary polymeric ASDs was largely improved, and the duration of supersaturation was extended. This suggests that the bile salt Na taurocholate and lecithin present in FaSSIF do improve both dissolution rate and supersaturation of ASDs, the two pillars of ASDs as oral enabling formulations. Indeed, bile salts are endogenous surfactants which, together with phospholipids, play an important role in the wetting, solubilization, and absorption of lipophilic compounds.
The aim of the third part of the present thesis was to study ASDs as formulation principles reducing the strong positive food effect of Compound A. By inclusion of Na taurocholate (NaTC) within the matrix of polymeric ASDs a significant improvement of the dissolution rate and the kinetic solubility in SIF were achieved. Transient supersaturated states of up to four orders of magnitude over the equilibrium solubility were obtained. Two ASDs were selected for further in vivo evaluation in dog. The first was a NaTC/Eudragit E based ASD meant to dissolve and release Compound A in the acidic environment of the stomach, where its solubility is the highest. The second relied on the release of Compound A in the neutral environment of the duodenum and jejunum by using an enterically dissolving polymer, HPMC-P. Releasing the API at the site of its putative absorption was an attempt to control supersaturation levels in the duodenum and to prevent portioning and thus dilution effects during transfer from the stomach. In fasted dogs, exposure from the NaTC/HPMC-P ASD was close to that of the reference Compound A formulation under fed conditions, which suggests an improved dissolution rate and kinetic solubility under fasted conditions (historical data). The exposure from the NaTC/Eudragit E ASD was twice as low as from the NaTC/HPMC-P ASD, and also lower compared to Compound A reference formulation, whereas in vitro the parachute effect of the NaTC/Eudragit E ASD was largely superior to that of the NaTC/HPMC-P ASD. A difference in the extend of the parachute could be related to differences in the thermodynamic activity of dissolved molecules from the two ASDs. Indeed, the high instability of the NaTC/HPMC-P ASD could stem from a high thermodynamic activity driving diffusion through membranes, whereas less instable solutions of NaTC/Eudragit E could indicate solubilization effects which often translate into a lower flux through the biological membrane. Additionally, the pH of the environment where dissolution takes place might be an important factor for absorption, and could also account for the difference in exposure from the two ASDs.
The aim of this thesis was to explore how the intimate environment of weak, poorly soluble bases could be functionalized to improve dissolution rate and kinetic solubility. The investigations highlighted that the performance of enabling oral delivery formulations of weak bases in aqueous media can be enhanced at different levels. At one end initial dissolution rate of ASDs can be tailored by introducing hydrotropes or/and bile salts within the polymeric matrix of ASDs. Bile salts, when combined with appropriate polymers, had also a precipitation inhibition effect enabling the maintenance of supersaturation for a bio-relevant period of time. These results set the ground for further investigations to comprehend specific interactions between bile salts and APIs, and potentially polymers at the molecular level. It will be interesting to explore how such complex systems can be exploited in the formulation design of poorly water-soluble APIs. In addition, it was observed that the duration of supersaturation generated by salts/co-crystals can be extended by the pertinent selection of counterions or coformers. The in vivo relevance of these tunings remains to be evaluated, as translation from closed, in vitro systems to the highly dynamic gastrointestinal environment is not straightforward. A better understanding of the contribution of each kinetic stage (dissolution, supersaturation, and precipitation) and their interplay with physiological factors impacting absorption is essential to facilitate the design of formulations with improved pharmacokinetics.
Einhergehend mit einer steigenden Lebenserwartung nimmt auch die Zahl der am Multiplen Myelom Erkrankten zu. Bis dato gibt es nur wenige Therapieansätze dieser selten vorkommenden Blutkrebserkrankung. Im Zusammenhang mit der Entstehung des Multiplen Myeloms stehen vor allem zwei bedeutende Hitzeschockproteine: Hsp90 und Hsp70. Beide haben die Aufgabe, Zellen vor Apoptose zu schützen. In proliferierenden Plasmazellen ist eine Überexpression an Hsp90 zu beobachten. Entwickelte Inhibitoren führten zwar zu einer verminderten Hsp90-Aktivität, allerdings wurde diese durch eine vermehrte Expression von Hsp70 kompensiert, weshalb Myelomzellen weiterhin proliferierten. Aus diesem Grund bietet sich Hsp70 als weiterer Angriffspunkt in der Therapierung des Multiplen Myeloms an. Die bislang entwickelten Inhibitoren binden entweder an die Nukleotid- oder Substratbindedomäne. Da beide Stellen unspezifisch sind, wurden durch virtuelles Screening potenzielle Inhibitoren für Hsp70 identifiziert, welche in vitro und in vivo tatsächlich Effekte hinsichtlich der Herunterregulierung von Hsp70 zeigten. Ob die entwickelten Substanzen jedoch direkt an Hsp70 binden, war die Fragestellung der vorliegenden Arbeit.
In dieser Arbeit wurde untersucht, inwiefern die entwickelten Inhibitoren an Hsp70 binden und dieses inhibieren. Die humane Hsp70-Familie besitzt sechzehn Mitglieder, die alle ähnliche Aufgaben und Strukturmerkmale aufweisen. Für die durchgeführten Versuche wurde die Hsp70-Isoform Hsc70 verwendet. In einem Protein-Ligand-Assay konnte gezeigt werden, dass die meisten Verbindungen durch Aggregatbildung zu einer Inhibition von Hsc70 führten. Durch Zugabe von Detergenz konnten die gebildeten Aggregate aufgebrochen und so der Inhibitionseffekt aufgehoben bzw. deutlich reduziert werden. Damit konnte gezeigt werden, dass die in Zell- und Mausversuchen beobachteten Effekte vermutlich nicht auf eine direkte Inhibition von Hsc70 zurückzuführen sind. Ob diese Effekte nun ebenfalls auf Aggregatbildung beruhen oder aber ein anderes Protein als das vermutete Hsc70 inhibiert wird, was über eine Signalkaskade zur Inhibition von Hsc70 führt, wäre eine interessante Fragestellung für weitere Untersuchungen.
Da sowohl in NMR-Versuchen als auch dem durchgeführten Protein-Ligand-Assay gezeigt werden konnte, dass die vormals als potenzielle Inhibitoren entwickelten Verbindungen nur schwach aktiv sind, wurde durch Fragment-basierte Ansätze eine andere Bindestelle für mögliche Inhibitoren identifiziert. Hierbei konnte N-Acetyl-D-Glucosamin in der Nukleotidbindedomäne von Hsc70 detektiert werden. Hieraus könnten sich neue Ansätze zur Entwicklung neuartiger in silico entwickelter Hsc70-Inhibitoren ergeben.
Ausgangspunkt für die Docking-Studien zur Entwicklung neuer Hsp70-Inhibitoren war die Kristallstruktur von bHsc70 ED 1-554, einer trunkierten Doppelmutante des nativen Hsc70. Bis dato ist diese 554 Aminosäuren umfassende Mutante die einzige Hsc70-Variante von der die Zweidomänenstruktur kristallisiert werden konnte. Für dieses Konstrukt wurde zunächst ein optimiertes Aufreinigungsprotokoll entwickelt, um dann Kristallisationsversuche mit ausgewählten AH-Verbindungen, die in den Docking-Studien entwickelt wurden, durchzuführen. Hierbei konnte jedoch keine Bindung festgestellt werden. Die Kristallisation mit Ver-155008, einem bekannten Hsc70-Inhibitor, führte jedoch zur ersten Zweidomänenstruktur von Hsc70 mit gebundenem Ver-155008.
Neben der obigen Fragestellung wurde außerdem untersucht, wie funktional aktiv das trunkierte Hsc70-Konstrukts ist. Hier zeigte sich, dass aufgrund des fehlenden C-Terminus zwar eine geringe Aktivität von 30 % im Vergleich zur Volllänge zu beobachten war. Für eine nahezu vollständige Rückfaltungsaktivität ist aber der C-Terminus essentiell. Weiterhin konnte in ITC-Versuchen der Kd-Wert von Ver-155008 an die verwendete Mutante ermittelt werden, der dem bereits bekannten Kd von Ver-155008 an das native Hsc70 ähnlich ist.
Upon approval of a drug, the stability of the API and the FPP has to be studied intensively because it determines the shelf-life. If a drug is found to be stable, the expiry date is arbitrary set to five years at the maximum, if a drug tends to undergo degradation, the expiry date is set shorter. The drug product must comply with predefined specifications in accordance with the ICH guidelines Q6A and Q6B during its entire market life. The content of the active substance is required to be within a specification of 95–105% of its labeled claim until expiry corresponding to the ICH guideline Q1A(R2). However, there is little or scattered literature information addressing the stability of drug products beyond their expiry dates. The objective of this thesis was to study and assess the long-term stability of a collection involving numerous pure drug substances and ampoules manufactured in the 20th century. The content and the impurity profile were examined by means of appropriate analytical methods, mainly using liquid chromatography. The results were compared to data being available in the literature. Assessing the stability regarding the dosage form and the affiliation of the drug class was conducted.
The experimental studies comprise the examination of 50 drug substances manufactured 20–30 years ago and 14 long expired ampoules which were older than 40 years in the time of analysis, exceeding many times the maximum shelf life of five years.
For investigation of the solid drug substances, pharmacopoeial methods were applied as far as possible. Indeed, results of the study showed that 44 tested substances still complied with the specification of the Ph. Eur. with regard to the content and impurity profile, even after more than two decades of storage.
For analysis of the injection solutions, HPLC-UV and HPLC-ESI/MS techniques were applied, commonly based on liquid chromatography methods of the Ph. Eur. for determination of related substances. Each method was further validated for its application to ensure accurate API quantification corresponding to ICH Q2(R1). Quite a few ampoules were identified to show surprisingly high stability. In spite of their age of 53–72 years, APIs such as caffeine, etilefrine, synephrine, metamizole sodium, furosemide, and sodium salicylate complied with the specified content that is valid nowadays, respectively. Nevertheless, typical degradation reaction, e.g. hydrolysis, oxidation, or isomerization, was observed in all remaining ampoules. Various degrees of hydrolysis were revealed for scopolamine, procaine, and adenosine triphosphate, the contents were decreased to 71%, 70%, and 15% of the declared concentrations, respectively. In the epinephrine and dipyridamole ampoules, oxidative degradation has been occurred, finding respective API contents of more or less 70%. For dihydroergotamine, excessive decomposition by epimerization was observed, resulting in an API content of 21% and degradation by isomerization was found in lobeline, still containing 64% of the labeled claim.
In conclusion, supported by the data of the present studies and the literature, defining and authorizing a longer shelf-life may be applicable to numerous pharmaceuticals which should be considered by pharmaceutical manufacturers and regulatory authorities, if justified based on stability studies. A general extension of the shelf-lives of drug products and the abolishment or extension of the maximum shelf-life limit of five years would prevent disposing of still potent medications and save a lot of money to the entire health care system.
Der Gruppe der Macrogole sowie den darauf basierenden Abkömmlingen, den Macrogolfettalkoholethern, Macrogolfettsäureestern und Polysorbaten, kommt in der modernen Galenik eine wichtige Rolle zu. Dienten sie vormals nur als gewöhnliche Emulgatoren, so finden sie heutzutage vor allem im Bereich der gezielten Wirkstofffreisetzung, der Erhöhung der Bioverfügbarkeit sowie als Löslichkeitsvermittler komplexer Systeme Anwendung. Diese vielschichtigen Anwendungsgebiete erfordern, auch aufgrund der polydispersen Strukturen der Macrogole, eine reproduzierbare und aussagekräftige Analytik.
Das Europäische Arzneibuch (Ph. Eur.) bietet zur Charakterisierung der Hilfsstoffe eine Handvoll Messgrößen, die sog. Fettkennzahlen, die eine Größenordnung vorhandener funktioneller Gruppen liefern. Zu diesen gehören Werte wie Hydroxylzahl, Iodzahl, Peroxidzahl oder Säurezahl. Diese bieten zwar einen Überblick über den Größenbereich der mittleren Kettenlängen oder einen möglichen Abbau der Strukturen, beispielsweise durch Autoxidation, jedoch geben sie keine Auskunft über die Polymerverteilung. Insbesondere diese kann jedoch, je nach Herstellungsweise, stark variieren. Außerdem ist die Methodik der Fettkennzahlenbestimmungen aufgrund der strikten Reaktionsabläufe und zahlreicher Reaktionsschritte einerseits sehr zeitaufwändig und andererseits anfällig für Fehler.
Die HPLC hat, insbesondere aufgrund der Automation, bereits seit Jahren den Status des Goldstandards in der pharmazeutischen Analytik inne. Gekoppelt mit der UV-Detektion bietet sie für zahlreiche Wirkstoffe die Möglichkeit zur schnellen, einfachen und robusten Analyse. Im Bereich der Hilfsstoffe verbreitet sich die HPLC-Analytik langsamer, da viele Hilfsstoffe keinen Chromophor aufweisen. Eine Anwendung der hochsensitiven Massenspektrometrie wäre zwar zur Detektion geeignet, würde sich für die Routineanwendung jedoch als zu komplex und kostenintensiv gestalten. Doch mit der Entwicklung der Aerosol-basierten Detektoren wie dem ELSD (evaporative light scattering detector), dem CAD (charged aerosol detector) und dem NQADTM (nano quantity aerosol detector) wurde auch für nicht-chromophore Substanzen ein Einsatz der HPLC möglich.
Die vorliegende Arbeit befasste sich mit der Entwicklung einer HPLC-CAD-Methode, die eine möglichst große Bandbreite der Macrogole und der darauf basierenden Hilfsstoffe erfassen kann. Die Trennung erfolgte an einer C18-Trennsäule. Es wurde eine Gradienten-Methode entwickelt, die aus mehreren linearen Gradientenstufen zusammengesetzt wurde, um verschiedene Kettenlängen der Polymere besser voneinander zu trennen. Als mobile Phasen dienten Wasser und Acetonitril, denen jeweils 0.1 % Ameisensäure zugesetzt wurden.
Es konnten Macrogole im Bereich PEG 300 bis PEG 3000 mit akzeptabler Auflösung aufgetrennt werden. Diese Ergebnisse wurden für PEG 300 – 1500 mittels Massenspektrometrie verifiziert. Es konnten fünf gesättigte und zwei ungesättigte Fettsäuren, sowie zwei Fettalkohole verschiedener Kettenlängen voneinander getrennt werden. Es wurden 13 Macrogol-basierte Hilfsstoffe mit der entwickelten Methode untersucht und erfolgreich getrennt. Die Macrogolfettalkoholether, -stearate und Polysorbate wurden insoweit aufgetrennt, dass die Polymerverteilung beobachtet werden konnte.
Freie PEGs in den Hilfsstoffen wurden getrennt und identifiziert. Anhand dieser konnten unterschiedliche Herstellungsweisen zugeordnet werden. Abhängig von der mittleren Kettenlänge der verarbeiteten PEGs konnten teilweise die freien Fettsäuren bzw. -alkohole von den Estern bzw. Ethern getrennt und identifiziert werden. Im Bereich der kürzeren mittleren Kettenlängen wurden die freien Fettsäuren und -alkohole von den Estern und Ethern überlagert.
Macrogolglycerolhydroxystearat (Cremophor® RH40) wurde in seine Komponenten aufgetrennt, mit Ausnahme der linearen Monoester, die mit den freien PEGs partiell koeluierten und die Glyceroltriester, die Größenausschlusseffekte zeigten.
Die Methode wurde für Stabilitätsuntersuchungen der ungesättigten Fettsäuren, Öl- und Linolsäure, eingesetzt. Hierzu wurden diese Säuren in Lösung chemisch (Wasserstoffperoxid) und thermisch (60 °C) gestresst und in bestimmten Zeitabständen analysiert. Es zeigte sich ein zeit- und temperaturabhängiger Abbau. Die teilweise Zuordnung der Abbauprodukte erfolgte durch Bestimmung des m/z mittels Massenspektrometrie. Die Methode war geeignet, um das Ausmaß eines oxidativen Abbaus von der Hauptsubstanz zu trennen und strukturell einzuordnen.
Generell bietet die Methode eine gute Basis, die eine Vielzahl an Substanzgruppen erfassen und charakterisieren kann. Sie bietet eine Ergänzung der Fettkennzahlen, die einen verringerten Arbeitsaufwand mit sich bringt. Für spezifischere Betrachtungen (Langzeitstabilität, verwandte Substanzgruppen) stellt sie einen guten Ausgangspunkt dar.
GPCRs, particularly muscarinic receptors (mAChRs), are significant therapeutic targets in many physiological conditions. The significance of dualsteric hybrids selectively targeting mAChR subtypes is their great advantage in avoiding undesired side effects. This is attained by exploitation of the high affinity of ligand-binding to the orthosteric site and the structural diversity of the allosteric site to target an individual mAChR subtype, as well as offering signal bias to avoiding undesired transduction pathways. Furthermore, dualsteric targeting of mAChR subtypes helps in the elucidation of the physiological role of each individual mAChR subtype.
The first project was the attempt of synthesis of the M2-preferring ligand AFDX-384. AFDX-384 is known to preferentially bind to the M2 receptor subtype as an orthosteric antagonist, with partial interaction with residues in the allosteric site. This project aimed to re-trace the synthesis route of AFDX-384, to open the door to its upscaling and the future synthesis of AFDX-type dualsteric ligands. The multi-step synthesis of AFDX-384 is achieved through the synthesis of its 2 precursors, the chloro acyl derivative VIII and the piperidinyl derivative IV. Upscaled synthesis of the piperidinyl derivative IV was attained. Synthesis of the chloro acyl compound VIII was attempted. Several trials to synthesize the benzopyridodiazepine nucleus as well as its chloro-acylation resulted in the production of the novel crystal structures V and VI. X-ray crystallography was also done for crystallized molecules of the closed-ring benzopyridodiazepine VII that was previously synthesized. Chloro-acylation reactions of compound VII using phosgene seem to be attainable when done using reflux overnight. However, the use of methanol to aid in elution during silica gel column chromatography converted the expected product to the carbamate analogue IX. Hence, further attempts in purification should refrain from the use of methanol. The use of triphosgene instead of phosgene demonstrates a cleaner route for further upscaled synthesis.
The second project was the synthesis of dualsteric ligands involving variable orthosteric and allosteric moieties. Four different types of hybrids have been created over multiple steps. Dualsteric ligands have been synthesized using either a phthalimido- or 1,8-naphthalimidopropylamino moiety as the allosteric-binding group, coupled to either N-desmethyl pirenzepine or N-desmethyl clozapine using variable chain lengths. Furthermore, the synthesis of the dualsteric ligands involving N-desmethyl clozapine linked to either the super-agonist iperoxo or acetylcholine, and being connected using variable alkane chain lengths. Several reaction conditions have been investigated throughout the analysis of the optimal condition to conduct the critical final step of synthesis of these dualsteric hybrids, which involves the linking of the two segments of the hybrid together. The optimal method, which produced the least side products and highest yield, was to connect the two intermediates of the compound in absence of base, catalyst or microwaves while stirring at 35 °C for several days using acetonitrile as solvent (silica gel TLC monitoring, 0.2 M aqueous KNO3/MeOH 2:3). The ideal purification methods for the final compounds were found to be either crystallization from the reaction medium or using C18 reverse phase silica gel flash chromatography (using H2O/MeOH solvent system). All the hybrids will be subjected to pharmacological testing using the appropriate FRET assays.
The aim of this thesis was the application of the functional prepolymer NCO-sP(EO-stat-PO) for the development of new biomaterials. First, the influence of the star-shaped polymers on the mechanical properties of biocements and bone adhesives was investigated. 3-armed star-shaped macromers were used as an additive for a mineral bone cement, and the influence on the mechanical properties was studied. Additionally, a previously developed bone adhesive was examined regarding cytocompatibility. The second topic was the examination of novel functionalization steps which were performed on the surface of electrospun fibers modified with NCO-sP(EO-stat-PO). This established method of functionalizing electrospun meshes was advanced regarding the modification with proteins which was then demonstrated in a biological application. Two different kinds of antibodies were immobilized on the fiber surface in a consecutive manner and the influence of these proteins on the cell behavior was investigated. The final topic involved the quantification of surface-bound peptide sequences. By functionalization of the peptides with the UV-reactive molecule 2-mercaptopyridine it was possible to quantify this compound via UV measurements by cleavage of disulfide bridges and indirectly draw conclusions about the number of immobilized peptides.
In the field of mineral biocements and bone adhesives, NCO-sP(EO-stat-PO) was able to influence the setting behavior and mechanical performance of mineral bone cements based on calcium phosphate chemistry. The addition of NCO-sP(EO-stat-PO) resulted in a pseudo-ductile fracture behavior due to the formation of a hydrogel network in the cement, which was then mineralized by nanosized hydroxyapatite crystals following cement setting. Accordingly, a commercially available aluminum silicate cement from civil engineering could be modified.
In addition, it could be shown that the use of NCO-sP(EO-stat-PO) is beneficial for adjusting specific material properties of bone adhesives. Here, the crosslinking behavior of the prepolymer in an aqueous medium was exploited to form an interpenetrating network (IPN) together with a photochemically curing poly(ethylene glycol) dimethacrylate (PEGDMA) matrix. This could be used for the development of a bone adhesive with an improved adhesion to bone in a wet environment. The developed bone adhesive was further investigated in terms of possible influences of the initiator systems. In addition, the material system was tested for cytocompatibility by using different cell lines.
Moreover, the preparation of electrospun fiber meshes via solution electrospinning consisting of poly(lactide-co-glycolide) (PLGA) as a backbone polymer and NCO-sP(EO-stat-PO) as functional additive is an established method for the application of the meshes as a replacement of the native extracellular matrix (ECM). In general, these fibers reveal diameters in the nanometer range, are protein and cell repellent due to the hydrophilic properties of the prepolymer and show a specific biofunctionalization by immobilization of peptide sequences. Here, the isocyanate groups presented on the fiber surface after electrospinning were used to carry out various functionalization steps, while retaining the properties of protein and cell repellency. The modification of the electrospun fibers involved the immobilization of analogs or antagonists of tumor necrosis factor (TNF) and the indirect detection of these by interaction with a light-producing enzyme. Here, a multimodal modification of the fiber surface with RGD to mediate cell adhesion and two different antibodies could be achieved. After culturing the cell line HT1080, the pro- or anti-inflammatory response of cells could be detected by IL-8 specific ELISA measurements.
Furthermore, the quantification of molecules on the surface of electrospun fibers was investigated. It was tested whether the detection by means of super-resolution microscopy would be possible. Therefore, experiments were performed with short amino acid sequences such as RGD for quantification by fluorescence microscopy. Based on earlier results, in which a UV-spectrometrically active molecule was used to detect the quantification of RGD, it was shown that short peptides can also be quantified in a small scale on flat functional substrates (2D) such as NCO-sP(EO-stat-PO) hydrogel coatings, and modified electrospun fibers produced from PLGA and NCO-sP(EO-stat-PO) (3D). In addition, a collagen sequence was used to prove that a successful quantification can be carried out as well for longer peptide chains.
These studies have revealed that NCO-sP(EO-stat-PO) can serve as a functional additive for many applications and should be considered for further studies on the development of novel biomaterials. The rapid crosslinking reaction, the resulting hydrogel formation and the biocompatibility are to be mentioned as positive properties, which makes the prepolymer interesting for future applications.
Substandard and falsified (SF) medicines have emerged as a global public health issue within the last two decades especially in low- and middle-income countries (LMICs). Serious consequences of this problem include a loss of trust and increased financial costs due to less disease control and more frequent complications during therapy. Of note, antimicrobial resistance is an additional long-term implication of poor-quality antimicrobials. This review covers information technology tools including medicines authentication tools (MAT) as mobile apps and messaging service, 2D barcoding approaches with drug safety alert systems, web based drug safety alerts, radiofrequency identification tags, databases to support visual inspection, digital aids to enhance the performance of quality evaluation kits, reference libraries for identification of falsified and substandard medicines, and quality evaluation kits based on machine learning for field testing. While being easy to access and simple to use, these initiatives are gaining acceptance in LMICs. Implementing 2D barcoding based on end-to-end verification and "Track and Trace" systems has emerged as a step toward global security in the supply chain. A breakthrough in web-based drug safety alert systems and data bases was the establishment of the Global Surveillance and Monitoring System by the World Health Organization in 2013. Future applications include concepts including "lab on a chip" and "paper analytical devices" and are claimed to be convenient and simple to use as well as affordable. The principles discussed herein are making profound impact in the fight against substandard and falsified medicines, offering cheap and accessible solutions.
Assay and impurity profiling of the pharmaceuticals are the key routine quality control methods employed worldwide for which High Performance Liquid Chromatography (HPLC) is the most widely used technique. The ability to carry out these routine laboratory procedures in low- and middle- income countries (LMICs) need the methods to be based upon simple instruments manageable with moderate levels of personnel skill and costs involved.
Simple, convenient, and cost effective reverse phase HPLC methods were developed using phosphate buffer and methanol as mobile phase with C18 column as stationary phase for the impurity profiling and assay of beta lactam antibiotics. Isocratic elution and UV detection was employed in these methods. Impurity profiling method was developed for coamoxiclav tablets and ceftriaxone bulk drug. The method for ceftriaxone included a supplementary method to quantify one of its known impurity (Impurity D of ceftriaxone). This method involved use of acetonitrile where as the two main methods were achieved on the targeted method design, described above. With the exception of impurity A of ceftriaxone, the methods developed can successfully quantify impurities to the concentration as low as ≤0.05%, which is in accordance with the current guidelines for the impurity profiling of antibiotics issued by European Medicines Agency.
As ensuring cost reduction was one of the key objectives of carrying out the method development exercise, in situ methods for the preparation of impurities were also identified and some new methods were introduced. The stability of beta lactam antibiotics and the choice of solvent were given due attention during the process of method development revealing information on the presence of new impurities. Deacetyl cefotaxime and 2-mercaptobenzathiazole were identified in this process as new impurities of ceftriaxone currently not listed under known impurities by United States Pharmacopoeia and European Pharmacopoeia. However, deacetyl cefotaxime is a known impurity of cefotaxime whereas the latter molecule is a degradation product of one of the synthesis impurities of ceftriaxone. This substance is reported to be carcinogenic and is resolved using the supplementary method developed for ceftriaxone, hence making its detection and quantification possible. A known inactive impurity of ceftriaxone (Impurity A, E-isomer of ceftriaxone) was` also shown to be produced by exposure to day light, thus warranting the light protection of the ceftriaxone solution, an information that is of critical importance in the clinical settings.
A series of experimentation was carried out on the finished products of beta lactam antibiotics sampled from Pakistan and few other countries, to identify key quality issues in the samples. Though the limited sample size and convenient sampling did not provide results that could yield a decisive figure for the country status for prevalence of substandard and falsified medical products, but the experiments have clearly indicated that the problems in drug quality do exist and beta lactam antibiotics form a class of high-risk medicine with respect to surveillance for poor-quality medicines. Isolation of unknown impurities was also carried out along with the introduction of new and modified methods for preparation of impurities of beta-lactam antibiotics.
In addition, detailed literature survey was carried out for understanding the complex problem of the poor-quality medicine, impact of poor quality antimicrobials on health care system and the magnitude of the problem at the global level. The country status of Pakistan regarding quality of medicines was recorded based upon the available documentary evidence. The current technologies and strategic options available for low- and middle-income countries in aiding fight for combating poor quality medicines was also laid down to design recommendations for Pakistan. A comprehensive review of the information technology tools used for identification and control of substandard and falsified medicines was also conducted.
Die Infektion mit dem Masernvirus (MV) stellt weltweit immer noch ein großes Problem dar. Trotz des vorhandenen Lebendimpfstoffs, der eine Erkrankung sicher zu verhindern vermag, haben nicht nur die Entwicklungsländer, in denen ein flächendeckender Impfschutz schwieriger zu erreichen ist, mit der Erkrankung und ihren Komplikationen zu kämpfen. Hat sich die Erkrankung klinisch manifestiert gibt es keine kausalen Therapiemöglichkeiten und es kann nur noch symptomatisch behandelt werden. Dies ist v.a. auch in Hinblick auf die schweren Komplikationen der Maserninfektion von Bedeutung. Bei Erstkontakt mit dem Masernvirus ist die Suszeptibilität nicht geimpfter Menschen sehr hoch. Das bedeutet, dass es in 95-98 % der Fälle nach einer Infektion mit dem Masernvirus auch zum klinischen Bild der Masern kommt, unabhängig von Alter und Geschlecht. Das Ziel dieser Arbeit war es daher, potentielle Hemmstoffe der Maserninfektion auf ihre Wirkung zu testen und zu verstehen, wo im Infektions- und Replikationszyklus des MV sie eingreifen. Es wurden eine Reihe Substanzen mit potentiell-inhibitorischen Eigenschaften in Infektions-Hemmtests und im Zytotoxizitätstest untersucht, von denen im Anschluss die drei besten Inhibitoren (JK80, QD6-8 und Droseron) weiter untersucht wurden. JK80 und QD6-8 waren beide mit IC50-Werten um 30 µM und SI-Werten von über 2 nur mäßig spezifisch antiviral wirksam. Während JK80 vermutlich den Eintritt des MV in die Zellen verhindert, hemmt QD6-8 die intrazelluläre Virusreplikation und wäre im Hinblick auf die Entwicklung neuartiger, spezifischer Medikamente gegen die Maserninfektion von grossem Interesse. Eine Zielmolekülanalyse der Substanz und die Testung anderer Derivate könnten Aufschluss darüber geben, wie Substanzen aussehen müssten, die eine spezifische Hemmung der intrazellulären Replikation bewirken können. Der Naturstoff Droseron könnte mit einer spezifischen Hemmung (IC50 ca. 10 µM; SIWert 6 im Fluoreszenzreader, bzw. IC50 ca. 2 µM; SI-Wert 30 in der Titration) eine mögliche Leitsubstanz für einen neuen MV-Inhibitor darstellen. Allerdings waren alle bisher getesteten Droseron-Derivate entweder weniger inhibitorisch wirksam oder deutlich zytotoxischer als Droseron selbst. Die Ergebnisse der Infektionshemmversuche mit Zugabe von Droseron vor, während oder nach der Infektion mit MV sprechen dafür, dass Droseron den Eintritt des Virus in die Zelle stört.
Two chiral chemical molecules being mirror images of each other, also referred to as enantiomers, may have different pharmacokinetic, pharmacodynamic, and toxicological effects. Thus, pharmaceutical manufacturers and authorities are increasingly interested in the approval of enantiopure drugs. However, the isomeric purity and the limits for isomeric impurities have to be specified applying enantioselective analytical methods, such as capillary electrophoresis.
The separation of enantiomers in capillary electrophoresis may be improved by the addition of ionic liquids to the background electrolyte. The aim of this work was to investigate the influence of different separation conditions on the enantioseparation of phenethylamines in background electrolytes containing ionic liquids based on tetrabutylammonium cations.
Best chiral separations were achieved at acidic pH values using phosphate buffers containing 125 mmol/L tetrabutylammonium based salts. Different reasons explaining enhanced enantioseparations in buffers containing ionic liquids were found. First, due to an improvement of the cyclodextrin solubility, the addition of ionic liquids to the background electrolyte enables the use of higher concentrations of these chiral selector. Furthermore, the adsorption of tetrabutylammonium cations to the negatively charged capillary surface results in a reduction of the electroosmotic flow. Hence, the resulting prolongation of migration times leads to a longer period of time for the separation of temporarily formed diastereomeric analyte cyclodextrin complexes, which yields improved enantioseparation. Additionally, due to a decrease of the adsorption of positively charged phenethylamine analyte molecules to capillary surface silanol groups, the adsorption of ionic liquid cations inhibits peak broadening. A further reason explaining an enhanced enantioseparation by the addition of ionic liquids to the background electrolyte is a competition between tetrabutylammonium cations and analyte enantiomers for the inclusion into cyclodextrin cavities.
Furthermore, the influence of different chiral counterions, combined with tetrabutylammonium cations, on the enantioseparation of phenethylamines was investigated. Solely anions based on the basic proteinogenic amino acids L lysine and L arginine yielded chiral separation results superior to those achieved using achiral tetrabutylammonium chloride as background electrolyte additive. Especially the application of tetrabutylammonium L argininate gave very good enantioseparations of all investigated ephedrine derivatives, which might be explained by the ability of L arginine to affect the formation of complexes between analytes and cyclodextrins.
Besides the investigation of the influence of ionic liquids on the enantioseparation, complexes between phenethylamine enantiomers and β cyclodextrin derivatives were characterized by affinity capillary electrophoresis. The binding constants between analyte enantiomers and cyclodextrins and the electrophoretic mobilities of the temporarily formed complexes were determined and compared to the observed chiral resolution values. While neither the calculated binding constants nor their differences correlated with the quality of the enantioseparation, a strong correlation between the differences of the electrophoretic mobilities of the complexes and the chiral resolution values was found.
Development of Novel Quinolone Amides Against the African Sleeping Sickness - A Fluorine Walk
(2019)
In recent years the transmission of the Human African Trypanosomiasis could be significantly reduced. The reported cases in 2016 reached a historic low level of 2184 cases and these achievements can be ascribed to intense control and surveillance programmes.118 However, most of the reported cases (>1000 in 2015) occurred in the Democratic Republic of the Congo and thus, need to be treated adequately. In particular, when the parasites have traversed the blood-brain barrier (BBB), treatment proved to be even more difficult. In addition, the number of cases always came in waves due to many reasons, e.g., development of resistances. Thus, it can be expected from experiences of the past that the number of cases will increase again. Hence, novel chemical entities are desperately needed in order to overcome the drawbacks which are associated with the current treatment options.
Our drug discovery approach included an initial drug repurposing strategy combined with a phenotypic screening. S. Niedermeier found novel active compounds derived from commercial fluoroquinolones. The most promising hit compound was further developed by G. Hiltensperger resulting in the lead quinolone amide GHQ168 (IC50 = 0.047 µM).
This doctoral thesis is about new insights into the SAR of the quinolone amides and the enhancement of the lead compound. Special consideration was given to the fluorine atom in the quinolone amides and how certain fluorine substitution patterns influence the antitrypanosomal activity, physicochemical properties and pharmacokinetics (i.e. ‘fluorine walk’). Moreover, the ability of the compound class crossing the BBB should be investigated. This feature is inevitable necessary in order to potentially treat African sleeping sickness stage II.
The Gould-Jacobs protocol was predominantly used for the synthesis of the quinolone core. Since former SAR studies mainly concentrated on the variation in positions 1, 3 and 7, quinolone scaffolds (2a-i) with diverse substitution patterns regarding positions 5, 6, 7 and 8 were synthesised in this thesis. The resulting quinolone amides were evaluated for their antitrypanosomal activity.
Voluminous residues in position C-5 resulted in diminished activities (compounds 13, 16 and 18) and solely small-sized moieties were tolerated. In particular the fluorine atom in position 5 revealed beneficial trypanocidal effects as shown for compounds 6 (IC50 = 0.05 µM), 8 (IC50 = 0.04 µM), and 24 (IC50 = 0.02 µM). Furthermore, having fluorine only in position 5 of the quinolone core could considerably reduce the cytotoxic effects (CC50 >100 µM, SI = >2000 for 6). Hence, the 5-fluoro-substituted quinolone amides were considered superior to GHQ168.
Regarding the C-6 position all other moieties (e.g., H in 9, OCH3 in 10, CF3 in 12) except of a fluorine atom decreased the activity against Trypanosoma brucei brucei. A double fluorination in C-6 and C-8 was not beneficial (IC50 = 0.06 µM for 7) and a single fluorine atom in C-8 even showed a negative effect (IC50 = 0.79 µM for 5).
The logP value is considered a surrogate parameter for lipophlicity and thus, affecting permeability and solubility processes. In particular the fluorine atom influences the lipophilicity due to versatile effects: Lipophilicity is increased by additional fluorine atoms on aromatic rings (7, 23) and reduced by fluorine atoms at an alkyl chain (49), respectively. Additionally, the 5-fluoro-substituted quinolone amides (6, 8, and 24) could prove the contrary effect of decreasing lipophilicity when the aromatic fluorine substituent is in vicinity to a carbonyl group.
For the most promising drug candidates 6, 23, and 24 the respective metabolites and the metabolic turnover were investigated by C. Erk. In comparison to GHQ168 the hydroxylation of the benzylamide was prevented by the para-fluorine atom. Hence, half-life was extended for compound 23 (t1/2 = 6.4 h) and N-desalkylation was the predominant pathway. Moreover, the respective fluorine substitution pattern of the quinolone core affected the metabolism of compound 6. The 5-fluoro-substituted quinolone amide was less prone for biotransformation (t1/2 = 7.2 h) and half-life could even be further prolonged for compound 24 (t1/2 = 7.7 h).
Due to the most appropriate safety profile of compound 6, this particular drug candidate was considered for in vivo study. Its poor solubility made a direct intraperitoneal administration unfeasible. Thus, an amorphous solid dispersion of 6 was generated using the spray-drying method according to the previous protocol. Unfortunately, the required solubility for the predicted in vivo study was not achieved.
Furthermore, the compound class of the quinolone amide was evaluated for its ability for brain penetration. The methanesulfonyl precursor 48 was synthesised and subsequently radiofluorinated in the group of Prof. Dr. Samnick (Department of Nuclear Medicine, University Hospital of Würzburg). The labelled compound [18F]49 was administered to mice, and its distribution throughout the body was analysed using positron emission tomography and autoradiography, respectively. The autoradiography of the murine brains revealed medium to high concentrations of [18F]49. Therefore, the quinolone amides are generally suitable for treating Human African Trypanosomiasis stage II.
A scaffold hopping approach was performed starting from the quinolone amides and concluding with the compound class of pyrazoloquinolin-3-ones. The intramolecular hydrogen bond between the sec. amide and the C-4 carbonyl moiety was replaced by a covalent bond. The two compound classes were comparable regarding the antitrypanosomal activity to some degree (IC50 = 7.9 µM (EK02) vs. 6.37 µM (53a)). However, a final evaluation of 59 was not possible due to poor solubility.
Insulin-like growth factor-I (IGF-I) is a 70-amino acid polypeptide with a molecular weight of approximately 7.6 kDa acting as an anabolic effector. It is essential for tissue growth and remodeling. Clinically, it is used for the treatment of growth disorders and has been proposed for various other applications including musculoskeletal diseases. Unlike insulin, IGF-I is complexed to at least six high-affinity binding proteins (IGFBPs) exerting homeostatic effects by modulating IGF-I availability to its receptor (IGF-IR) on most cells in the body as well as changing the distribution of the growth factor within the organism.1-3 Short half-lived IGF-I have been the driving forces for the design of localized IGF-I depot systems or protein modification with enhanced pharmacokinetic properties. In this thesis, we endeavor to present a versatile biologic into which galenical properties were engineered through chemical synthesis, e.g., by site-specific coupling of biomaterials or complex composites to IGF-I. For that, we redesigned the therapeutic via genetic codon expansion resulting in an alkyne introduced IGF-I, thereby becoming a substrate for biorthogonal click chemistries yielding a site-specific decoration.
In this approach, an orthogonal pyrrolysine tRNA synthetase (PylRS)/tRNAPyl CUA pair was employed to direct the co-translational incorporation of an unnatural amino acid—¬propargyl-L-lysine (plk)—bearing a clickable alkyne functional handle into IGF-I in response to the amber stop codon (UAG) introduced into the defined position in the gene of interest. We summarized the systematic optimization of upstream and downstream process alike with the ultimate goal to increase the yield of plk modified IGF-I therapeutic, from the construction of gene fusions resulting in (i) Trx-plk-IGF-I fusion variants, (ii) naturally occurring pro-IGF-I protein (IGF-I + Ea peptide) (plk-IGF-I Ea), over the subsequent bacterial cultivation and protein extraction to the final chromatographic purification. The opportunities and hurdles of all of the above strategies were discussed. Evidence was provided that the wild-type IGF-I yields were pure by exploiting the advantages of the pHisTrx expression vector system in concert with a thrombin enzyme with its highly specific proteolytic digestion site and multiple-chromatography steps. The alkyne functionality was successfully introduced into IGF-I by amber codon suppression. The proper folding of plk-IGF-I Ea was assessed by WST-1 proliferation assay and the detection of phosphorylated AKT in MG-63 cell lysate. The purity of plk-IGF-I Ea was monitored with RP-HPLC and SDS-PAGE analysis. This work also showed site-specific coupling an alkyne in plk-IGF-I Ea by copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC) with potent activities in vitro. The site-specific immobilization of plk-IGF-I Ea to the model carrier (i.e., agarose beads) resulted in enhanced cell proliferation and adhesion surrounding the IGF-I-presenting particles. Cell proliferation and differentiation were enhanced in the accessibility of IGF-I decorated beads, reflecting the multivalence on cellular performance.
Next, we aimed at effectively showing the disease environment by co-delivery of fibroblast growth factor 2 (FGF2) and IGF-I, deploying localized matrix metalloproteinases (MMPs) upregulation as a surrogate marker driving the response of the drug delivery system. For this purpose, we genetically engineered FGF2 variant containing an (S)-2-amino-6-(((2-azidoethoxy)carbonyl)amino)hexanoic acid incorporated at its N-terminus, followed by an MMPs-cleavable linker (PCL) and FGF2 sequence, thereby allowing site-directed, specific decoration of the resultant azide-PCL-FGF2 with the previously mentioned plk-IGF-I Ea to generate defined protein-protein conjugates with a PCL in between. The click reaction between plk-IGF-I Ea and azide-PCL-FGF2 was systematically optimized to increase the yield of IGF-FGF conjugates, including reaction temperature, incubation duration, the addition of anionic detergent, and different ratios of the participating biopharmaceutics. The challenge here was that CuAAC reaction components or conditions might oxidize free cysteines of azide-PCL-FGF2 and future work needs to present the extent of activity retention after conjugation. Furthermore, our study provides potential options for dual-labeling of IGF-I either by the introduction of unnatural amino acids within two distinct positions of the protein of interest for parallel “double-click” labeling of the resultant plk-IGF-I Ea-plk or by using a combination of enzymatic-catalyzed and CuAAC bioorthogonal coupling strategies for sequentially dual-labeling of plk-IGF-I Ea.
In conclusion, genetic code expansion in combination with click-chemistry provides the fundament for novel IGF-I analogs allowing unprecedented site specificity for decoration. Considerable progress towards IGF-I based therapies with enhanced pharmacological properties was made by demonstrating the feasibility of the expression of plk incorporated IGF-I using E. coli and retained activity of unconjugated and conjugated IGF-I variant. Dual-labeling of IGF-I provides further insights into the functional requirements of IGF-I. Still, further investigation warrants to develop precise IGF-I therapy through unmatched temporal and spatial regulation of the pleiotropic IGF-I.
The title compound, C\(_{12}\)H\(_{9}\)N\(_{3}\)O, is an intermediate in the synthesis of the muscarinic M2 receptor antagonist AFDX-384. The seven-membered ring adopts a boat conformation and the dihedral angle between the planes of the aromatic rings is 41.51 (9)°. In the crystal, molecules are linked into [001] chains of alternating inversion dimers formed by pairs of N-H・・・O hydrogen bonds and pairs of N-H・・・N hydrogen bonds. In both cases, R\(_{2}\)\(^{2}\)(8) loops are generated.
Four new tetromycin derivatives, tetromycins 1-4 and a previously known one, tetromycin B (5) were isolated from Streptomyces axinellae Pol001(T) cultivated from the Mediterranean sponge Axinella polypoides. Structures were assigned using extensive 1D and 2D NMR spectroscopy as well as HRESIMS analysis. The compounds were tested for antiparasitic activities against Leishmania major and Trypanosoma brucei, and for protease inhibition against several cysteine proteases such as falcipain, rhodesain, cathepsin L, cathepsin B, and viral proteases SARS-CoV M(pro), and PL(pro). The compounds showed antiparasitic activities against T. brucei and time-dependent inhibition of cathepsin L-like proteases with K(i) values in the low micromolar range.
Alzheimer’s disease is a complex network of several pathological hallmarks. These characteristics always occur concomitantly and cannot be taken as distinct features of the disease. While there are hypotheses trying to explain the origin and progression of the illness, none of them is able to pinpoint a definitive cause. This fact challenges researchers not to focus on one individual hallmark but, bearing in mind the big picture, target two or more indications at once. This work, therefore, addresses two of the major characteristics of AD: the cholinergic hypothesis and neurotoxic oxidative stress. The former was achieved by targeting the postsynaptic muscarinic M1 acetylcholine receptor to further investigate its pharmacology, and the latter with the synthesis of neuroprotective natural antioxidant hybrids.
The first aim was the design and synthesis of dualsteric agonists of the muscarinic M1 acetylcholine receptor. Activation of this receptor was previously shown to improve AD pathologies like the formation of Aβ and NFTs and protect against oxidative stress and caspase activation. Selectively targeting the M1 receptor is difficult as subtypes M1 – M5 of the muscarinic AChRs largely share the same orthosteric binding pocket. Orthosteric ligands are thus unsuitable for selective activation of one specific subtype. Secondary, allosteric binding sites are more diverse between subtypes. Allosteric ligands are, however, in most cases dependent on an orthosteric ligand to cause downstream signals. Dualsteric ligands thus utilize the characteristics of both orthosteric and allosteric ligands in form of a message-address concept. Bridged by an alkylene-linker, the allosteric part ensures selectivity, whereas the orthosteric moiety initiates receptor activation. Two sets of compounds were synthesised in this sense. In both cases, the orthosteric ligand carbachol is connected to an allosteric ligand via linkers of different chain length. The first set utilizes the selective allosteric M1 agonist TBPB, the second set employs the selective M1 positive allosteric modulator BQCA. Six compounds were obtained in twelve-step syntheses each. For each one, a reference compound lacking the carbachol moiety was synthesised. The dualsteric ligands 1a-c and 2a c were tested in the IP1 assay. The assay revealed that the TBPB-dualsterics 1 are not able to activate the receptor, whereas the respective TBPB-alkyl reference compounds 27 gave signals depending on the length of the alkylene-linker, suggesting allosteric partial agonism of alkyl compounds 27 and no dualsteric binding of the putatively dualsteric compounds 1. The dualsteric BQCA molecules 2, however, activated the receptor as expected. Efficacy of the C5 linked compound 2b was the highest, yet C3 and C8 compounds (2a and 2c) also showed partial agonism. In this case, the reference compounds 31 showed no receptor activation, implying the intended dualsteric binding mode of the BQCA-carbachol compounds 2. Further investigations will be conducted by the working group of Dr. Christian Tränkle at the Department of Pharmacology at the University of Bonn to confirm binding modes and determine affinities as well as selectivity of the synthesised dualsteric compounds.
The second project dealt with the design, synthesis and biological evaluation of neuroprotective esters of the flavonolignan silibinin. While silibinin is already a potent antioxidant, it has been observed that the 7-OH group has a pro-oxidative character, making this position attractive for functionalisation. In order to obtain more potent antioxidants, the pro-oxidative position was esterified with other antioxidant moieties like ferulic acid 35 and derivatives thereof. Seventeen esters of silibinin 32, including pure diastereomers of 7 O feruloylsilibinin (43a and 43b) and a cinnamic acid ester of 2,3-dehydrosilibinin 46, were synthesised by regioselective esterification using acyl chlorides under basic conditions. The physicochemical antioxidant properties were assessed in the FRAP assay. This assay revealed no improvement of the antioxidant properties except for 7-O-dihydrosinapinoylsilibinin 39b. These results, however, do not correlate with the neuroprotective properties determined in the HT-22 hippocampal neuronal cell model. The assay showed overadditive neuroprotective effects of the esters exceeding those of its components and equimolar mixtures with the most potent compounds being 7-O-cinnamoylsilibinin 37a, 7-O-feruloylsilibinin 38a and the acetonide-protected caffeic acid ester 40a. These potent Michael system bearing compounds may be considered as “PAINS”, but the assays used to assess antioxidant and neuroprotective activities were carefully chosen to avoid false positive readouts. The most potent compounds 37a and 38a, as well as the diastereomers 43a and 43b, were further studied in assays related to AD. In vitro ischemia, inhibition of microglial activation, PC12 cell differentiation and inhibition of Aβ42 and τ protein aggregation assays showed similar results in terms of overadditive effects of the synthesised esters. Moreover, the diastereomers 43a and 43b showed differences in their activities against oxytosis (glutamate-induced apoptosis), inhibition of Aβ42 and τ protein aggregation, and PC12 cell differentiation. The stereospecific effect or mode of action against Aβ42 and τ protein aggregation is more pronounced than that of silybin A (32a) and silybin B (32b) reported in literature and needs to be elucidated in future work. Stability measurements in cell culture medium revealed that the esters do not only get hydrolysed but are partially oxidised to their respective 2,3-dehydrosilibinin esters. Because dehydrosilibinin 45 itself is described as a more potent antioxidant than silibinin 32, 7 O cinnamoyl-2,3-dehydrosilibinin 46 was expected to be even more potent than its un-oxidised counterpart 37a in terms of neuroprotection. The oxytosis assay, however, showed that the neurotoxicity of 46 is much more pronounced, especially at higher concentrations, reducing its neuroprotective potential. Dehydrosilibinin esters are therefore inferior to the silibinin esters for application as neuroprotectants, because of the difficulty of their synthesis and their increased neurotoxicity. A synergistic effect of both species (silibinin and the oxidised form) might, however, be possible or even necessary for the pronounced neuroprotective effects of silibinin esters. As the dehydro-species show distinct neuroprotective properties at low concentrations, their continuous formation over time might make an essential contribution to the overall neuroprotection of the synthesised esters. Due to solubility issues for some of the ester compounds, 7-O-cinnamoylsilibinin 37a was converted into a highly soluble hemisuccinate. The vastly improved solubility of 7 O cinnamoyl-23-O-succinylsilibinin 48 was confirmed in shake-flask experiments. Contrary to expectation, stability examinations showed that the succinyl compound 48 is not cleaved to form 7-O-cinnamoylsilibinin 37a. Neuroprotection assays confirmed that 48 is not a prodrug of the corresponding ester. It was determined that the main site of hydrolysis is the 7-position, cleaving 37 to silibinin 32 and cinnamic acid thus reducing the compound’s neuroprotective effects. Nevertheless, the compound still showed neuroprotection at a concentration of 25 µM. The improved solubility might be more beneficial than the higher neuroprotection of the poorly soluble parent compound 37a in vivo. 7 O Cinnamoylsilibinin 37a was further investigated to reduce Aβ25 35 induced learning impairment in mice. While tendencies of improved short-term and long-term memory in the animals were observed, the effects are not yet statistically significant in both Y-maze and passive avoidance tests. A greater number of test subjects is necessary to ensure correctness of the preliminary results presented in this work. However, an effect of ester 37a is observable in vivo, showing blood-brain barrier penetration. The esters synthesised are a novel approach for the treatment of AD as they show strong neuroprotective effects and their hydrolysis products or metabolites are only non-toxic natural products.
Heart failure is one of the growing causes of death especially in developed countries due to longer life expectancy. Although many pharmacological and instrumental therapeutic approaches have been introduced for prevention and treatment of heart failure, there are still limitations and challenges. Nuclear cardiology has experienced rapid growth in the last few decades, in particular the application of single photon emission computed tomography (SPECT) and positron emission tomography (PET), which allow non-invasive functional assessment of cardiac condition including neurohormonal systems involved in heart failure; its application has dramatically improved the capacity for fundamental research and clinical diagnosis. In this article, we review the current status of applying radionuclide technology in non-invasive imaging of neurohormonal system in the heart, especially focusing on the tracers that are currently available. A short discussion about disadvantages and perspectives is also included.
Background
Genetic code expansion has developed into an elegant tool to incorporate unnatural amino acids (uAA) at predefined sites in the protein backbone in response to an amber codon. However, recombinant production and yield of uAA comprising proteins are challenged due to the additional translation machinery required for uAA incorporation.
Results
We developed a microtiter plate-based high-throughput monitoring system (HTMS) to study and optimize uAA integration in the model protein enhanced green fluorescence protein (eGFP). Two uAA, propargyl-L-lysine (Plk) and (S)-2-amino-6-((2-azidoethoxy) carbonylamino) hexanoic acid (Alk), were incorporated at the same site into eGFP co-expressing the native PylRS/tRNAPyl CUA pair originating from Methanosarcina barkeri in E. coli. The site-specific uAA functionalization was confirmed by LC-MS/MS analysis. uAA-eGFP production and biomass growth in parallelized E. coli cultivations was correlated to (i) uAA concentration and the (ii) time of uAA addition to the expression medium as well as to induction parameters including the (iii) time and (iv) amount of IPTG supplementation. The online measurements of the HTMS were consolidated by end point-detection using standard enzyme-linked immunosorbent procedures.
Conclusion
The developed HTMS is powerful tool for parallelized and rapid screening. In light of uAA integration, future applications may include parallelized screening of different PylRS/tRNAPyl CUA pairs as well as further optimization of culture conditions.
Background
Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan parasites of the genus Leishmania. CL causes enormous suffering in many countries worldwide. There is no licensed vaccine against CL, and the chemotherapy options show limited efficacy and high toxicity. Localization of the parasites inside host cells is a barrier to most standard chemo- and immune-based interventions. Hence, novel drugs, which are safe, effective and readily accessible to third-world countries and/or drug delivery technologies for effective CL treatments are desperately needed.
Methodology/Principal
Findings Here we evaluated the antileishmanial properties and delivery potential of polyhexamethylene biguanide (PHMB; polyhexanide), a widely used antimicrobial and wound antiseptic, in the Leishmania model. PHMB showed an inherent antileishmanial activity at submicromolar concentrations. Our data revealed that PHMB kills Leishmania major (L. major) via a dual mechanism involving disruption of membrane integrity and selective chromosome condensation and damage. PHMB's DNA binding and host cell entry properties were further exploited to improve the delivery and immunomodulatory activities of unmethylated cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN). PHMB spontaneously bound CpG ODN, forming stable nanopolyplexes that enhanced uptake of CpG ODN, potentiated antimicrobial killing and reduced host cell toxicity of PHMB.
Conclusions
Given its low cost and long history of safe topical use, PHMB holds promise as a drug for CL therapy and delivery vehicle for nucleic acid immunomodulators.
Functionalization of cells, extracellular matrix components and proteins for therapeutic application
(2019)
Glycosylation is a biochemical process leading to the formation of glycoconjugates by linking glycans (carbohydrates) to proteins, lipids and various small molecules. The glycans are formed by one or more monosaccharides that are covalently attached, thus offering a broad variety depending on their composition, site of glycan linkage, length and ramification. This special nature provides an exceptional and fine tunable possibility in fields of information transfer, recognition, stability and pharmacokinetic. Due to their intra- and extracellular omnipresence, glycans fulfill an essential role in the regulation of different endogenous processes (e.g. hormone action, immune surveillance, inflammatory response) and act as a key element for maintenance of homeostasis. The strategy of metabolic glycoengineering enables the integration of structural similar but chemically modified monosaccharide building blocks into the natural given glycosylation pathways, thereby anchoring them in the carbohydrate architecture of de novo synthesized glycoconjugates. The available unnatural sugar molecules which are similar to endogenous sugar molecules show minimal perturbation in cell function and - based on their multitude functional groups - offer the potential of side directed coupling with a target substance/structure as well as the development of new biological properties. The chemical-enzymatic strategy of glycoengineering provides a valuable complement to genetic approaches.
This thesis primarily focuses on potential fields of application for glycoengineering and its further use in clinic and research. The last section of this work outlines a genetic approach, using special Escherichia coli systems, to integrate chemically tunable amino acids into the biosynthetic pathway of proteins, enabling specific and site-directed coupling with target substances. With the genetic information of the methanogen archaea, Methanosarcina barkeri, the E. coli. system is able to insert a further amino acid, the pyrrolysine, at the ribosomal site during translation of the protein. The natural stop-codon UAG (amber codon) is used for this newly obtained proteinogenic amino acid.
Chapter I describes two systems for the integration of chemically tunable monosaccharides and presents methods for characterizing these systems. Moreover, it gives a general overview of the structure as well as intended use of glycans and illustrates different glycosylation pathways. Furthermore, the strategy of metabolic glycoengineering is demonstrated. In this context, the structure of basic building blocks and the epimerization of monosaccharides during their metabolic fate are discussed.
Chapter II translates the concept of metabolic glycoengineering to the extracellular network produced by fibroblasts. The incorporation of chemically modified sugar components in the matrix provides an innovative, elegant and biocompatible method for site-directed coupling of target substances. Resident cells, which are involved in the de novo synthesis of matrices, as well as isolated matrices were characterized and compared to unmodified resident cells and matrices. The natural capacity of the matrix can be extended by metabolic glycoengineering and enables the selective immobilization of a variety of therapeutic substances by combining enzymatic and bioorthogonal reaction strategies. This approach expands the natural ability of extracellular matrix (ECM), like the storage of specific growth factors and the recruitment of surface receptors along with synergistic effects of bound substances. By the selection of the cell type, the production of a wide range of different matrices is possible.
Chapter III focuses on the target-oriented modification of cell surface membranes of living fibroblast and human embryonic kidney cells. Chemically modified monosaccharides are inserted by means of metabolic glycoengineering and are then presented on the cell surface. These monosaccharides can later be covalently coupled, by “strain promoted azide-alkyne cycloaddition“ (SPAAC) and/or “copper(I)-catalyzed azide-alkyne cycloaddition“ (CuAAC), to the target substance. Due to the toxicity of the copper catalysator in the CuAAC, cytotoxicity analyses were conducted to determine the in vivo tolerable range for the use of CuAAC on living cell systems. Finally, the efficacy of both bioorthogonal reactions was compared.
Chapter IV outlines two versatile carrier – spacer – payload delivery systems based on an enzymatic cleavable linker, triggered by disease associated protease. In the selection of carrier systems (i) polyethylene glycol (PEG), a well-studied, Food and Drug Administration approved substance and very common tool to increase the pharmacokinetic properties of therapeutic agents, was chosen as a carrier for non-targeting systems and (ii) Revacept, a human glycoprotein VI antibody, was chosen as a carrier for targeting systems. The protease sensitive cleavable linker was genetically inserted into the N-terminal region of fibroblast growth factor 2 (FGF-2) without jeopardizing protein activity. By exchanging the protease sensitive sequence or the therapeutic payload, both systems represent a promising and adaptable approach for establishing therapeutic systems with bioresponsive release, tailored to pre-existing conditions.
In summary, by site-specific functionalization of various delivery platforms, this thesis establishes an essential cornerstone for promising strategies advancing clinical application. The outlined platforms ensure high flexibility due to exchanging single or multiple elements of the system, individually tailoring them to the respective disease or target site.
Mutationstests werden in vitro und in vivo durchgeführt. Insbesondere die phänotypselektiven Mutationstests sind meist beschränkt auf die Detektion von Mutationen im Exon und gegebenenfalls in Promotorregionen. Um zunächst die Datenlage zu den üblicherweise verwendeten in vitro Mutationstests zu erweitern und somit eine Bewertung der zu untersuchenden Substanz zu erleichtern, sollte eine Methode zur Erfassung des Mutationsspektrums etabliert und im Rahmen der Untersuchung des mutagenen Potentials des Lebensmittelinhaltsstoffes Irilon angewendet werden.
Es wurde eine Methode entwickelt, welche die Sequenzierung eines jeden einzelnen im Hypoxanthin-Guanin-Phosphoribosyltransferase-Test enstandenen 6-Thioguanin-resistenten Mutanten erlaubt und somit auch Rückschlüsse auf Mechanismen der Mutationsentstehung zulässt. Im Rahmen der Untersuchung zum mutagenen Potential des Lebensmittelinhaltsstoffes Irilon, wurde zwar kein Unterschied in der Mutantenfrequenz, jedoch sehr wohl ein mit steigenden Deletionen und sinkenden Basenpaarsubstitutionen verändertes Mutationsspektrum detektiert. Die Auswertung des Mikrokerntests unterstützte die Annahme, dass Irilon Chromosomenmutationenen induziert. Zudem wies Irilon ein starkes aneugenes Potential auf. Im Gegensatz zu den phänotypselektiven Mutationstests weisen genotypselektive Tests hingegen theoretisch keine Limitierungen hinsichtlich der zu untersuchenden Zielsequenz und der Organwahl auf. Ein Vertreter der genotypselektiven Tests ist der Random Mutation Capture Assay, der 2005 von Bielas und Loeb für das Intron 6 des humanen TP53-Gens publiziert wurde. Ein weiteres Ziel dieser Arbeit war es zu untersuchen ob die Technik des Random Mutation Capture Assays auf die Ratte übertragbar und ob bzw.unter welchen Bedingungen die Bestimmung von spontanen und induzierten Mutationsfrequenzen in verschiedenen Zielsequenzen möglich ist. Deshalb wurden zunächst das für das Tumorsuppressor Protein 53 kodierenden Gen p53, die für die 18S ribosomale RNA kodierenden DNA und das mitochondriale Cytochrom b Gen als Zielsequenzen gewählt und deren Eignung für die Anwendung im Random Mutation Capture Assays geprüft. Für jede Zielsequenz wurden alle für die Durchführung des Random Mutations Capture Assays benötigten molekularen Werkzeuge unter optimierten PCR-Bedingungen hergestellt und verifiziert. Für die Quantifizierung der Gesamtkopiezahl wurde je Zielsequenz eine spezifische Echtzeit-PCR-Methode entwickelt, welche TaqMan®-Sonden-basiert ist. Nach Optimierung der PCR-Bedingungen wurden je Zielsequenz Wiederfindungen im angestrebten Bereich von ca. 90-100% mit Schwankungen von maximal 20% erreicht. Ausgenommen hiervon war die für die 18S ribosomale DNA kodierende Zielsequenz. Eine Änderung der Echtzeit-PCR-Bedingungen führte zu keiner praktikablen Methode. Daher war diese Zielsequenz, welche trotz geringer DNA-Mengen versprach mehr DNA Kopien zu erhalten und somit die Bestimmung von geringen Mutationsfrequenzen zu erleichtern, nicht im Random Mutation capture Assay anwendbar.
Für die Wahl einer DNA-Isolierungsmethode wurden 5 Methoden hinsichtlich einer für die Mutationsfrequenz-Bestimmung ausreichenden Kopiezahlausbeute, der Reinheit und des Kosten-/Zeitaufwands verglichen. Mit zwei der fünf Methoden wurde aus 100 mg Gewebe die höchste nukleären Kopienzahl isoliert, ausreichend um Mutationsfrequenzen im Bereich 1-2*10-7/bp zu bestimmen. Um jedoch die erwarteten Mutationsfrequenzen im Bereich von 1-3*10-8/bp (Intron) bzw. 2-3*10-9/bp (Exon) zu detektieren, wären 2-3 g Gewebe bzw. 3 mg DNA notwendig. Auf Grund der anatomischen Organgewichte wäre die Durchführung des nukleären Random Mutation Capture Assays somit auf vereinzelte Organe wie Leber, Dünndarm und Gehirn beschränkt. Zudem bestanden mit der Hybridisierung und dem Uracil-DNA-Glycosylase-Verdau zwei zusätzliche kritische Punkte, welche zu einer Minimierung der Kopiezahl oder einer fehlerhaften Einschätzung der Mutationsfrequenz führen können. Aus diesen Gründen wurde eine Entwicklung des Random Mutation Capture Assays für die Zielsequenz im p53-Gen verworfen. Die Kopiezahlausbeuten der mitochondrialen DNA waren ab 50 mg Gewebeeinsatz bei jeder der 5 untersuchten Methoden ausreichend zur Bestimmung einer angestrebten Spontanmutationsfrequenz zwischen 6-100*10-7/bp. Bei Gewebemengen unter 50 mg erwies sich die Aufarbeitung mit DNAzol® auf Grund zu niedriger Kopiezahlausbeuten als ungeeignet. In dieser Arbeit wurde nachfolgend die Phenol-Chloroform-Extraktion nach Vermulst et al (2008) verwendet.
Im Rahmen der Etablierung der PCR zur Erfassung der Anzahl mutierter Kopien (Mutations-PCR) wurde ein Mutanten-Standard zur Anwendung als Positivkontrolle in PCR und Agarose-Gelelektrophorese hergestellt, verifiziert und fluorimetrisch quantifiziert. Wiederfindungsexperimente bestätigten, dass mit der etablierten Mutations-PCR eine einzelne Kopie amplifizier- und detektierbar ist. Um eine Auswertung einer Sequenzierung hinsichtlich Anzahl der Mutanten als auch der Sequenz an sich zu gewährleisten, wurde der akzeptierte Bereich an detektierten 1-19 (80 Reaktionen) gesetzt.
Nachfolgend wurde in der gesunden Leber von männlichen und weiblichen Ratten erfolgreich die mitochondriale Spontanmutationsfrequenz mit dem entwickelten Random Mutation Capture Assay bestimmt. Diese betrug innerhalb einer mitochondrialen DNA-Lösung 3,2 ± 3,1 *10-6/bp (Median 2,7). Die Mutationsfrequenzen von 3 unabhängigen mitochondrialen DNA-Lösungen -isoliert aus demselben Organpulver- betrugen durchschnittlich 11,5 ± 8,6 *10-6/bp (Median 8,0) und waren somit ca. 3-mal höher. Ein Vergleich zwischen den Mutationsfrequenzen der männlichen und weiblichen Tiere resultierte in mitochondrialen Mutationsfrequenzen zwischen 1,6-34,4 *10-6/bp (männlich) und 3,0-12,9 *10-6/bp (weiblich), wobei zwischen männlichen und weiblichen Tieren kein statistischer Unterschied bestand (Mann-Whitney-Test; p<0,05). Um zu prüfen, ob die Mutationsraten bestimmt mit dem mitochondrialen Random Mutation Capture Assay und einem phänotypselektiven Mutationstest zu gleichem Maße auf ein mutagenes Potential hinweisen, wurde als nächstes der phänotypselektive Hypoxanthin-Guanin-Phosphoribosyltransferase-Test für normale Nierenepithelzellen der Ratte (NRK-Zelllinie) entwickelt. Nach einer 24 h Inkubation mit 0,1 µM 4-Nitrochinolin-1-oxid, einem bekannten Adduktbildner, stieg die Mutationsfrequenz im Exon des Hypoxanthin-Guanin-Phosphoribosyltransferase-Gens um den Faktor 5 im Vergleich zur Lösemittelkontrolle an. Mit Hilfe des entwickelten Random Mutation Capture Assays wurde in der DNA -isoliert zum Zeitpunkt der Selektion- eine dreifache Steigerung der Mutationsfrequenz im mt-Cytb-Gen detektiert. Somit war mit beiden Tests eine Erhöhung der Mutationsfrequenz in der gleichen Größenordnung detektierbar, wobei der phänotypselektive Mutationstest sensitiver war.
Nachdem die Mutations-PCR ca. 1,5 Jahren angewendet wurde, stieg innerhalb von 4 Monaten unabhängig von der verwendeten Templatkonzentration sowohl die Häufigkeit der detektierten Schmierbanden als auch die des DNA hang up an. In 7 Mutations-PCRs, welche nach diesen Phänomenen nur mit Blindwerten durchgeführt wurden, lag der Anteil an detektierten DNA-Schmierbanden pro Mutations-PCR zwischen 25,0% und 38,8%, der des DNA hang up zwischen 17,5% und 48,8%. Das war häufiger als in Reaktionen mit Templat; ein Hinweis dafür, dass das Vorliegen von Templat Nebenreaktionen zu einem gewissen Grad verdrängte und dass die unspezifische Amplifizierung am Mastermix der Mutations-PCR lag. Eine Änderung von chemischen oder physikalischen Parametern innerhalb der PCR-Reaktion führte zu keiner Reduktion der Nebenprodukte. Somit war der für das mitochondriale Cytochrom b-Gen entwickelte Random Mutation Capture Assay nicht robust gegenüber Nebenreaktionen und ist daher nicht für einen routinemäßigen Einsatz geeignet. Zusammenfassend war eine Entwicklung der Primer und der molekularen Werkzeuge des Random Mutation Capture Assays vom Mensch auf Ratte mit allen drei gewählten Zielsequenzen möglich. Im Rahmen der Experimente zeigte sich, dass die Kopiezahl-PCR der Zielsequenz in der 18S ribosomale RNA kodierenden DNA nicht praktikabel und eine Bestimmung der Mutationsfrequenzen für das Tumorsuppressor Protein 53 kodierenden Gen p53 nur unter Berücksichtigung einer eingeschränkten Organauswahl möglich war. Für die Zielsequenz des mitochondrialen Cytochrom b Gens war der Random Mutation Capture Assay durchführbar. Allerdings erwies sich die Mutations-PCR als instabil. Folglich ist eine Bestimmung von Mutationsfrequenzen mit dem Random Mutation Capture Assay in Rattus norvegicus nur sehr begrenzt möglich.
1 Verlängerung der kardialen Repolarisationsdauer unter psychiatrischer Medikation bei gleichzeitigem genetischen Basisrisiko
Vielen Psychopharmaka wird eine repolarisationsverlängernde Wirkung zugeschrieben. Diese unerwünschte Arzneimittelwirkung, erkennbar an einer Verlängerung des QT-Intervalls im Elektrokardiogramm, ist in den vergangenen Jahren, aufgrund des Zusammenhanges mit lebensbedrohlichen Torsades-de-Pointes-Tachyarrhythmien, in den Fokus der klinischen Forschung gerückt. Aufgrund dieser Nebenwirkung werden viele gut wirksame Arzneimittel einer erneuten eingehenden Nutzen-Risiko-Analyse unterzogen und in manchen Fällen führte dies zu einer Limitierung der pharmakologischen Möglichkeiten.
Als Hauptmechanismus für eine Psychopharmaka-induzierte QT-Zeit-Verlängerung gilt die Blockade von kardialen Kaliumkanälen. Aber auch genetische Veränderungen unterschiedlicher kardialer Ionenkanäle gelten als Risikofaktoren, ebenso wie Effekte anderer ionenabhängiger Signalwege. Da Patienten mit genetischer Prädisposition ein defacto erhöhtes Risiko für eine pharmakologisch induzierte QT-Zeit-Verlängerung aufweisen, spricht man von reduzierter Repolarisationsreserve, mit erhöhtem Basislinienrisiko für kardiale Nebenwirkungen.
Ziel war es, über einen additiven genetischen Risikoscore eine Quantifizierung individueller Vulnerabilität zu erreichen und zu zeigen, dass dieses Risiko durch die Kontrolle von Medikamenten-Serumspiegeln modulierbar sein kann.
Aus einer prospektiven Studie, mit 2062 an endogener Psychose leidenden Patienten des Zentrums für Psychische Gesundheit des Universitätsklinikums Würzburg, wurden 392 Patienten (mittleres Alter bei Studieneinschluss 41,0 ± 15,0 Jahre, 36,2 % Frauen) rekrutiert. Primäres Einschlusskriterium für die angeknüpfte, retrospektive Studie war das Vorliegen einer Serumspiegelbestimmung der psychiatrischen Medikation binnen drei Tagen vor oder nach einer elektrokardiographischen Untersuchung (N = 392). Die den Einschlusskriterien entsprechenden 392 Patienten wurden daraufhin auf 62 Einzelpolymorphismen, die in Verbindung mit einer verlängerten QT-Zeit stehen, getestet und die Ergebnisse mit den patientenspezifischen Daten aus den elektrokardiographischen Untersuchungen korreliert.
Des Weiteren wurden, basierend auf vier großen Publikationen des internationalen „Cardiac Safety Consortium“ (77-79, 148), bekannte polygene Risikoscores, die diese Risikopolymorphismen enthalten, anhand des eigenen Patientenkollektivs berechnet und durch Korrelation mit der QT-Zeit überprüft. Diese Scores funktionieren jeweils nach einem Additionsmodell, bei dem nach unterschiedlicher Gewichtung das individuelle Risiko, das durch das Vorhandensein eines bekannten Risikopolymorphismus quantifizierbar wird, zu einem Gesamtrisiko aufsummiert wird.
Darüber hinaus ist das Patientenkollektiv auf einen Zusammenhang zwischen dem Serumspiegel der psychiatrischen Medikation und der QT-Zeit geprüft worden. Dazu wurde das Gesamtkollektiv in medikamentenspezifische Subgruppen unterteilt (Amitriptylin (N = 106), Clomipramin (N = 48), Doxepin (N = 53), Mirtazapin (N = 45), Venlafaxin (N = 50), Aripiprazol (N = 56), Clozapin (N = 127), Haloperidol (N = 41), Olanzapin (N = 37), Perazin (N = 47), Quetiapin (N = 119) und Risperidon (N = 106)).
Abschließend wurden die Subkollektive in einem kombinierten Rechenmodell daraufhin geprüft, ob Zusammenhänge zwischen den genetischen Risikoscores nach Strauss et al. (148) mit dem jeweiligen Medikamenten-Serumspiegel auf die QT-Zeit bestehen.
13 der 62 untersuchten Einzelpolymorphismen zeigten einen signifikanten Zusammenhang mit einer verlängerten Repolarisationsdauer. Ebenfalls korrelieren polygene Risikoscores einer verlängerten kardialen Repolarisation und erklären einen dabei signifikanten Anteil der Varianz. Die Ergebnisse der Literatur, bezüglich der Scores nach Pfeufer et al. (77) (R = 0,124, p = 0,014; N = 392), nach Noseworthy et al. (79) (R = 0,169; p = 0,001; N = 392), sowie nach Strauss et al. (148) (R = 0,199; p = 0,000; N = 392) konnten anhand des eigenen Kollektives reproduziert werden, wohingegen der Score von Newton-Cheh et al. (78) keinen signifikanten Zusammenhang mit der QT-Zeit zeigte (R = 0,029; p = 0,568; N = 392).
In der Subgruppenanalyse konnte ein stark vom Serumspiegel abhängiger, verlängernder Effekt auf die QT-Zeit für die Arzneistoffe Amitriptylin, Nortriptylin, Clomipramin, und Haloperidol nachgewiesen werden. Die Analyse der mit Amitriptylin behandelten Patienten (N = 106) ergab für Nortriptylin (F (1,104) = 5.986; p = .016, R = .233), als auch für den Summenspiegel aus Amitriptylin und Nortriptylin (F (1,104) = 4.408, p = .038, R = .202) einen signifikanten, nach Cohen einen mittelstarken Zusammenhang mit der QT-Zeit. Starke Effekte auf die QT-Zeit wurden im Zusammenhang mit den Serumspiegeln der Medikamente Clomipramin (F (1,46) = 39.589, p < .001, R = .680, N = 48) und Haloperidol (F (1,39) = 12.672, p = .001, korrigiertes R2= .245, N = 41) errechnet.
Ein kombiniertes Rechenmodell, das sowohl den Einfluss des jeweiligen Serumspiegels, als auch des genetischen Risikoscores nach Strauss et al. (148) berücksichtigte, erlaubte bei diesen Arzneistoffen eine signifikant höhere Varianzaufklärung der QT-Zeit, als die jeweiligen Effekte für sich genommen.
Die QT-Zeit gilt als erwiesenermaßen genauso abhängig von der individuellen genetischen Ausstattung, wie auch von Serumspiegeln potentiell als QT-verlängernd eingestufter Medikamente. Diese Effekte scheinen additiv verknüpfbar, so dass das von Roden et al. entwickelte Konzept der reduzierten Repolarisationsreserve (54) als bestätigt gelten darf. Die jeweiligen Einzeleffekte vom genetischen Risiko, sowie der Medikation haben zusammen einen größeren Einfluss auf die gemessenen QT-Zeit als für sich alleine genommen. Durch die Genetik lässt sich somit tatsächlich eine grobe vorab-Risikoabschätzung treffen. Dies könnte nach sorgfältiger Nutzen-Risiko-Analyse durch Kontrollen des EKGs und des Serumspiegels moduliert werden und somit vielfältigere therapeutische Möglichkeiten erhalten.
2 Entwicklung und Validierung einer Dried-Blood-Spot-Methode zum therapeutischen Drug Monitoring von Clozapin und Quetiapin
Die Technik der Extraktion und Analyse von Stoffen aus getrocknetem Blut ist bereits seit den 1960er Jahren bekannt, wurde bis zur jüngeren Vergangenheit aber eher zu diagnostischen Zwecken angewendet. Durch Fortschritte in der Analytik im Sinne ausgefeilterer Chromatographie und sensitiverer Detektion wurde das Verfahren der Dried-Blood-Spot-Analytik auch für die Spiegelbestimmung von Arzneistoffen interessant. So wurden auch im Bereich des Therapeutischen Drug Monitorings bereits Methoden, beispielsweise für Antibiotika, Antiepileptika, Virostatika und in jüngerer Zeit auch Antidiabetika publiziert. Die Vorteile in der Probenhandhabung und durch geringeren Aufwand bei der Blutentnahme sowie geringeres Probenentnahmevolumen werden durch weitere Fortschritte im Bereich der Analytik vordergründiger.
Ziel war es, ein Extraktionsverfahren zu entwickeln und zu validieren, dass die gemeinsame Quantifizierung der häufig verabreichten Antipsychotika Clozapin und Quetiapin aus einem einzelnen getrockneten Blutstropfen ermöglicht.
Die Extraktion mit einer Mischung aus 99 % Acetonitril und 1 % 1 M Salzsäure und anschließender HPLC-Analyse mit Säulenschaltung und photometrischer Detektion wurde nach den Richtlinien der Gesellschaft für toxikologische und forensische Chemie (GTFCh) (146) validiert. Sie entsprach sämtlichen Anforderungen bezüglich Linearität, Bestimmungsgrenze, Stabilität, Genauigkeit, Extraktionsausbeute und Robustheit.
Somit gilt diese Methode in der Praxis als anwendbar und dürfte, nach Überprüfung der therapeutischen Bereiche für kapillares Vollblut im Vergleich zu den bereits definierten Bereichen für venöse entnommene Serumproben, Eingang in die klinische Praxis finden.
Progressive loss of skeletal muscle mass, strength and function poses a major threat to independence and quality of life, particularly in the elderly. To date, sarcopenia therapy consists of resistance exercise training in combination with protein supplementation due to the limited efficacy of available pharmacological options in counteracting the effects of muscle wasting. Therapeutic intervention with growth factors including insulin-like growth factor I (IGF-I) or inhibitors of myostatin a potent suppressor of myogenesis hold potential to rebalance the altered activity of anabolic and catabolic cytokines. However, dosing limitations due to acute side effects and disruptions of the homeostasis have so far precluded clinical application.
Intending to provide a therapy with a superior safety and efficacy profile by directing drug release to inflamed tissue and minimizing off-target activity, we designed bioresponsive delivery systems for an anti-catabolic peptide and anabolic IGF-I responding to local flares of muscle wasting.
In Chapter I, current concepts for bioorthogonal conjugation methods are discussed and evaluated based on various drug delivery applications. With a focus on protein delivery, challenges and potential pitfalls of each chemical and enzymatic conjugation strategy are analyzed and opportunities regarding their use for coupling of biomolecules are given. Based on various studies conjugating proteins to polymers, particles and biomaterials using different site-directed approaches, the chapter summarizes available strategies and highlights certain aspects requiring particular consideration when applied to biomolecules. Finally, a decision process for selection of an optimum conjugation strategy is exemplarily presented.
Three of these bioorthogonal coupling reactions are applied in Chapter II detailing the potential of site-directed conjugation in the development of novel, homogenous drug delivery systems. The chapter describes the design of a delivery system of a myostatin inhibitor (MI) for controlled and local release counteracting myositis flares. MI release from the carrier is driven by increased matrix metalloproteinase (MMP) levels in compromised muscle tissues cleaving the interposed linker, thereby releasing the peptide inhibitor from the particulate carrier. Release experiments were performed to assess the response towards various MMP isoforms (MMP-1, -8, -9 and -13) – as upregulated during skeletal muscle myopathies – and the release pattern of the MI in case of disease progression was analyzed. By selection of the protease-sensitive linker (PSL) showing variable susceptibilities to proteases, release rates of the MI can be controlled and adapted. Immobilized MI as well as released MI as response to MMP upregulation was able to antagonize the effects of myostatin on cell signalling and myoblast differentiation.
The approach of designing bioresponsive protein delivery systems was also applied to the anabolic growth factor IGF-I, as described in Chapter III. Numerous studies of PEGylated proteins or peptides reveal, that successful therapy is challenged by safety and efficacy issues, as polymer attachment considerably alters the properties of the biologic, thereby jeopardizing clinical efficacy. To this end, a novel promising approach is presented, intending to exploit beneficial effects of PEGylation on pharmacokinetics, but addressing the pharmacodynamic challenges by releasing the protein upon entering the target tissue. This was realized by integration of a PSL between the PEG moiety and the protein. The soluble polymer conjugate was produced by site-directed, enzymatic conjugation of IGF-I to the PSL, followed by attachment of a 30 kDa-PEG using Strain-promoted azide-alkyne cycloaddition (SPAAC). This strategy illustrates the potential of bioorthogonal conjugation (as described in Chapter I) for generation of homogenous protein-polymer conjugates with reproducible outcome, but also emphasizes the altered protein properties resulting from permanent polymer conjugation. As compared to wild type IGF-I, the PEGylated protein showed considerable changes in pharmacologic effects – such as impaired insulin-like growth factor binding protein (IGFBPs) interactions, submaximal proliferative activity and altered endocytosis patterns. In contrast, IGF-I characteristics were fully restored upon local disintegration of the conjugate triggered by MMP upregulation and release of the natural growth factor.
For successful formulation development for the proteins and conjugates, the careful selection of suitable excipients is crucial for a safe and reliable therapy. Chapter IV addresses one aspect by highlighting the chemical heterogeneity of excipients and associated differences in performance. Polysorbate 80 (PS80) is a surfactant frequently used in protein formulations to prevent aggregation and surface adsorption. Despite being widely deployed as a standard excipient, heterogeneous composition and performance entails the risk of eliciting degradation and adverse effects on protein stability. Based on a comprehensive study using different batches of various suppliers, the PS80 products were characterized regarding chemical composition and physicochemical properties, facilitating the assessment of excipient performance in a formulation. Noticeable deviations were recorded between different suppliers as well as between batches of the same suppliers. Correlation of all parameters revealed, that functionality related characteristics (FRCs) could be reliably predicted based on chemical composition alone or by a combination of chemical and physicochemical properties, respectively.
In summary, this thesis describes and evaluates novel strategies for the targeted delivery and controlled release of biologics intended to counteract the imbalance of anabolic and catabolic proteins observed during aging and musculoskeletal diseases. Two delivery platforms were developed and characterized in vitro – (i) using anti-catabolic peptides immobilized on a carrier for local delivery and (ii) using soluble IGF-I polymer conjugates for systemic application. Both approaches were implemented by bioorthogonal coupling strategies, which were carefully selected in consideration of limitations, side reactions and efficiency aspects. Bioresponsive release of the active biomolecules following increased protease activity could be successfully realized. The therapeutic potential of these approaches was demonstrated using various cell-based potency assays. The systems allow targeted and controlled release of the growth factor IGF-I and anti-catabolic peptides thereby overcoming safety concerns of current growth factor therapy and thus positively impacting the benefit-risk profile of potent therapeutics. Taking potential heterogeneity and by-product concerns into account, comprehensive excipient characterization was performed and a predictive algorithm for FRCs developed, in order to facilitate formulation design and guarantee a safe and efficient therapy from start to finish.
Renin–angiotensin system (RAS) plays an important role in the regulation of blood pressure and hormonal balance. Using positron emission tomography (PET) technology, it is possible to monitor the physiological and pathological distribution of angiotensin II type 1 receptors (AT\(_1\)), which reflects the functionality of RAS. A new \(^{18}\)F-labeled PET tracer derived from the clinically used AT\(_1\) antagonist valsartan showing the least possible chemical alteration from the valsartan structure has been designed and synthesized with several strategies, which can be applied for the syntheses of further derivatives. Radioligand binding study showed that the cold reference FV45 (K\(_i\) 14.6 nM) has almost equivalent binding affinity as its lead valsartan (K\(_i\) 11.8 nM) and angiotensin II (K\(_i\) 1.7 nM). Successful radiolabeling of FV45 in a one-pot radiofluorination followed by the deprotection procedure with 21.8 ± 8.5% radiochemical yield and >99% radiochemical purity (n = 5) enabled a distribution study in rats and opened a path to straightforward large-scale production. A fast and clear kidney uptake could be observed, and this renal uptake could be selectively blocked by pretreatment with AT\(_1\)-selective antagonist valsartan. Overall, as the first \(^{18}\)F-labeled PET tracer based on a derivation from clinically used drug valsartan with almost identical chemical structure, [\(^{18}\)F]FV45 will be a new tool for assessing the RAS function by visualizing AT\(_i\) receptor distributions and providing further information regarding cardiovascular system malfunction as well as possible applications in inflammation research and cancer diagnosis.
In resent years the rate of biologics (proteins, cytokines and growth-factors) as newly registered drugs has steadily risen. The greatest challenge for pharmaceutical biologics poses its arrival at the desired target location due to e.g. proteolytic and pH dependent degradation, plasma protein binding, insolubility etc. Therefore, advanced drug delivery systems, where biologics are site directed immobilized to carriers mimicking endogenous storage sites such as the extra cellular matrix can enormously assist the application and consequently the release of exogenous administered pharmaceutical biologics. We have resorted to the fibroblast growth factor 2/ heparansulfate/ fibroblast growth factor bindingprotein 1 system as a model.
Phase I deals with the selection and subcloning of a wild type murine FGF-2 construct into the bacterial pHis-Trx vector system for high yields of expression and fast, feasible purification measurements. This first step enables the provision of mFGF-2, which plays a pivotal part as a growth factor in the wound healing process as well as the vascularization of tumors, for future investigations. Therefore, the correct expression of mFGF-2 was monitored via MALDI-MS and SDS-PAGE, whereas the proper folding of the tertiary beta-trefoil structure was assessed by fluorescence spectroscopy. The MTT assay allowed us to ensure that the bioactivity was comparable to sourced FGF-2. In the last step, the purity; a requirement for future binding- and protein-protein interaction assays was monitored chromatographically (RP-HPLC). In addition, a formulation for freeze-drying was developed to ensure protein stability and integrity over a period of 60 days. Altogether, the bacterial expression and purification proved to be suitable, leading to bioactive and stable production of mFGF-2.
In Phase II the expression, purification and characterization of FGFBP1, as the other key partner in the FGF-2/ HS/ FGFBP1 system is detailed. As FGFBP1 exhibits a complex tertiary structure, comprised of five highly conserved disulfide bonds and presumably multiple glycosylation sites, a eukaryotic expression was used. Human embryonic kidney cells (HEK 293F) as suspension cells were transiently transfected with DNA-PEI complexes, leading to expression of Fc-tagged murine FGFBP1. Different PEI to DNA ratios and expression durations were investigated for optimal expression yields, which were confirmed by western blot analysis and SDS-PAGE. LC-MS/MS analysis of trypsin and elastase digested FGFBP1 gave first insights of the three O-glycosylation sites. Furthermore, the binding protein was modified by inserting a His6-tag between the Fc-tag (for purification) and the binding protein itself to enable later complexation with radioactive 99mTc as radio ligand to track bio distribution of administered FGFBP1 in mice. Overall, expression, purification and characterization of mFGFBP1 variants were successful with a minor draw back of instability of the tag free binding protein.
Combining the insights and results of expressed FGF-2 as well as FGFBP1 directed us to the investigation of the interaction of each partner in the FGF-2/ HS/ FGFBP1 system as Phase III. Thermodynamic behavior of FGF-2 and low molecular weight heparin (enoxaparin), as a surrogate for HS, under physiological conditions (pH 7.4) and pathophysiological conditions, similar to hypoxic, tumorous conditions (acidic pH) were monitored by means of isothermal titration calorimetry. Buffer types, as well as the pH influences binding parameters such as stoichiometry (n), enthalpy (ΔH) and to some extent the dissociation constant (KD). These findings paved the way for kinetic binding investigations, which were performed by surface plasmon resonance assays. For the first time the KD of full length FGFBP1 and FGF-2 was measured. Furthermore the binding behavior of FGF-2 to FGFBP1 in the presence of various heparin concentrations suggest a kinetic driven release of bound FGF-2 by its chaperone FGFBP1.
Having gathered multiple data on the FGF-2 /HS /FGFBP1 system mainly in solution, our next step in Phase IV was the development of a test system for immobilized proteins. With the necessity to better understand and monitor the cellular effects of immobilized growth factors, we decorated glass slides in a site-specific manner with an RGD-peptide for adhesion of cells and via the copper(I)-catalyzed-azide-alkyne cycloaddition (CuAAC) a fluorescent dye (a precursor for modified proteins for click chemistry). Human osteosarcoma cells were able to grow an the slides and the fluorescence dye was immobilized in a biocompatible way allowing future thorough bioactivity assay such as MTT-assays and phospho-ERK-assays of immobilized growth factors.